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With the rising rates of preterm birth, an in-depth understanding of the molecular 
mechanisms that govern preterm labour and uterine quiescence is needed, as this 
may lead to identifying drug targets that can prevent preterm labour or lead to 
reliable tests that identify those are at risk for premature labour. This thesis, focuses 
on Phospholipase C like-1 (PLCL-1). PLCL-1 is a protein that is similar in structure to 
PLC-δ1, however PLCL-1 is catalytically inactive. PLCL-1 has been shown to be down-
regulated in the myometrium of woman that are in labour compared to those that 
are not, this suggests a possible role for PLCL-1 in uterine quiescence and exploring 
the role PLCL-1 plays in uterine quiescence might explain one molecular pathway that 
leads to parturition. Calcium imaging disclosed that PLCL-1 reduced IP3 mediated 
calcium release in primary myometrial cells. Western blotting and RT-PCR illustrated 
that PLCL-1 transcription is induced by progesterone, this indicates that PLCL-1 is a 
progesterone responsive gene. High-throughput RNA sequencing showed that a loss 
in PLCL-1 resulted in an increase in phosphodiesterases, this led to a reduction in the 
levels of the pro-quiescent molecule: cAMP. In conclusion, this thesis demonstrates 
that PLCL-1 is downregulated in the labouring myometrium because it functions as a 
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1.1- Preterm Birth: Global Rates, Outcomes, Risk Factors and Current 
Treatments  
The number of preterm births worldwide is estimated to be around 15 million 
annually. The rate of preterm birth for each country varies between 5% and 18%, in 
the UK 7.2% of all births are classified as preterm (Blencowe et al, 2012) (Blencowe 
et al, 2013) (Office of National Statistics, 2018) (WHO, 2018).  The World Health 
Organisation (WHO) defines preterm birth as any birth that occurs before the 37 
weeks of gestation and preterm birth is subcategorised subject to gestational age 
(WHO, 1977). Births that occur between weeks 32 to 37 are categorised as 
moderately preterm, and those between 28 to 32 weeks are considered as very 
preterm. Any birth before the 28th week of gestation is categorised as extremely 
preterm. Preterm birth is the primary cause of perinatal mortality; in the UK 50% of 
neonatal deaths are attributed to prematurity (Liu et al,2016) (Blencowe et al, 2013) 
(Office of National Statistics, 2018). The likelihood of survival decreases the earlier 
the baby is delivered (Saigal and Doyle, 2008) (Moser et al, 2008) (Costeloe et al, 
2012).  Premature neonates who do survive have a greater risk of suffering from 
morbidities. Preterm birth is associated with a higher risk of motor disability, 
cognitive impairment, vision and hearing impairments, periventricular leukomalacia, 
sepsis and respiratory distress syndrome (Marlow et al, 2005) (Blencowe et al, 2013) 
(Petrini et al, 2009) (Bolisetty et al, 2014) (Pierson et al, 2004) (Stoll et al, 2002).  
  
30% of preterm births are medically indicated due to maternal or foetal distress, 25% 
are caused by premature preterm rupture of the membranes (PPROM) and 45% are 
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idiopathic. There are a few associated risk factors for either PPROM or idiopathic 
preterm birth and they include: a previous history of preterm birth or cervical 
surgery, multiple pregnancy, race, low body mass index, periodontal disease, vaginal 
infection, tobacco or alcohol use and socio-economic status (Figure 1.1) (Goldenberg 










Figure 1.1- Risk factors of Preterm Birth. The risk factors associated with preterm 
birth are both environmental and genetic. Figure adapted from Romero et al, 2014.  
 
 
Clinicians rely on transvaginal sonographic cervical length (CL) and cervicovaginal 
foetal fibronectin (fFN) measurements, to predict the likelihood of a woman going 
into preterm birth. Foetal fibronectin is present in the amniotic fluid and placenta 
and damage to foetal membranes results in the release of fFN into the cervix and 
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vagina, which can then be measured as a biochemical marker for preterm birth (Iams 
et al, 1996) (Matsuura et al, 1985) (Lockwood et al, 1991).  However, both methods 
have a low positive predictive rate, 21% for CL and 17% for fFN (Arisoy and Yayla, 
2012).  
Tocolytics are drugs that are used to delay the onset of labour when preterm birth 
has been diagnosed, this allows for transfer of the woman to receive tertiary care 
and antenatal corticosteroids to improve foetal lung function (Goldenberg, 2002) 
(Liggins et al, 1972) (Roberts et al, 2017). Tocolytics are grouped depending on their 
target and mode of action and they include: betamimetics, calcium channel blockers, 
oxytocin receptor blockers, prostaglandin inhibitors, nitrates and magnesium 
sulphate.  Although some tocolytics can delay the onset of labour, there is no clear 
evidence that they reduce neonatal mortality and morbidity rates. Therefore, there 
is a need for more reliable diagnostic tests for preterm births and for more effective 
tocolytics (Anotayanonth et al, 2004) (King et al, 2003) (Papatsonis et al, 2005) (King 
et al, 2005) (Crowther et al, 2006).  
 
1.2 - Uterine Anatomy and Myometrial Function During Pregnancy  
The uterine corpus (main body) is made up of three walls: an inner mucosal layer 
that lines the uterine cavity (endometrium), a middle smooth muscle layer 
(myometrium) and a thin outer layer called the perimetrium. The myometrium is 
separated into three poorly demarcated layers:  the stratum supravasculare that is 
adjacent to the perimetrium, which is adjacent to the extremely vascularised stratum 
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vasculare, which is adjacent to the stratum subvasculare (Blanks et al, 2007).  The 
myometrium is made up of myometrial smooth muscle cells (MSMCs), which are 
arranged into ~300µm ±100µm diameter bundles, each bundle is separated by 
connective tissue and microvasculature. The bundles are then arranged into 1–2 mm 
diameter cylindric structures called fasciculi, which are surrounded by a dense 
collagen matrix and blood vessels (Figure 1.2) (Goetller, 1968).  
Throughout pregnancy, the myometrium is in a non-contractile (quiescent) state to 
allow for full in-utero development of the foetus until term is reached.  Whilst in the 
quiescent state, the myometrium undergoes physiological remodelling, via 
hyperplasia and hypertrophy in preparation for powerful uterine contraction to 
support parturition (Douglas et al, 1988) (Reynolds et al, 1992) (Shynlova et al, 2007) 
(Jaffer et al, 2009). The spatial orientation of the muscle fibres of the myometrium 
produces a directional force to aid the expulsion of the foetus from the uterus and 
through the cervix and vagina. Weiss et al and Lutton et al both describe circular 
muscle fibres in the stratum subvaculare near the uterine cavity and longitudinal 
muscle fibres near the cervix. Whilst the rest of the myometrium was found to be 
arranged in a disorderly manner with different fibres in erratic orientations (Weiss et 






Figure 1.2- Structure of the Uterus and Myometrium. The uterus wall is made up of 
the endometrium (facing the uterine cavity), myometrium (middle layer) and 
perimetrium (outer layer). The myometrium is made up of bundles which are 
arranged in cylindric structure called fasciculus. The basic unit of the myometrium is 
the smooth muscle cell (myocyte). Figure adapted from Karnezis et al, 2017.  
 
 
1.3- Molecular Basis of Contraction 
The key basis for contraction in the MSMC is the cyclic cross-bridge formation 
between myosin and actin filaments.  The 20kDa Myosin light chain (MLC-20) 
attaches and detaches from the actin filaments; attachment causes shortening 
(contraction) of the MSMC and detachment causes relaxation. The cross-bridge 
formation is activated by myosin light chain kinase (MLCK), which phosphorylates the 
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globular head of MLC-20, thereby activating myosin ATPase activity to allow for ATP 
hydrolysis (Rayment et al, 1993) (Ishijima et al, 1998) (Figure 1.3).  ATP hydrolysis 
provides the energy needed for MLC-20 to bind to actin, causing actin filament 
sliding, leading to shortening of the MSMC i.e. contraction (Word et al, 1993).  
 
A rise in intracellular calcium concentration [Ca2+]i leads to the activation of MLCK. 
Activation of MLCK is crucial for contraction to occur in the myometrium. Inhibition 
of MLCK using wortmannin and ML-9, inhibits myometrium contraction (Longbottom 
et al, 2000). Initially 4 calcium ions bind to calmodulin, which has two EF hand Ca2+ 
binding sites in its N-terminus and another two EF hand Ca2+ binding sites in its C-
terminus. When the calcium ions bind to calmodulin, it undergoes a conformational 
change, which causes the exposure of a hydrophobic pocket (Johnson et al, 1996) 
(LaPorte et al, 1980). The activated calmodulin bound to 4 calcium ions can then 
activate MLCK. Action potential (AP) firing on MSMC plasma membrane leads to the 
opening of the voltage operated calcium channels (VOCC). The AP mediated calcium 







Figure 1.3 - Actin-myosin Cross Bridge Cycling in the Smooth Muscle Cell.  
 
1.3.1- Excitation-Contraction Coupling 
The myometrium displays spontaneous electrical behaviour without any stimuli from 
the central nervous system or from hormones. There has been no definitive proof of 
any pacemaker cells within the myometrium, although a pacemaker region in the 
maternal-placental interface of the rat myometrium has been recently identified 
(Lutton et al, 2018). MSMCs maintain a concentration gradient of ions: (Cl-, Ca2+, K+ 
and Na+) across the plasma membrane. MSMC maintain the concentration gradient 
by the active transport of ions using ion pumps and transporters present on the 
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plasma membrane. The intracellular resting membrane potential of MSMCs is around 
-55mV. Action potential firing requires cellular depolarisation to reach threshold 
potential. The opening of ion channels on the plasma membrane allows the 
movement of ions down their electrochemical gradient. Action potential firing in the 
MSMC is due the opening of calcium channels, which causes the inward flow of 
calcium into the MSMC through L type VOCC (L-VOCC) (Shmigol et al, 1998). The 
human myometrium also expresses T-type VOCC (T-VOCC), and inhibiting T-VOCC 
using nickel reduces the contraction frequency (Blanks et al, 2007).   Repolarisation 
of the MSMC is instigated by the opening of potassium channels leading to an efflux 
of potassium ions, this leads to a loss of positively charged potassium ions, leading to 








Figure 1.4- Excitation-Contraction Coupling. A) The electrochemical gradients of 
potassium and calcium ions present on the MSMC plasma membrane. Potassium ions 
have higher concentration (mmol/L) inside the cell, and will flow outwards, Calcium 
ions have higher concentration outside the cell and will flow inwards. B) The basis of 
an action potential in the MSMC. The flow of calcium ions into the cells causes 
depolarisation and action potential firing, the flow of potassium ions out the cells 
causes repolarisation. C) Excitation of MSMC activates MLCK, which phosphorylates 
myosin light chain (MLC-20) causing ATP hydrolysis, binding of myosin head to actin 







1.4 - Phases of Pregnancy and Parturition  
Pregnancy and parturition can be divided into 5 different phases. These phases 
are: i) implantation of the blastocyst, and placentation ii) myometrial quiescence 
to allow for foetal growth and development iii) activation of molecular pathways 
that promote uterine contractility iv) stimulation, which involves cervical ripening 
and active labour v) involution, whereby the uterus reverts to a non-pregnant 
condition (Rubens et al, 2014). 
 
During the quiescent phase of pregnancy, the uterus is dominated by pro-
quiescent factors such as progesterone (P4), nitric oxide (NO), cyclic AMP (cAMP) 
and cyclic GMP (cGMP). There is a loss in pro-quiescent factors during the 
activation and stimulation phase and there is upregulation and activation of 
contraction associated proteins (CAPs) such as: oxytocin (OT), oxytocin receptor 
(OTR), prostaglandin F2α (PGF2α) and connexin 43 (Cx43) (Figure 1.5) (Smith, 2007) 






Figure 1.5 - Phases of Pregnancy and Parturition. The uterus is in a quiescent state 
for majority of the pregnancy to allow for embryogenesis and foetal maturation. 
Progesterone and other pro-quiescent factors maintain the uterus in the non-
contractile phase.  At the end of the third trimester there is upregulation of 
contraction associated proteins (CAPs) and oestrogen in preparation for 
parturition.  Figure from Rubens et al, 2014.  
 
 
1.5- The Quiescence Phase of Pregnancy  
1.5.1- The Role of Cyclic Nucleotides in Maintaining Uterine Quiescence.  
Cyclic nucleotides: cAMP and cGMP play an important role in minimising the effects 
of calcium in MSMC and keeping the myometrium quiescent. Cyclic AMP is 
synthesised from ATP by adenylate cyclase (AC), which is a transmembrane protein, 
with 12 membrane spanning motifs. The highly conserved and hydrophobic catalytic 
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core of AC is made of up of two regions: C1a and C2a and can bind both Gαs and ATP 
(Tesmer et al, 1997). AC is activated by Gαs, which upon binding causes a 
conformational change in AC, allowing it to synthesise cAMP from ATP. There are 9 
isoforms of AC and all were found to be expressed in the human myometrium (Price 
et al, 2000). All AC isoforms are activated by Gαs, however other modulators have 
opposing effects on different isoforms. For example, Protein Kinase C (PKC) inhibits 
AC9 but can activate AC2, AC4, AC5 and AC7 (Cumbay and Watts, 2004) (Halls and 
Cooper, 2011).  Β-adrenergic agonist such as relaxin and prostacyclin maintain 
uterine quiescence by   activating AC mediated synthesis of cAMP (Challis et al, 2000) 
(Norwitz, 1997).  
 
Protein Kinase A (PKA) is one the effector proteins of cAMP. PKA is a tetrameric 
protein and has two regulatory subunits (R) and two catalytic subunits (C). Two cAMP 
molecules bind to the two R subunits, causing the catalytic units to detach from the 
R subunits. The catalytic units are then free to phosphorylate their substrates (Tillo 
et al, 2017).  
 
One of the substrates of PKA is MLCK. Phosphorylation of MLCK by PKA, causes MLCK 
to lose its affinity for calcium-calmodulin, thus PKA inhibits MLCK, leading to smooth 
muscle cells (SMCs) relaxation. PKA expression decreases in pregnant human 
myometrium, during the latter stages of gestation (Ku et al, 2005).  There is 
conflicting evidence on the effect of cAMP/PKA pathway on L type VOCC in SMCs. 
Activation of the cAMP/PKA has been shown to inhibit VOCC (Liu et al, 1997), it has 
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also been shown to activate VOCC (Ruiz-Velasco et al, 1998). PKA phosphorylates and 
enhances the BKCa channel activity in pregnant rat myometrium, causing an outward 
flow of K+ ions, which inhibits AP firing and excitation-contraction coupling (Perez 
and Toro, 1994). PKA phosphorylates and inhibits PLCβ3, thus PKA is able to inhibit 
Gαq mediated calcium release (Yue et al, 1998).  
 
Additionally, cAMP/PKA maintain quiescence in the uterus by inhibiting calcium 
sensitisation (CS). The effects of calcium in the MSMC can be amplified, without the 
need for a rise in calcium concentration and therefore increase contractile force; this 
is a process called calcium sensitisation (CS). Calcium sensitisation is thought to 
depend on the phosphorylation state of myosin light chain (Somlyo and Somlyo, 
2003). Myosin light chain phosphatase (MLCP) is a protein that dephosphorylates 
myosin light chain and inhibits contraction(Somlyo and Somlyo, 1994). CS in SMCs is 
regulated by the small GTPase rhoA. Gαq11 and Gαq12/13 activate rhoA, which in turn 
activates Rho kinase (ROCK), which phosphorylates the PP1C catalytic subunit of 
MLCP, this inhibits MLCP (Hirata et al, 1992) (Gong et al, 2001).  Following the 
inhibition of MLCP myosin light chain is able to stay in an active, phosphorylated, 
state (Noda et al, 1995).  There is an up-regulation of Rho kinase mRNA during 
pregnancy, and this indicates heightened CS in the myometrium with increasing 
gestational duration (Moore et al, 2000). However, during the quiescence phase of 




PKA inhibits calcium sensitisation by phosphorylating rhoA, causing rhoA to 
translocate from the membrane to the cytosol and preventing the activation of ROCK 
(Murthy et al, 2003). PKA also inhibits Gαq13 by phosphorylation, which blocks Gαq13 




Figure 1.6 - Major Cellular Mechanisms Controlling Contraction and Quiescence in 
SMCs. Pathways leading to contraction are shown in red, and pathways linked to 
relaxation are shown in blue. Abbreviations: DAG, diacylglycerol; IP3, inositol 1,4,5-
trisphosphate; MLC20, 20kDA light chain of myosin; MLCP, myosin light chain 
phosphatase; NO, nitric oxide; NSCC, nonselective cation channels; PKA, cAMP-
dependent protein kinase; PKG, cGMP-dependent protein kinase; PLCβ, 
phospholipase Cβ; VDCC, voltage-dependent Ca2+ channels; ZIPK, zipper-interacting 




Heat shock proteins (HSPs) are synthesised as a reaction to any physical cellular 
stresses such as heat. Some HSPs are able to prevent actin polymerisation and thus 
inhibit contraction (Mounier  and Arrigo, 2002) . Heat shock protein 20 (HSP20) is a 
substrate of PKA. Phosphorylated HSP20 has been found to induce vascular smooth 
muscle relaxation (Woodrum et al, 2003). In MSMCs, PKA phosphorylates HSP20, 
which then co-localises with α-actin, this illustrates a mechanism for myometrial 
relaxation (Tyson et al, 2008).  
 
Another substrate of PKA is the human ether-a-go-go-related gene (hERG) 
potassium channel. PKA phosphorylation increases hERG protein abundance (Chen 
et al, 2009). The hERG channel subdues myometrial contractile amplitude and 
duration prior to labour and its activity is reduced during labour. Therefore 
cAMP/PKA promotes uterine quiescence by increasing the activity of the hERG 
channel (Parkington et al, 2014).  
 
Endothelial nitric oxide synthase (eNOS) is found in MSMC and synthesises nitric 
oxide from L-arginine (Khorram et al, 1999). One of the targets of nitric oxide is 
guanylyl cyclase, which synthesises cGMP from GTP. Both NO and cGMP caused 
uterine relaxation in pregnant rats (Yallampalli et al, 1994). In human MSMC; cGMP 




1.5.2- Progesterone: Synthesis, Mechanism of Action and its Pro-quiescent 
Functions  
Progesterone is a steroid hormone that plays a functional role in a wide variety of 
biological processes such as in the immune system, reproductive system and 
neuronal activity. In reproductive health, progesterone’s main function is in the 
decidualisation of the endometrium and keeping the uterus in a non-contractile state 
during pregnancy. Progesterone is produced by the adrenal gland, corpus luteum, 
ovaries and the placenta (Gellersen et al, 2009). In the inner membrane of the 
mitochondria, cholesterol is first converted to pregnenolone by cytochrome P450scc, 
thereafter pregnenolone is synthesised into progesterone by 3β-hydroxysteroid 
dehydrogenase (Figure 1.7) (Schumacher et al, 2001).  
 
Figure 1.7-Progesterone Synthesis. Figure from Schumacher et al, 2001.  
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Steroidogenic cells secrete biologically active progesterone into the blood stream. 
Corticosteroid-binding globulin binds to secreted progesterone with a high affinity, 
hence it’s able to regulate the concentration of free progesterone that is available 
for progesterone sensitive cells (Hammond, 2016).  Unbound progesterone diffuses 
across the plasma membrane and binds to progesterone receptors. There are two 
known isoforms of the progesterone receptor: PRA and PRB, which are transcribed 
from the same gene that utilises two different promoters (Kastner et al, 1990). PRA 
and PRB regulate different biological processes. For example, a lack of PRB causes 
aberrations in mammary gland development. Whilst PRA null mice were not able to 
ovulate, undergo decidualisation and were infertile (Mulac-Jericevic et al, 2003) 
(Mulac-Jericevic et al, 2000).  
 
PRA and PRB have a very similar structure; they both have a ligand binding domain 
(LBD), a DNA binding domain (DBD) and an N-terminus domain (NTD) (Figure 1.8).  
PRB has an extended NTD and is a longer than PRA by 164 amino acids. PRA has two 
regions termed transcriptional activation functions (AF1 and AF2), the two regions 
can operate independently or synergistically. PRB has an extra transcriptional 
activation function (AF3) in the extended part of the NTD (Sartorius et al, 1994). The 
presence of AF3 in PRB is attributed to the difference in transcriptional activity 
between the two progesterone receptor isoforms (Dong et al, 2004). PRB is a 
stronger transcriptional activator than PRA. The synergism between AF1, AF2 and 
AF3 that is not present in PRA makes PRB a stronger transcriptional activator. Loss of 
AF3 region in PRB significantly reduces the transcriptional activity of PRB (Tung et al, 
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2006). In addition to the structural differences between the progesterone receptors, 
PRA supresses PRB functional activity (Vegeto et al, 1993).  
 
                                                                                                                                        
Figure 1.8- Schematic Representation, Showing the Structural Differences of 
Progesterone Receptor A (PR-A) and Progesterone Receptor B (PR-B). 
Abbreviations: N-terminus domain (NTD), DNA binding domain (DBD), ligand binding 
domain (LBD), p (phosphorylation sites), h (hinge domain), AF (activation functions). 
Figure from Hill et al, 2012  
 
 
Binding of progesterone to PR, causes PR to dimerise and undergo a conformational 
change, and disassociate from regulatory proteins (Smith et al, 1990). PRA can 
dimerise as homodimers or heterodimers (Hill et al, 2012). During the secretory 
phase of the human menstrual cycle, progesterone binding to PR causes the receptor 
to translocate to nuclear aggregates (Arnett- Mansfield et al, 2007).  After 
progesterone binding to PR, it binds to progesterone response elements on target 
genes. PR recruits co-regulators that help to either activate or repress transcription 
of various genes. There are over 300 co-regulators of PR (Scarpin et al, 2009). The 
functional differences between PRA and PRB can be partially attributed to differential 
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recruitment of co-regulators to the two progesterone receptor isoforms (Giangrande 
et al, 2000).  
 
The putative function of progesterone in the myometrium is to keep the uterus in a 
non-contractile state, this is to allow for full development of the foetus until the 
foetus is ready for extrauterine survival.  One of the ways progesterone keeps the 
myometrium in a quiescent form is by regulating ion channel expression on the 
MSMC membrane. 
  
Potassium channels are important in keeping the membrane potential close to the 
reversal potential for K+, making it unlikely for AP firing and subsequent excitation-
contraction coupling. The Na/K ATPase pump is important for maintaining the 
potassium concentration gradient present between the extracellular space and the 
MSMC cytoplasm. Progesterone upregulates the mRNA encoding the Na/K ATPase 
β1 subunit of luminal epithelial cells of the mouse uterus (Deng et al, 2013). 
Progesterone upregulates mRNA of BKCa and the voltage operated potassium 
channel KCND3 (Shi et al, 2015). P4 also upregulates protein levels of other voltage 
gated potassium channels, such as KCNH1 (Ramirez et al, 2013).  Additionally, P4 
increases the outward current flow from delayed rectifier potassium channels in 
cultured MSMC, this decreases the likelihood of AP firing and any subsequent 
excitation-contraction coupling (Knock et al, 2001).  
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In vascular smooth muscle cells progesterone decreases intracellular calcium ion 
concentration and inhibits L-VOCC inward current (Barbagallo et al, 2001). 
Progesterone also inhibits L-VOCC inward current in gallbladder smooth muscle cells 
(Wu and Shen, 2010). In striatal neurons, progesterone is known as a potent 
protector against neurotoxicity caused by excessive calcium concentration, by 
inhibiting L-VOCC inward current (Luoma et al, 2011). Therefore, progesterone can 
inhibit contraction in SMCs by inhibiting influx of calcium ions through L-VOCC.  
 
Progesterone Increases Expression of Agonists of Uterine Quiescence  
Progesterone increases levels of Atrial Natriuretic Peptide (ANP) in primary MSMCs 
by increasing expression of the serine protease corin. Pro-ANP is the precursor of 
ANP, and Pro-ANP is converted into ANP by corin (Soloff et al, 2011). ANP decreases 
the frequency of contractions observed in human myometrium (Cootauco et al, 
2008). ANP activates guanylyl cyclase (GC) and increases cGMP production in 
myometrium (Carvajal et al, 2001). The GC/cGMP/PKG pathway is a well-known 
pathway that is involved in smooth muscle cell relaxation.  
 
Progesterone increases transcription of Calcitonin gene-related peptide (CGRP) and 
adrenomedullin in rat myometrium (Thota and Yallampalli, 2005). Both CGRP and 
adrenomedullin bind to GPCR coupled to Gαs subunit which activates adenylyl 
cyclase. As stated previously, the AC/cAMP/PKA pathway is involved in upholding 
uterine quiescence.  CGRP is upregulated in rat plasma in pregnancy, but is 
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downregulated during labour (Gangula et al, 2000). CGRP decreases contraction in 
myometrium obtained from pregnant women, this effect is reduced in myometrium 
obtained from women in active labour. Furthermore, the relaxant effects on the 
myometrium due to CGRP treatment is lost when a selective CGRP or guanylyl cyclase 
antagonist is added, this indicates that CGRP regulates both adenylyl cyclase and 
guanylyl cyclase (Dong et al, 1999).  
 
Progesterone Decreases Expression of Agonist of Uterine Contraction 
Progesterone reduces expression of endothelin 1 in human MSMCs (Soloff et al, 
2011). Endothelin 1 (ET-1) is a well characterised and effective vasoconstrictor 
peptide. Concentrations of ET-1 in rat myometrium increase with increasing 
gestation time, with the highest concentration measured during the early 
postpartum period (Kajihara et al, 1996). ET-1 binds to ET receptors on MSMC plasma 
membrane and causes contractions in the rat uterus, by opening VOCC (Kozuka et al, 
1989). ET receptors are GPCR coupled to Gαq and ET-1 ligand binding causes 
activation of phospholipase C (PLC) and release of intercellular calcium stores and 
MLC-20 phosphorylation in human myometrial cells (Takuwa et al, 1989) (Word et al, 
1990). Progesterone attenuates ET-1 induced increases in intracellular calcium in 
human myometrium cells; this may be a model in how progesterone maintains 
uterine quiescence. Although the mechanism by which progesterone inhibits ET-1 
induced rise in intracellular calcium is not known; it could be that progesterone 
utilises an effector protein (Fomin et al, 1999).  
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Progesterone decreases expression of the CAPS: connexin 43 (Cx43) and 
cyclooxygenase-2 (COX-2), which are important in the stimulation phase and 
activation phase respectively (Zhao et al, 1996) ( Hardy et al, 2006).  
 
Progesterone inhibits oxytocin receptor (OTR) transcription in rat myometrium 
(Soloff et al, 1983). Progesterone dependent reduction of OTR expression could be 
mediated by interleukin 1 (IL-1) signalling.  IL-1 recruits NF-𝜅b to the OTR promoter, 
disrupting the binding of RNA polymerase II to OTR promoter and subsequent OTR 
transcription (Soloff et al, 2006). Progesterone induces IL-1 signalling by upregulating 
interleukin 1 receptor expression (Soloff et al, 2011).  
 
Progesterone also decreases expression of phosphodiesterases 4B and 1C. 
Phosphodiesterase causes degradation of the pro-quiescent second messengers 
cAMP and cGMP (Soloff et al, 2011).  
 
1.6 The Activation Phase of Pregnancy  
1.6.1 –Foetal HPA Axis 
The exact mechanism of activation of parturition in humans has not been very well 
defined, as it has been in other species. For example, in sheep parturition is initiated 
by activation of the foetal hypothalamic pituitary adrenal axis (HPA) (Liggins et al, 
1973) (Liggins et al 1967). Sheep with lesions in the foetal hypothalamus undergo 
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prolonged labour (Gluckman et al, 1991). Activation of foetal HPA in sheep causes 
the secretions of corticosteroids, which activate enzymes 17a hydroxylase and 17–
20 lyase; these enzymes then favour the conversion of cholesterol to oestrogen 
rather than progesterone (Mason et al, 1989). The switch in endocrine expression 
promotes prostaglandin production, cervical softening and increased myometrial 
contractions (Bernal, 2003) (Beshay et al, 2007). Foetal HPA does not play a major 
role but rather a supportive role in activating parturition in humans, as women who 
carry an anencephalic foetus have the same gestation length as women who carry a 
non-anencephalic foetus. Although, there was a huge increase in the variance of the 
mean delivery dates in anencephalic pregnancies compared to non-anencephalic 
pregnancies (Honnebier and Swaab, 1973).  
 
1.6.2- Corticotropin-Releasing Hormone (CRH)  
The activation phase of pregnancy is characterised by an increase in uterotropins, 
which upregulate the expression of CAPs, which subsequently cause biochemical and 
cellular changes that prime the uterus for labour. CAPs stimulate uterine contractility 
by enhancing actin-myosin cross bridge formation, increasing MSMC excitability and 
improving cell-to cell connectivity to allow for coordinated contractions (Smith, 2007) 
(Norwitz, 1999).  A key uterotropin during the activation phase is oestrogen. 
Corticotropin releasing hormone (CRH) stimulates the synthesis of oestrogens. CRH 
is a 41 amino acid neuropeptide that is secreted by the hypothalamus and the 






Figure 1.9 – Foetal Hypothalamic- Pituitary-Adrenal-Placental Axis. Increase in 
foetal cortisol levels in the latter stages of pregnancy, stimulates the production of 
corticotropin-releasing hormone (CRH) from the syncytiotrophoblast in the placenta. 
CRH stimulates the secretion of adrenocorticotropic hormone (ACTH). Placental CRH 
also stimulates the production cortisol and dehydroepiandrosterone sulphate 
(DHEA-S) by the foetal membranes and placenta. Figure from Williams Obstetrics, 
23rd Edition, Chapter 6.  
 
The levels of free CRH in maternal system circulation and the foetal fluids increases 
with increasing gestational age (Sorem et al, 1996) (Frim et al, 1988).  In the early 
stages of pregnancy, the circulatory levels of free CRH is low as it is bound to its serum 
binding protein (CRH-BP), in the latter stages of pregnancy CRH-BP levels are reduced 
in the maternal plasma and the amniotic fluid (Linton et al, 1988) (Orth et al, 1987). 
The reduction of CRH-BP in the latter stages increases the levels of free of CRH (Florio 
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et al, 1997). CRH binds to CRH receptors, which are GPCR that are found in the 
maternal myometrium and pituitary gland and the foetal membranes, pituitary and 
adrenal glands. Activation of CRH receptors promotes uterine quiescence for most of 
the pregnancy, during the latter stages of pregnancy (activation phase) CRH receptor 
signalling promotes uterine contractility, this is thought to be partly due to changes 
in CRH receptor subtype expression. Different subtypes of the CRH receptor couple 
to different G-proteins. There is evidence to suggest that during the quiescence 
phase of pregnancy CRH activates the Gαs and the adenylyl cyclase/cAMP pathway. 
However, during labour CRH activates the Gαq and the PLC/IP3 pathway, due to 
differential expression in CRH receptor subtype (Grammatopoulos, 2007) (Beshay et 
al, 2007) (Grammatopoulos et al, 1998). CRH receptor signalling promotes the 
synthesis of dehydroepiandrosterone sulphate (DHEA-S) which is converted into the 
oestrogens: estradiol (E2) and estriol (E3).  Oestrogens bind to nuclear receptors. 
Activation of E2 receptor on the myometrium leads to increased expression of the 
CAPs such as: OTR and prostaglandin receptors (Smith et al, 1998) (Welsh et al, 2012) 





Figure 1.10 - The Key Hormones and Paracrine and Autocrine Factors Implicated in 
the Activation Phase. Corticotropin-releasing hormone (CRH), DHEAS 
dehydroepiandrosterone sulphate (DHEA-S), and spontaneous rupture of the foetal 
membranes (SROM). Figure from Norwitz et al, 1999.  
 
1.6.2- Gap Junctions  
Gap junctions are channels that span the plasma membrane of two cells, to allow for 
the passage of ions and small molecules from one cell to another (Figure 1.11).  The 
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flow of ions between adjacent cells propagates action potential firing across the 
myometrium, leading to synchronised contraction during birth (Garfield et al, 1977). 
A gap junction between two adjacent cells is formed when two connexon proteins; 
one from each cell are merged, which creates a hydrophilic open pore in the plasma 
membrane. A connexon protein is made up of 6 subunits (connexins) which assemble 
in a hexameric arrangement.  There are 21 different isoforms of connexins and the 
myometrium expresses four of them: Cx26, Cx40, Cx43 and Cx45 (Garfield et al, 1977) 




Figure 1.11 - Schematic Representation of Gap Junctions Between Adjacent 





The expression of Cx43 increases with increasing gestational age, with the highest 
levels found just prior to the onset of labour (Hendrix et al, 1992) (Chow and Lye, 
1994).  Although Cx43 is upregulated in both mice and humans prior to parturition, 
there is a difference in the mechanism of regulation between the two. In mice, during 
the quiescence phase Cx43 is directly inhibited by high levels of circulatory 
progesterone, which acts on PR to recruit the transcriptional co-repressors such as 
p54NRB, to inhibit expression of Cx43 (Ou et al, 1997) (Dong et al, 2009). During the 
activation phase a drop in circulatory progesterone and an increase in oestrogen 
leads to an increase in Cx43 expression. The promoter for the Cx43 gene in mice 
contains half palindromic oestrogen response elements (ERE) (Lye et al, 1993) 
(Petrocelli and Lye, 1993) (Kidder and Winterhager, 2015). In humans, PR represses 
expression of Cx43 by recruiting transcriptional repressors such as polypyrimidine 
tract binding protein-associated splicing factor (PSF), which recruits histone 
deacetylases (HDAC) to the Cx43 promoter (Xie et al, 2012). In contrast to mice, the 
human Cx43 gene is upregulated independently of oestrogen receptor by 
prostaglandin F2α (PGF2α) (Geimonen et al, 1998) (Xu et al, 2013). Treating human 
MSMCs with indomethacin (prostaglandin inhibitor) reduces expression of Cx43 (Xu 
et al, 2013). Therefore, in humans Cx43 expression is upregulated in the activation 
phase due to a reduction in PR transcriptional co-repressors (e.g. PSF) and an 




The significance of gap junctions for normal labour is illustrated in Cx43 knockout 
mice. Cx43 null mice experienced delayed labour compared to wildtype mice, 
however they did deliver suggesting that there is compensation for Cx43 by other 
connexins (Doring et al, 2006). The delayed labour experienced by Cx43 null mice 
shows the importance of gap junctions in allowing numerous myocytes to contract 
in concert, which produces the powerful synchronised contractions observed during 
labour.  
                                                                        
1.7- The Stimulation Phase of Parturition  
1.7.1- Cervical Ripening  
Cervical ripening occurs in the last weeks of gestation, whereby the   cervix becomes 
thin and flexible, which allows for stretching without rupture and the passage of the 
foetus during labour (Word et al, 2007). The structure of the cervix prior to cervical 
ripening is characterised by condensed highly organised collagen bundles, with 
hypertrophy and hyperplasia of cervical fibroblast and SMCs. During cervical ripening 
there is decrease in collagen concentration. The decrease in collagen is attributed to 
an increase in hydrophilic glycosaminoglycan (HA), non-collagenous proteins and 
aquaporin water channels (Straach et al, 2005) (Buhimschi et al, 2004) (Obara et al, 
2001) (Anderson et al, 2006). HA are highly polar molecular that attract water. An 
increase in HA and aquaporin channels results in increased hydration, this solubilises 
the collagen, causing dispersal and a disarrangement of the collagen fibres. HA also 
decreases the interactions between collagen and fibronectin, which causes further 
disorganisation of the collagen fibres (Timmons et al, 2010) (Word et al, 2007).   
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1.7.2- Progesterone Withdrawal  
Progesterone obstructs contractions and administering drugs that inhibit 
progesterone during pregnancy causes a termination of the pregnancy or preterm 
birth, this evidence suggest that progesterone is essential for maintaining pregnancy.  
In most mammals there is a reduction in circulating free progesterone before 
parturition.  In non-human primates (great ape and old-world monkeys) and humans, 
progesterone levels remain elevated throughout pregnancy and birth, thus there is a 
hypothesis of a “functional” withdrawal of progesterone before parturition (Csapo 
and Pinto-Dantas, 1965). Functional withdrawal of progesterone is the concept that 
progesterone sensitivity in human myometrium is lost through several diverse 
molecular pathways.  Through a combination of the loss in sensitivity to 
progesterone by the myometrium and the upregulation of CAPs, parturition is 
achieved (Brown et al, 2004).   
 
One way a functional withdrawal of progesterone can be achieved is through changes 
in PR expression in the myometrium, however the evidence for this is differing. When 
PR expression in myometrial biopsies obtained from women in labour (IL) and those 
not in labour (NIL) were compared, it showed a decrease in PR expression in biopsies 
from women IL (How et al, 1995). A study by Bernard et al, showed no change in 
myometrial PR expression, when comparing IL and NIL samples (Bernard et al, 1988). 
Conflictingly, another study illustrated that PR expression increased in the 




Changes in progesterone receptor isoform expressed in the myometrium, may be 
one method for functional progesterone withdrawal. The PR isoform expressed in 
the myometrium of the pregnant rhesus macaques is dependent on the gestational 
age; from PRB dominance in mid gestation to PRA dominance during labour (Haluska 
et al, 2002). PRA has been shown to repress PRB activated transcription. Using a 
progesterone responsive gene in a luciferase reporter assay, it was found that only 
PRB expression was able to activate transcription of the progesterone responsive 
gene. Co-expressing of PRA and PRB, inhibited PRB mediated transcriptional 
activation (Pieber et al, 2001).  The increase in PRA expression in late gestation 
leading to an inhibition of PRB mediated quiescent pathways, without the lowering 
of progesterone, is another example of “functional” progesterone withdrawal.  
 
Increasing metabolism of progesterone into inert metabolites has been proposed as 
one of the mechanisms of functional progesterone withdrawal. Both 5α-reductase 
and 20-α-hydroxysteroid dehydrogenase (20α-HSD) metabolise progesterone into 
the inactive progestin: dihydroprogesterone. One study found that the activity of 
20α-HSD increased in the amniochorion when term was reached, subsequently more 
dihydroprogesterone was detected (Mitchell and Wong, 1993). Another study also 
found increased expression of 20α-HSD in myometrium biopsies collected from 
women who were undergoing term and preterm labour, compared to women NIL 
resulting in unliganded progesterone receptors (Nadeem et al, 2016). Furthermore, 
the creation of knockout mice which lack the 5α-reductase enzyme, resulted in the 
mice failing to deliver during labour due to impaired cervical ripening, which suggest 
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that 5α-reductase is important in inhibiting progesterone signalling for successful 
parturition (Mahendroo et al, 1999).  
 
PR has numerous co-factors that aid its ability to activate or repress transcription of 
genes. Changes in co-factors can inhibit progesterone activity, without a need for a 
reduction in progesterone concentration i.e. “functional progesterone withdrawal”.  
One of the co-factors of PR is steroid hormone co-activator (SRC) (Onate et al, 1995). 
SRC has inherent histone acetyltransferase activity (HAT) in its carboxyl terminus and 
can acetylate histone 3 and 4. Acetylation of histones causes chromatin opening, 
which facilitates transcription (Spencer et al, 1997). Myometrial samples from IL have 
a reduced expression of SRC2 and SRC3 in compared to those NIL. Additionally, 
myometrial samples from women IL were found to have decreased acetylation of 
histone 3 (Condon et al, 2003).   
 
Inflammation plays a vital role in cervical ripening, foetal membrane rupturing and 
enhancing myometrial contractions. Inflammation may also play a role in functional 
progesterone withdrawal. Prior to birth, pro-inflammatory interleukins are elevated 
(Young et al, 2002). Many of the interleukins activate the transcription factor NF-κB, 
which in turn binds directly to PR and inhibits it ability to activate transcription 
(Kalkhoven et al, 1996).  Amnion cells obtained before and during labour showed that 
there was an increased activity of NF-κB during labour (Allport et al, 2001). 
Prostaglandin F2α (PGF2α) is an activator of contractions in the myometrium and a 
pro-inflammatory effector. PGF2α has been found to upregulate expression of PRA, 
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but not PRB. Therefore, PGF2α can inhibit the pro-quiescent effects of PRB, by 
enhancing the PRA induced repression of PRB (Madsen et al, 2004).  
 
1.7.3 - Role of Oxytocin in the Stimulation Phase 
Many studies have shown that oxytocin plays an extensive role in maintaining uterine 
contractions, for successful parturition. Oxytocin is synthesised in the large 
magnocellular neurones of the hypothalamus; whose axons terminate in the 
posterior pituitary gland. Oxytocin is a short neuropeptide hormone that is 
conjugated to a carrier protein (neurophysin), it is initially synthesised as an inactive 
precursor peptide and packed into secretory granules in the Golgi apparatus. The 
granules transport the precursor protein along the axon and it simultaneously 
undergoes post-translational modifications, to turn it into a mature active 
neuropeptide. Depolarisation at the nerve terminals in the pituitary gland causes 
oxytocin to be exocytosed into the blood stream (Brownstein et al, 1980).   
 
There is overwhelming evidence indicating that oxytocin plays a role in parturition, 
there is more evidence to suggest that oxytocin is involved in the expulsion phase of 
labour rather than initiation of labour (Blanks and Thornton, 2003). Oxytocin 
secretion is pulsatile and is peaks with the expulsion of the foetus.  In sheep, cow and 
rhesus monkey, maximal concentration of oxytocin is detected at birth (Glatz et al, 
1981) (Landgraf et al, 1983) (Hirst et al, 1993). In the rat, large pulses of oxytocin are 
secreted when each pup is expelled (Higuchi et al, 1986). Therefore, there is 
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considerable evidence showing that oxytocin is important for the expulsion of the 
foetus.  
 
Studies in humans have shown widespread differences in measured oxytocin levels 
before and during labour. The discrepancies can be ascribed to the difficulty in 
measuring oxytocin levels, as oxytocin is released in short pulses. (Blanks and 
Thornton, 2003).  However, a study by Fuchs et al was able to overcome the 
difficulties in measuring oxytocin release in humans, and they found oxytocin levels 
in the blood was higher in women undergoing spontaneous labour compared to non-
labouring women. Oxytocin was found to be released into the blood stream in 
discrete pulses that had a short duration.  The frequency of the pulses increased 
during labour (Fuchs et al, 1991). Despite the increase in secreted oxytocin during 
labour, oxytocin knockout mice experience normal deliveries. Although, the offspring 
from the oxytocin null mice die, but this is because of the inability of the mother to 
lactate. Therefore, in mice oxytocin is vital for lactation but not for parturition 
(Nishimori et al, 1996) (Young et al, 1996). Nonetheless, there is a lot of evidence 
that oxytocin does play a role in parturition and due to this role, the oxytocin receptor 
(OTR) is tightly regulated during pregnancy (Blanks et al, 2007) In mice and rats the 
OTR promoter has a full ERE site, the human OTR promoter contains three half 
palindromic ERE sites (Kubota et al, 1996) (Bale and Dorsa, 1997) (Inoue et al, 1994). 
Treatment of ovariectomized rats with oestrogen increases expression of OTR and 
strengthens binding of oxytocin to OTR (Larcher et al, 1995). PR antagonist (RU-486) 




The oxytocin receptor is a GPCR that is coupled to Gαq. Activation of Gαq coupled GPCR 
stimulates contraction in smooth muscle cells by increasing intracellular calcium 
concentrations. There is also some evidence that oxytocin increases inward current 
of L-VOCC, external removal of calcium decreases oxytocin induced rise in 
intracellular calcium concentrations (Arnaudeau et al, 1994). The effects of oxytocin 
on L-VOCC may explain why oxytocin augments the plateau element of the complex 
AP in the human myometrium (Nakao et al, 1997) (Kawarabayashi et al, 1986). 
Oxytocin is also involved in calcium sensitisation by activation the G12/13/rhoA/ROCK 
pathway (Somlyo and Somlyo, 2000). Inhibition of ROCK reduces the force measured 
in rat myometrium after treatment with oxytocin (Mckillen et al, 1999) (Tahara et al, 
2002). Oxytocin also causes transcriptional changes by activating the MAPK pathway, 
and this may lead to an increase in cyclo-oxygenase (COX-2) activity, which 
subsequently causes an increase in PGF2α production (Figure 1.12) (Kim et al, 2015). 
In summary, the role of oxytocin/OTR in the uterus is not to initiate parturition but 
to aid parturition during the stimulation phase, by increasing the frequency and force 










Figure 1.12 - Oxytocin Mediated Pathways Leading to Contraction in the 
MSMC.  Red pathways indicate signalling pathways with direct influences on [Ca]I, 
whereas purple and turquoise lines indicate Ca2+‐independent pathways to 
contraction, including Ca2+sensitisation (purple lines) and the production of 
prostaglandins (turquoise pathways). Dotted lines indicate where mechanisms are 
not yet fully determined. Abbreviations: COX‐2, cyclooxygenase‐2; ROC, Receptor 
operated channel; VOCC, voltage operated Ca2+ channel; LTCC, L‐type Ca2+ channel; 
TRP, transient receptor potential channel; Ca2+‐CaM, Ca2+‐calmodulin complex; ERK, 
extracellular signal‐regulated protein kinase; SOCE, store‐operated Ca2+ entry. Figure 
from Arrowsmith and Wray, 2014 
 
 
1.7.4- Role of Prostaglandins in the Stimulation Phase  
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Prostaglandins (PG) are significant regulators of parturition, and are involved in 
membrane rupture, cervical ripening and myometrial contractions. Prostaglandins 
are synthesised in the amnion, chorion and the decidua from membrane 
phospholipids. Phospholipase A2 (PLA2) converts membrane phospholipids into 
arachidonic acid (AA), which is then converted into prostaglandin H2 (PGH2), by the 
enzyme COX-2.   PGH2 can then be converted into various eicosanoids including 
prostaglandins by prostaglandin synthases (PGE2, PGD2 and PGF2α  synthases ) (Gibb, 
1998). COX-1, PLA2 and PGF2α receptor null mice all fail to undergo labour due to a 
failure in luteolysis and progesterone withdrawal, this shows the importance of PG 
in initiating labour in mice (Uozumi et al, 1997) (Sugimoto et al, 1997) (Langenbach 
et al, 1995). Women who fail to initiate labour and were induced with oxytocin 
showed a decrease in expression of PLA2 in their myometrium compared to women 
who underwent spontaneous labour, this shows the importance of prostaglandins in 
the activation of contraction (MacIntyre et al, 2009).  
 
Prostaglandin contributes to the pathway to parturition and with increasing 
gestational duration there is an increase in prostaglandin concentration in the 
myometrium of rats (Gu et al, 1990) and the amnion of Rhesus monkeys (Walsh et 
al, 1984). Additionally, in humans, PG concentration rises in amniotic fluid prior to 
the onset of labour (Romero et al, 1996). The increase in prostaglandin levels is 
thought to be due to an increase in COX-1 expression (Mijovic et al, 1997) and a 
reduction in 15-hydroxyprostaglandin dehydrogenase (PGDH) activity, during labour 
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(Giannoulias et al, 2002) (Johnson et al, 2004).  PGDH is an enzyme that metabolises 
prostaglandins, so a reduction on PGDH leads to an increase in prostaglandins.  
 
Prostaglandins bind to GPCR receptors expressed in MSMCs. The PGF2α and PGE2 
isoforms of prostaglandin bind to the receptors EP1/EP3 and FP, respectively and 
activation of these receptors causes the human myometrium to contract (Senior et 
al, 1998). The molecular mechanism by which prostaglandins can cause myometrial 
contraction is similar to the mechanism employed by oxytocin, as prostaglandin 
receptors are coupled to Gαq, and activate phospholipase C.  Moreover, PGF2α is able 
to regulate transcription in the myometrium, by upregulating the transcription of pro 
contractile genes such as: COX-1, OTR and Cx43 (Xu et al, 2013).   
 
1.8- Phospholipase C Like 1: Structure, Function and Possible Role in 
Uterine Quiescence  
1.8.1 - PLCL-1: Discovery, Structure and Binding Partners 
Phospholipase C like 1 was first discovered as a novel IP3 binding protein. Kanematsu 
et al, used an IP3 affinity column to look for binding partners of IP3 in rat brain cytosol. 
Two binding partners of IP3 were discovered, an 85kDa and a 130kDa protein. Amino 
acid sequencing revealed that the 85kDa protein was the δ1-isomer of phospholipase 
C (PLC-δ1), and that the 130kDa was an unidentified novel protein that was named 
p130 (Kanematsu et al, 1992).  
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DNA sequencing of p130 found that it had significant sequence homology with PLC-
δ1. The pleckstrin homology (PH) domain and the catalytic X and Y domain of PLC-δ1 
were found to have 35.2%, 48.2% and 45.8% homologies with the corresponding 
domains in p130, respectively. P130 was then cloned into COS-1 cells and was again 
found to bind to IP3 using an affinity column. As p130 had significant structural 
similarities with the catalytic domains of PLC-δ1 and it was able to bind to IP3, the 
ability of p130 to hydrolyse PIP2 into DAG and IP3 was examined. It was found that 
p130 had no catalytic capabilities. Due to the structural similarities between p130 
and PLC-δ1 and the catalytic inactivity of p130, p130 was renamed phospholipase C-
related, but catalytically inactive protein 1 (PRIP-1), it is also known as phospholipase 
c like 1 (PLCL-1) (Kanematsu et al, 1996).  
 
Northern blot analysis of tissues from rat showed that the highest expression of PLCL-
1 mRNA to be in the cerebellum and cerebrum followed by the kidney, lung and 
spleen, in this order. There was significantly less PLCL-1 mRNA observed in the heart, 
liver or skeletal muscle. Using situ hybridisation, it was shown that in the cerebellum, 
the PLCL-1 mRNA was found in the granular cell and Purkinje cell layers, and 
cerebellar nuclei. In the cerebrum, the PLCL-1 mRNA expression was concentrated in 
hippocampal pyramidal cells, dentate granule cells and pyramidal and/or granule 
cells of the cerebral cortex (Matsuda et al, 1998).  
 
Using protein trypsinisation and SDS/PAGE analysis; the different domains present in 
PLCL-1 were elucidated. Trypsin treatment of PLCL-1, discovered 4 major polypeptide 
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bands of the sizes: 55, 33 and 25kDa and a minor band at 48kDa. With increasing 
trypsinisation time a new band at 40kDa appeared and the three major bands 
disappeared, apart from the band at 25kDa. The trypsinisation pattern of PLCL-1 was 
found to be very similar to PLC-δ1, suggesting that the two proteins have similar 
domains presents. The major difference between the two proteins, apart from the 
lack of catalytic activity of PLCL-1, was the unique 25kDa polypeptide present in the 
C terminus of PLCL-1. The 25kDa polypeptide was found to be resistant to cleavage 
and rigid in structure, and this domain was termed the D domain (Kanematsu et al, 






Figure 1.13 - Schematic Representation of the Differences in Structure Between 
PLCL-1 and PLC-δ and the Domains Present in Each Protein. Abbreviations: PH 
(Pleckstrin domain).  
 
The four amino acids: His311, His356, Asp343 and Glu390 in the X domain of PLC‐δ1 
are crucial for its catalytic activity as they function as stabiliser amino acids for a 
calcium–substrate complex (Essen et al, 1996). Two of these four amino acids, His356 
and Glu390 in PLC‐δ1, are not conserved in PLCL-1 and are substituted by asparagine 
and glycine, respectively, and this may explain the lack of catalytic activity of PLCL-1 
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(Kanematsu et al, 2001). Apart from IP3, there are 6 other binding partners of PLCL-1 
and they include: phosphatase 1c (PP1c), phosphatase 2A (PP2ac), Akt, syntaxin 







Figure 1.14 - The Known Binding Partners of PLCL-1. 
 
1.8.2 - PLCL-1: Possible Role in Reproduction 
PLCL-2 is an isomer of PLCL-1, that was discovered to also be able to bind to IP3 but 
display no catalytic PLC activity (Otsuki et al, 1999). Matsuda et al, created transgenic 
double knockout mice whereby the genes for PLCL-1 and PLCL-2 were knocked out.  
When transgenic male and female mice were cross bred together, it was observed 
that they had reduced number of pups and longer intervals between litter events, 
compared to wild type mice. This observation was the first to signify that PLCL-
1/PLCL-2 might play a role in reproduction. Following on from the initial observation, 
the reproductive organs of the transgenic mice were examined. The only difference 
perceived between the organs of wild type and transgenic mice, was found in the 
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uterus (Figure 1.15). The uteri of the transgenic mice were smaller than wild type, 










Figure 1.15 - Wet weights of WT and Knockout Mice Reproductive Organs. Bodies 
(A) were weighed, and pituitary gland (B), testis (C), ovary (D), and uterus (E). Figure 
from Matsuda et al, 2009.  
 
To further characterise the reproductive physiology of the transgenic mice; the 
oestrous cycle was studied, from vaginal smears. Knockout mice had longer oestrus 
days compared to wild type, and this indicated dysfunction in gonadotropin levels of 
the knockout mice. The knockout mice had a higher basal level of both LH and FSH in 
their plasma compared to wild type mice (Figure 1.16). Elevated LH/FSH levels could 
potentially influence progesterone and oestrogen levels. Serum progesterone was 
significantly lower in knockout mice compared to wild type, but no change was seen 












                                                                                                                                 
Figure 1.16 - Blood Levels of LH and FSH in Wild Type and Knockout Mice. (A) LH 
levels, (B) FSH levels of 5 mice. Different colours represent measurements from the 
different mice. Figure from Matsuda et al, 2009.  
 
1.8.3 - PLCL-1: Possible Role in Calcium Signalling and Maintaining Uterine 
Quiescence  
Since PLCL-1 binds to IP3, and IP3 releases intracellular calcium from the ER; the 
possible role PLCL-1 may play in the regulation of calcium concentration was 
investigated. Increasing concentrations of IP3 added to COS-1 cells, caused an 
equivalent surge in intracellular calcium concentrations.  However, IP3 mediated 
release of calcium was reduced when the PH domain of PLCL-1 was overexpressed. 
Full length PLCL-1 was also able to decrease release of calcium from intracellular 
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stores. Bradykinin activates PLC and causes an increase in cytosolic calcium levels. 
PLCL-1 overexpression dampened bradykinin induced increase in intracellular 
calcium concentrations; this experiment was done in the absence of any external 
calcium, suggesting the PLCL-1 effects are on intracellular calcium stores (Takeuchi 
et al, 2000). Knocking out PLCL-1 in mice neuronal cells causes an increase in IP3 
mediated calcium release ( Harada et al, 2005).   
 
PLCL-1 was found to be a progesterone responsive gene in human endometrial 
stromal cell (HESC). Treating cells with progesterone analogue: 
medroxyprogesterone acetate (MPA) in conjunction with cAMP, increased 
expression of PLCL-1, both at the mRNA and protein level. PLCL-1 knockdown 
decreased intracellular calcium levels in HESCs (Muter et al, 2016).  
 
Myometrial strips were collected from women who either in labour (IL) or not in 
labour (NIL), thereafter, high-thorough put RNA sequencing was done on extracted 
RNA. PLCL-1 mRNA was found to be significantly down-regulated in women who 
were IL compared to those that were NIL (Chan et al, 2014) (Sharp et al, 2016). The 
results from the RNA sequencing coupled with the fact that PLCL-1 is a progesterone 
responsive gene and that PLCL-1 decreases intracellular calcium concentration, 
signals that PLCL-1 may play role in maintaining uterine quiescence (Muter et al, 
2016) (Harada et al, 2005).  There is also evidence showing a reduction in PLCL-1 




The hypothesis of this thesis is that PLCL-1 is downregulated in the labouring 
myometrium because it is a pro-quiescent protein. The overall aim of this thesis is to 
understand the function of PLCL-1, the mechanism in which it acts as a pro-quiescent 
protein and can PLCL-1 be used as a future tocolytic target or as a biochemical marker 
for a preterm diagnostic test.  Calcium imaging will be used to see if PLCL-1 has a 
similar effect on intracellular calcium concentrations in MSMC as it does in COS-1 
cells, neuronal cells and HESCs. As changes in calcium have been shown to effect 
transcription; using RNA-sequencing, the effect of PLCL-1 on the transcriptome of 
MSMCs can be explored and identify if PLCL-1 affects transcription of pro-quiescent 
genes and CAPs. One explanation for PLCL-1 being downregulated in the 
myometrium is that it is an effector protein for progesterone. RT-PCR, western 
blotting, and ChIP-qPCR will be used to see if PLCL-1 is a progesterone responsive 
gene. Finally, PLCL-1 might be downregulated not just in the labouring myometrium, 
but also in the maternal systemic circulation. Collecting blood samples from women 
IL and NIL will show if there is a universal downregulation of PLCL-1 during labour, 
this will highlight if PLCL-1 is a potential biochemical marker for a reliable preterm 













Chapter 2  











2.1 - Antibodies  
Table 2.1 - Antibodies 
 
2.2 – siRNAs and Vectors 
Table 2.2- siRNA and Vectors 
 
Antibody Dilution Manufacturer 
PLCL-1 1:1000 Sigma 
β-Actin  1:5000 Sigma 
Desmin 1:100 Abcam 
Vimentin 1:100 Dako 




Anti-mouse Alexa Fluor 
488 
1:200 Thermofisher 
Anti rabbit Alexa Fluor 
488 
1:200 Thermofisher 
PDE7B 1:1000 Abcam 
Anti-rabbit HRP 1:5000 Dako 
Anti-mouse HRP 1:5000 Dako 
Anti-goat HRP  1:5000 Dako 
CTCF 2µg/per sample Merck Millipore 
IgG 2µg/per sample Merck Millipore 
ZNF143 2µg/per sample Abcam 
YY1 2µg/per sample Abcam 
Description  Manufacturer 
siControl: ON-TARGET plus Non-








MGC Human PLCL-1 Full sequence 







2.3 – Primers 
Table 2.3 - Primers 
 
 
2.4 – Kits 
Table 2.4 - Kits 
 
Gene Forward Reverse 
PLCL-1 GCAGCAGCATCATCAAGG GCTGCTGAAAGACACGGTT 
L19 GCGGAAGGGTACAGCCAAT GCAGCCGGCGCAAA 
OTR GGGGAGTCAACTTTAGGTTCG GAATCCTCTACCGGCCACAA 
FP GGAGCCCATTTCTGGTTACAA GATTCCATGTTGCCATTCGGA 
Desmin TTCTTCCATCCCAGGACACC GATGGGCTATGTCGCTGTTG 
Vimentin AAGGAGGAAATGGCTCGTCA AGCTTCCTGTAGGTGGCAAT 
CACNA1C GAAGATGACTGCTTATGGGG AGCAGGTCCAGGATGTTGAA 
PDE7B TCCTGGATGAAGTTGCTGGAT AATGCCGTGAAATCTCTGAGC 
PDE2A AGGACGCCTTGCTGAGTCT TAGACAGTTTCCACTCGGGG 
PDE3A GGCCAAGAGGATCACAGTCTT TGGAAGAGAAGGGTCTGCC 
WNT5A CAGACGTTTCGGCTACAGAC CCCAGTTCATTCACACCACA 
PAQR5 ACCTACTGGCCTTGCCAATC TTGCTCATGGAACACCTGGG 
CACNA1H CACTTTCCCCAGCCCAGA CACAGCGAGTGAATGGAGC 
WNT7B CACAGAAACTTTCGCAAGTGGA ATGACAGTGCTCCGAGCTTCA 
EFHD1 CCGTACTGTCCCTGTGAAGG CCAGCGTCATACTGCAACTC 
ChIP-qPCR ACCAGAGGTCACTGCTACTCT TGGGCTACAACCAGCCAGA 
Kit Manufacturer 
QuantiTect Reverse Transcription Kit Qiagen, Germany 
QIAquick Gel Extraction Kit Qiagen, Germany 
QIAquick PCR Purification Kit Qiagen, Germany 
PAXgene Blood RNA Kit IVD Qiagen, Germany 
QIAamp ccfDNA/RNA Kit Qiagen, Germany 
cAMP assay kits Cisbio, France 
Basic Nucleofector Kit for Primary 
Mammalian Smooth Muscle Cells 
Lonza, Germany 
Human Phospho-MAPK Array Kit R&D Systems 
GeneJet Endo-free Plasmid maxiprep 
kit  
Thermo Scientific, Lithuania 
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2.5 – Chemical Reagents  
Table 2.5 – Chemical Reagents  
Product Manufacturer  
2-[(2-Hydroxy-1,1-
bis(hydroxymethyl)ethyl)amino]ethanesulfonic 
acid (TES)  
Sigma Aldrich, USA 




Sigma Aldrich, USA 
Ammonium Persulphate (APS)  Thermofisher, USA 
Boric Acid Thermofisher, USA 
Calcium Chloride (CaCl2)  Sigma Aldrich, USA 
Chloroform Sigma Aldrich, USA 
Dimethyl sulfoxide (DMSO) Life Technologies, USA 
Ethidium Bromide Sigma Aldrich, USA 
Ethylenediaminetetraacetic acid (EDTA) Sigma Aldrich, USA 
Glycine Sigma Aldrich, USA 
Isopropanol  Sigma Aldrich, USA 
Lithium Cholride (LiCl)  Sigma Aldrich, USA 
Magnesium Chloride (MgCl2) Sigma Aldrich, USA 
Magnesium Sulphate (MgSO4) Sigma Aldrich, USA 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 
Sigma Aldrich, USA 
NP-40  Thermofisher, USA 
Pluronic Acid Sigma Aldrich, USA 




2.6 – Miscellaneous Materials  
Table 2.6 – Miscellaneous Materials  
Product Manufacturer  
Halt protease cocktail inhibitor Thermofisher, USA 
Phosphatase Inhibitor Cocktail 2  Sigma Aldrich, USA 
Phosphatase Inhibitor Cocktail 3  Sigma Aldrich, USA 
Collagenase Type IV  Life Technologies, USA 
DMEM (High Glucose/Glutamax) Life Technologies, Paisley Scotland 
Penicillin/Streptomycin  Thermofisher, USA 
Foetal Bovine Serum Hyclone, South America 
Trypsin/EDTA (0.25%)  Life Technologies, Paisley Scotland 
Potassium phosphate monobasic 
( KH2PO4) 
Sigma Aldrich, USA 
Sodium Bicarbonate  (NaHCO3) Sigma Aldrich, USA 
Sodium butyrate Sigma Aldrich, USA 
Sodium Chloride (NaCl) Sigma Aldrich, USA 
Sodium Deoxycholate Sigma Aldrich, USA 
Sodium dodecyl sulfate (SDS)  Sigma Aldrich, USA 
STAT-60 Amsbio, UK 
Tris Sigma Aldrich, USA 
Triton X-100 Sigma Aldrich, USA 
Tween 20  Sigma Aldrich, USA 
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Lonza’s Basic Nucleofector Solution for 
Mammalian smooth muscle cells 
Lonza, Germany 
Ampicillin  Sigma Aldrich, China  
LB powder  Sigma Aldrich, USA 
Agarose Powder  Life Technologies, USA 
Sybr-green Master Mix Thermofisher, USA 
Loading dye  Thermofisher, Lithuania  
Bovine Serum Albumins (BSA) Sigma Aldrich, USA  
Bradford Reagent Sigma Aldrich, USA 
Ripa Lysis Buffer  Millipore, USA 
mini protease inhibitor tablet Roche, Germany 
phosphatase inhibitor cocktail Sigma Aldrich, USA 
Nupage Sample Buffer  Life Technologies, USA 
DTT Sigma Aldrich, Switzerland 
Nitrocellulose Membrane Amersham, Germany 
Milk Block Powder  Bio-Rad, UK 
ECL Detection Reagent Amersham, Germany 
25 mm coverslips VWR, Germany 
Indo-1-AM  Life Technologies, USA 
Fluo4-am Life Technologies, USA 
Goat Serum Sigma Aldrich, USA 
VECTASHIELD® Antifade Mounting 
Medium with DAPI 
Vector, USA 
Glass Slides VWR,USA 
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Nuclease Free Water Life Technologies, Netherlands 
Bioruptor Picotubes Diagnode 
Lobind Tube Eppendorf, Germany 
Protein A/G Beads  Thermofisher, USA 
DynaMag Thermofisher 
Proteinase K  Life Technologies, Netherlands 
PAXgene Blood RNA Tubes BD Bioscience, UK 
BD Vacutainer Venous Blood Collection 
Tubes 














2.7 – Criteria for Collecting Myometrial Biopsies  
Myometrial biopsies for women NIL were taken from an incision of the midline from 
elective caesareans from full term women (≥37 weeks) before the onset of labour. 
The medical indications for the elective caesareans were due to: placenta previa, 
malpresentations and more than one previous history of a caesarean. There were 
also biopsies taken from elective caesareans for non-medical reasons due to 
maternal wish. Emergency caesareans due to a failure to progress were excluded. 
Any patient that was given oxytocin was excluded.  
Myometrial biopsies from labouring women were undergoing caesareans for reasons 
of undiagnosed breech or large baby/cephalopelvic disproportion. Labour was 
defined as regular contractions (<3 min apart), membrane rupture, and cervical 
dilatation (>2 cm) with no augmentation.  
 
2.8 - Cell Culturing  
Myometrial biopsies from an incision of the midline at caesarean section undertaken 
for clinical reasons. Biopsies were stored in 15ml Krebs buffer (133mM NaCl, 4.7mM 
KCL, 11.1mM, 1.2mM MgSO4, 1.2mM KH2PO4, 10mM TES and 2.5mM CaCl2). 40mg 
of collagenase type IV was added to 20ml of DMEM, which contained 1% 
penicillin/streptomycin. The blood vessels were removed, and the biopsy was cut up 
using a scalpel for 15 minutes. The biopsy   was then placed in 20ml DMEM media 
and incubated in a shaking water bath for 3 hours at 37○C. The sample was then 
centrifuged at 215 x g for 3 minutes. The supernatant was removed, and the pellet 
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was resuspended in 20ml PBS buffer, the sample was centrifuged at 215 x g for 3 
minutes. The supernatant was removed, and the pellet was resuspended in 20ml PBS 
buffer, the sample was then centrifuged at 215 x g for 3 minutes. The sample was 
then resuspended in 25ml standard DMEM, which contained 1% 
penicillin/streptomycin and 10% foetal bovine serum. The primary myometrium cells 
were grown in 37○C and 5% CO2, the cells were not used after passage 4.   
 
2.9 - Cell Transfection-Electroporation 
Primary MSMCs were grown until 70% confluency. Media was removed from primary 
myometrium cells and washed twice with 15ml PBS buffer. The PBS buffer was 
discarded and 5ml of 0.25% trypsin/EDTA was added to the cells. The cells were 
incubated for 5 minutes in 37○C and 5% CO2. 10ml of DMEM media was added to 
detached cells and centrifuged at 215 x g for 5 minutes. The supernatant was 
removed, and the pellet was resuspended in 15ml of DMEM media, the number of 
cells/ml were counted using Luna automated cell counter. For each transfection 1 
x106 cells per ml were used, the cells were then spun at 215 x g for 5 minutes. The 
supernatant was removed, and the cells were resuspended in 100µl of Lonza’s Basic 
Nucleofector Solution for Mammalian smooth muscle cells.  200nM of siControl or 
siPLCL1 or 1µg of PLCL1 plasmid DNA was added the cells. The mixture was then 
placed in an Amaxa cuvette and then inserted into the Amaxa machine (Nucleofector 
2b Device), an electric field was applied to the cells using the A-023 Amaxa 
programme. 1ml of DMEM media was added to the cuvette. The transfected cells 
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were then split into 4 wells of a 6 well plate, 2ml of DMEM media was added to each 
well. Cells were grown for 48 hours post-transfection and then harvested.  
 
2.10 - Plasmid Extraction from Transformed Cells 
Glycerol stock of transformed E.coli with PLCL-1 plasmid DNA was thawed at room 
temperature. 100µg/ml of ampicillin was added to 250ml of LB broth. 1ml of 
transformed E.coli was added to 250ml of LB broth. E.coli cells were then grown 
overnight at 37○C in a shaking rotor. To extract the PLCL-1 DNA plasmid from the cells 
the GeneJet Endo-free Plasmid maxiprep kit’s manual procedure was followed. The 
cells were centrifuged for 10 minutes at 4000 x g and the pellet was resuspended in 
7ml resuspension solution containing 40µl of RNAse solution. 7ml of lysis solution 
was added to the mixture and it was mixed gently until the solution became clear. 
The mixture was then incubated at room temperature for 3 minutes. 7ml of 
neutralisation solution was added to mixture and then mixed gently. 1ml of 
endotoxin solution was added and mixed gently and thoroughly, the mixture was 
incubated at room temperature for 10 minutes. 4ml of isopropanol was added to the 
mixture and mixed gently. The mixture was centrifuged at 4000 x g for 20 minutes. 
The supernatant was transferred to GeneJet Maxi Endo-free Filtration Column. The 
column was centrifuged at 500 x g for 2 minutes. The column was discarded and the 
8ml of isopropanol was added to the flow through and mixed gently. The mixture 
was then transferred to another filtration column and was centrifuged at 3000 x g for 
3 minutes, this was then repeated to process any remaining lysate through the 
filtration column. The flow through was discarded and the column was placed back 
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into the same collection tube. 25ml of isopropanol was added to 75ml of wash 
solution I, 8 ml of wash solution was then added to the filtration column. The column 
was then centrifuged at 3000 x g for 2 minutes, the flow through was discarded and 
the column placed back into the same collection tube. 125ml of ethanol (100%) was 
added to 75ml of wash solution II, 16ml of wash solution II was added to the filtration 
column and centrifuged at 3000 x g for 2 minutes. The flow through was discarded 
the column was placed back into the same collection tube. The column was 
centrifuged at 3000 x g for 5 minutes, the collection tube was discarded and the 
column was transferred to a new collection tube. 1ml of elution buffer was added to 
the centre of the column and was incubated at room temperature for 2 minutes. The 
column was centrifuged at 3000 x g for 5 minutes to elute the plasmid DNA.  The 
column was discarded and the flow through containing the purified plasmid DNA was 
stored at -20○C.  
 
2.11 - 1% Agarose Gel Preparation  
1g of agarose powder was added to 100ml of 1X TBE buffer (0.1M TRIS, 0.1M Boric 
Acid, 2.5mM EDTA, pH 8.0). The mixture was heated up until all the agarose powder 
solubilised. The mixture was incubated at room temperature for 30 minutes and 
thereafter 2µl of ethidium bromide was added. The mixture was placed in a gel 





2.12 - Primer Optimisation 
Primers were chosen using Primer-Blast NCBI. 19µl of Sybr green master mix 
containing 20µM of reverse and forward primers were added to each well, in a 96 
well plate. 1µl of cDNA or nuclease free water was added to each well. The above 
steps were repeated twice more, creating triplicate repeats for each primer set. The 
triplicate samples were pooled together and loading dye was added. The samples 
were run on 1% agarose gel for 45 minutes at 100V. The DNA was visualised on the 
gel using UV light. The DNA was removed from the gel using Qiagen gel extraction 
kit. The purified DNA was then in succession diluted from 100pg/µl to 10ag/µl with a  
10-fold dilution factor in nuclease free water. The diluted samples were amplified 
using qPCR. The log of the concentrations were plotted against the CT values and the 
primer efficiency was calculated using the equation: Primer efficiency = 10 (-
1/gradient of the line).   
 
2.13 - Qiagen Gel Extraction Kit 
DNA was removed from the gel using a scalpel. The gel was weighed and 3x 
volumes/per 1x volume of buffer QG was added. The gel was incubated in a heat 
block set at 55°C for 10 minutes. 1x gel volume of isopropanol was added and the 
mixture was placed in column and centrifuged at 16000 x g for 1 minute. The flow 
through was discarded and 750µl of buffer PE was added to the column. The column 
was centrifuged at 16000 x g for 1 minute and the flow through was discarded. The 
column was placed in a nuclease free 1.5ml microcentrifuge tube and 50µl of buffer 
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EB was added to the centre of the column. To elute the purified DNA , the column 
was centrifuged at 16000 x g for 1 minute.  
 
2.14 - RNA Extraction  
The culture media was removed and the cells washed twice with PBS. 200µl of stat-
60 was added to each well in a 6 well plate. The cells were scraped thoroughly into 
1.5ml nuclease free Eppendorf tube. The samples were kept on ice throughout the 
RNA extraction procedure and all centrifugation was done at 4○C. 20% of the total 
volume of ice-cold chloroform was added to the each sample and vortexed 
vigorously. The samples were then centrifuged at 16000 x g for 30 minutes. The top 
aqueous phase was then transferred to a new nuclease free Eppendorf tube and 
100µl of ice-cold isopropanol was added to each sample.  The samples were vortexed 
thoroughly and stored at -80○C for 30 minutes. The samples were thawed on ice and 
centrifuged at 16000 x g for 15 minutes. The supernatant was discarded and the 
pellet resuspended in 500µl of ice-cold 75% ethanol. The samples were centrifuged 
at 16000 x g for 15 minutes.  The supernatant was discarded and the pellet 
resuspended in 500µl of ice-cold 75% ethanol. The samples were centrifuged at 
16000 x g for 15 minutes. The supernatant was discarded and the pellet was air dried 
for 7-10 minutes, the pellet containing the RNA was resuspended in 30µl of nuclease 
free water. The total RNA concentration was verified by pipetting 1.5µl of sample on 




2.15 - cDNA Synthesis for RT-PCR  
Samples containing extracted total RNA were thawed on ice. The QuantiTect Reverse 
Transcription Kit manual procedure was followed to make cDNA from total RNA. For 
each sample:  1µg of total RNA was added to 2µl of gDNA wipeout buffer, and the 
total volume was made up to 14µl, using RNAse free water.  The gDNA wipeout buffer 
removed any genomic DNA from the sample. The samples were mixed gently and 
incubated at 42○C for 2 minutes and then placed back on ice immediately. A master 
mix was created containing 4µl of Quantiscript RT buffer, 1µl RT primer mix and 1µl 
of Quantiscript Reverse transcriptase for each sample. 6µl of the master mix was 
added to each sample, thus making the total volume of each sample 20µl. The 
samples were incubated at 42○C for 30 minutes and thereafter incubated at 95○C for 
3 minutes to inactivate the Reverse Transcriptase. The samples were then either 
stored at -20○C or used for RT-PCR immediately.  
 
2.16 - RT-PCR 
19µl RT-PCR master mix 20µl (10 µl Sybrgreen, 0.3 µl forward primer, 0.3 µl reverse 
primer, 8.4 µl nuclease free water) was added to each well of a 96 well PCR plate. 
The cDNA samples were thawed on ice and diluted by adding 30µl of nuclease free 
water. 1µl of diluted cDNA was added to each well of the PCR plate making the total 
volume in each well 20µl and the total cDNA in each well 20ng. The plate was sealed 
and then centrifuged at 160 x g for 3 minutes and thereafter placed in the PCR 
machine.  The thermocycling conditions were:   i) 50°C , 2 minutes ii) 95°C , 10 
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minutes iii) 95°C,  15 seconds iv) 60°C ,1 minute for 40 cycles. The PCR results were 
analysed using the delta delta CT method, with each sample being adjusted to the 
corresponding CT values from the housekeeper gene (L19). The test samples were 
normalised to the control samples to calculate the expression fold change between 
control samples and test samples.  
 
2.17 - HiSeq Sequencing and Sample Preparation  
Primary myometrium cells at passages 1-3 were transfected with either siControl or 
siPLCL-1 (Section 2.9) for 48 hours and then harvested. The RNA was then extracted 
(Section 2.14). The RNA was then quantified using a Nanodrop spectrophotometer, 
1µg/µl of the RNA was then converted into cDNA (Section 2.15) and used in RT-PCR 
and the rest stored in -80○C. 1.5µl of the total RNA was taken for purity analyses using 
a 2100 Bioanalyzer (Agilent Technologies). 1µg of total RNA for each sample was then 
processed for TruSeq Stranded mRNA library preparation. 
 
2.18 - Measuring Protein Concentration  
A working solution of BSA was made by diluting the stock solution (10mg/ml) 100-
fold in distilled water. 8 standards were made by diluting the working solution of BSA 
from 10µg/ml to 0µg/ml to a total volume of 500µl. The protein lysates were diluted 
20-fold to a total volume of 500µl using distilled water. 500µl of Bradford reagent 
was added to each  test sample and the standards. The mixtures were incubated at 
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room temperature for 15 minutes. 200µl of the mixture was loaded in triplicate into 
a well in a 96 well plate end the absorbance was read at 595nm using PHERAstar Fs 
plate reader. The mean OD from each sample was calculated and the mean OD of the 
standards were plotted against the concentration for a standard curve. A linear 
trendline was plotted from the standard curve. The unknown protein concentrations 
were calculated from the linear line using the equation y=mx + c. The final 
concentration was calculated using the equation: concentration x dilution factor.  
 
2.19 - Western Blot Analysis  
Primary myometrium cells were grown in a 6 well plate at 37⁰C and 5% CO2 and 
transfected with either DNA or siRNA for 48 hours. The cells were washed with PBS 
twice. 1X Ripa lysis buffer was made by diluting 10x Ripa lysis buffer 10-fold in 
deionised water and adding one complete mini protease inhibitor tablet and 100µl 
of phosphatase inhibitor cocktail. The cells were lysed using 200µl of 1x Ripa lysis for 
each well in a 6 well plate. The lysates were stored at -20○C. 50µg/60µl of total 
protein was added to 25µl of Nupage sample buffer and 10µl of DTT.  The samples 
were then incubated in 95○C for 5 minutes. A 10% gel (3.25ml 30% acrylamide/bis 
solution, 2.5ml  1.5M TRIS-HCL pH 8.8, 4ml H2O, 100µl 10% SDS, 125µl 10% APS, 5µl 
TEMED) was made in a 0.75mm spacer; isopropanol was added before gel 
polymerisation. After polymerisation, the isopropanol was discarded and stacking gel 
(1ml 30% acrylamide protogel,1.5ml 0.5M TRIS-HCL pH 6.8,3.4ml H2O, 60µl 10% SDS, 
80µl 10% APS,5µl TEMED)  was added, and then a comb placed before the stacking 
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gel polymerised. 1X running buffer was made by mixing 100ml of 10x running buffer 
(1litre; 250mM Tris Base, 1.9 M Glycine, 1 % SDS) with 900ml of H2O. 30µl of each 
sample was then run down the 10% gel for ~1¼ hour at 150 volts in ∼1 litre of 1X 
running buffer. One litre of 10X transfer buffer (250mM Tris, 1.9M Glycine) was 
made. 1X transfer buffer was made by adding 100ml of 10X transfer buffer to 200ml 
of methanol and 700ml of H2O. The gel was transferred on to a nitrocellulose 
membrane at ∼10 volts for 2¾ hours in ∼1 litre of ice-cold transfer buffer. The gel 
was discarded, and the membrane was blocked for one hour in 25ml of blocking 
buffer (5% milk/TBST). The membrane was then incubated in 5ml of diluted primary 
antibody overnight at 4⁰C.  The membrane was washed 3 times for 15 minutes using 
TBST. The membrane was then incubated in 10ml of diluted secondary antibody for 
1 hour. The membrane was washed 3 times for 15 minutes each using TBST. The 
membrane was then incubated in ECL detection reagent for 3 minutes. The 
membrane was developed using a Syngene chemiluminescence detection machine.  
 
2.20 - Calcium Signalling Assay  
Primary myometrium cells were grown on 25 mm coverslips in a 6 well plate until 
confluent. 1mM of indo-1-AM or 1mM of Fluo4-am stock solution was prepared in 
DMSO. One litre of 1X PSS buffer was prepared (136mM NaCl, 5mM KCl, 1.8mM 
CaCl2.2H2O, 0.25mM MgCl2,10mM Glucose, 5mM HEPES). 30mg of Pluronic acid was 
dissolved in 120µl of DMSO. For each well in a 6 well plate; 10µl of indo-1-AM  or 
Fluo4-am stock solution and 10µl of Pluronic acid was added to 2ml of PSS buffer and 
the mixture was vortexed. Each well was washed with 3ml of PSS buffer and the 
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coverslip transferred to a 35mm dish. The cells were washed twice with 3ml PSS 
buffer and then incubated with indo1-AM, Fluo4-AM/Pluronic acid mixture for 45 
minutes at room temperature. The cells were washed twice with PSS buffer and then 
left in PSS buffer for 15 minutes at room temperature. The cells were then treated 
with Oxytocin and the fluorescence change monitored using a fluorescent 
microscope. For Indo1-am measurements, a perfusion station was connected to an 
inverted Olympus fluorescent microscope with a water immersion lens (10× 
objective N.A.0.4). The excitation wavelength was 340nm and the emitted 
wavelengths at   400 and 475 nm were recorded at 20 frames per second. The 
microscope was connected to a computer workstation running an Andor software. 
The ratio between the two wavelengths (F400/F475) was calculated. For Fluo-4am 
measurements a perfusion station was connected to a Zeiss LSM 510 META confocal 
microscope with a x 40 oil immersion objective lens. Cells were excited at 488 nm 
using a krypton/Argon laser and emitted light wavelength was recorded at 510 nm 
at 1 frame per second. The microscope was connected to a computer workstation 
running an LSM image analysis software. Mean fluorescence intensity was quantified 
in regions of interest positioned over different cells and stated as a fold increase from 
time 0 (F/F0). Calcium traces were plotted, and the baseline was determined, from 
the baseline the area under curve was calculated using GraphPad PRISM software.  
 
2.21 - Immuno-cytochemistry  
Cells were grown on 25 mm coverslips to confluency in a 6 well plate  and washed 
with twice with PBS (2.5ml/per well). The PBS was discarded, and the cells were fixed 
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using 2.5ml/per well of ice cold 100% methanol at -20°C for 10 minutes. The cells 
were blocked with 10% goat serum/PBS (v:v) for 30 minutes. Cells were washed with 
1% goat serum/PBS (v:v). Primary antibody was diluted in a solution of 1% goat 
serum/PBS. Cells were incubated overnight at 4°c with 1.5ml/per well of primary 
antibody solution. The cells were washed using 2.5ml/per well of 1% goat serum/PBS. 
Secondary antibody was diluted in a solution of 1% goat serum/PBS. The cells were 
incubated with 1.5ml/per well of the secondary antibody for 1 hour at room 
temperature, away from any light. The cells were washed using 2.5ml/per well of PBS 
twice and the PBS was discarded. The excess PBS was gently removed using tissue 
paper before mounting with one drop/per coverslip of VECTASHIELD® Antifade 
Mounting Medium with DAPI. Excess mounting medium was removed gently from 
coverslip edges using tissue paper. Coverslip was placed cell side down on glass slides 
and adhered onto slides using nail polish on the coverslip edges. Fluorescence was 
detected using EVOS m5000 fluorescent microscope.  
 
2.22 - Chromatin Immunoprecipitation (ChIP)  
Buffer Preparation : 
50ml of 10X swelling buffer in nuclease free water: 0.25M HEPES, 0.015M MgCl2, 
0.02M KCl, 500µl NP40, pH 7.9.  
 
1X swelling buffer: 10X swelling buffer was diluted 10-fold in nuclease free water, 
165µl of protease inhibitor cocktail was added, 1 tablet each of phosphatase inhibitor 




50ml of 10X SDS lysis buffer in nuclease free water: 0.65M TRIS-HCl, 0.1M EDTA, 
0.07M SDS, 0.12M sodium deoxycholate, 5ml Triton X-100, pH 8.1.  
 
1X SDS lysis buffer: 10X SDS lysis buffer was diluted 10-fold in nuclease free water, 
165µl of protease inhibitor cocktail was added, 1 tablet each of phosphatase inhibitor 
cocktail  2 and  3 were  added . 330µl of 1M sodium butyrate was added.  
 
1X low salt wash buffer: 0.01% SDS, 1% Triton X-100, 2mM EDTA, 20mM TRIS-HCl, 
150mM NaCl, pH 8.0.  
 
1X High Salt buffer: 0.01% SDS, 1% Triton X-100, 2mM EDTA, 20mM TRIS-HCl, 
500mM NaCl, pH 8.0.  
 
1X lithium chloride wash buffer: 0.25M LiCl, 1% NP-40, 0.02M Sodium Deoxycholate, 
1mM EDTA, 10mM TRIS-HCl, pH 8.0  
 
TE buffer: 10mM Tris, 1mM EDTA, pH 8.0  
 




1X IP buffer: 0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM TRIS-HCl, 16.7mM 
NaCl.  
 
Cells were grown to 80% confluency in 10mm dish and washed with PBS twice before 
being incubated in serum free DMEM media containing  1% penicillin/streptomycin 
for 24 hours. The cells were then treated with 1µM MPA, and/or 0.5mM 8-bromo-
cAMP (cAMP) for 96 hours at 37○C and 5% CO2. Cells were washed twice with 
10ml/per well PBS. The cells were then fixed with 2ml/per well of 1% 
formaldehyde/nuclease free water for 10 minutes at  37○C. 200µl of 1.25M glycine 
was added to each well and incubated at room temperature for 5 minutes. The dish 
was placed on ice and the cells washed with sterile PBS twice. 1ml of 1X swelling 
buffer was added to each dish and the dish was placed on ice for 10 minutes. The 
cells were scraped into 1.5ml Bioruptor Picotubes. The cells were then homogenized 
for 1 minute. The cells were centrifuged at 16000 x g for 3 minutes at 4°C. The 
supernatant was discarded, and the samples were resuspended in 500µl of 1X SDS 
lysis buffer. The samples were sonicated in Diagenode Bioruptor 300, the sonicator 
was run for 30 cycles with 30 seconds on and 30 seconds off at a high setting at 4°C. 
The samples were centrifuged at 16000 x g for 10 minutes at 4°C. The supernatant 
was transferred to a clean 2ml lobind tube. The sonicated chromatin was diluted 10-
fold in 1X IP buffer. 20µl/per sample of protein A/G beads was added to a clean lobind 
tube. The beads were placed in a DynaMag and the liquid was discarded. The tubes 
were removed from the DynaMag and washed with 20µl/per sample of ice-cold IP 
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buffer. 1ml of diluted chromatin was added to 20µl of beads. The samples were 
rotated at 4°C for 3 hours. The samples were placed in the DynaMag and the 
chromatin supernatant was transferred to a clean lobind tube, 50µl was taken as 
input control and stored at -80°C. 100µl of protein A/G beads were added to a clean 
lobind tube (2x tubes), the tubes were placed in the DynaMag, and washed with 
100µl of IP buffer per tube. 1ml of ice-cold IP buffer was added to each tube. 2µg of 
antibody per sample was added to the tubes and the tubes were rotated for 3 hours 
at 4°C. The antibody/beads tubes were aliquoted into a clean lobind tube (one tube 
for each chromatin sample) and were placed in a DynaMag and the supernatants 
removed. 1ml chromatin samples were equally divided; half was added to target 
antibody/beads and half was added to IgG control/beads. The tubes were rotated at 
4°C overnight. The tubes were placed in the DynaMag and the supernatant was 
discarded. The chromatin/antibody/beads samples were washed with 300µl low salt 
wash buffer by rotating for 5 minutes at 4C. The samples were placed in the DynaMag 
and the low salt wash  buffer was removed. The washing step were repeated using 
high salt buffer, then lithium chloride buffer and then the TE buffer. The TE buffer 
was removed and discarded and each sample was incubated in 250µl of elution 
buffer for 15 minutes at room temperature. The tubes were placed in the DynaMag, 
and the supernatant was placed in a clean lobind tube. The input control samples 
were defrosted  and  200µl of elution buffer was added. 50µl of 1M NaCl was added 
to each sample. The samples were incubated overnight at 65°C. 10mM EDTA, 40mM 
TRIS-HCl pH 8.0 and Proteinase K (40µg/ml) was added to each sample and the 
samples were incubated at 55 for one hour. The DNA was purified using QIAquick 
PCR purification kit and the DNA was used for qPCR.  
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2.23 - DNA Purification Using PCR Purification Kit  
1.5ml of buffer PB was added to 300µl of DNA  obtained from ChIP . The mixture was 
placed in a column and centrifuged at 16000 x g for 1 minute, the flow through was 
discarded. 750µl  of buffer PE was added to the column and centrifuged at 16000 x g 
for 1 minute, and the flow through was discarded. The empty column was 
centrifuged at 16000 x g for 1 minute, and the flow through was discarded.  The 
column was placed in nuclease free microcentrifuge tube and 30µl  of buffer EB was 
added to the centre of the column and it was centrifuged at 16000 x g for 1 minute. 
The purified DNA was stored at -20°C for qPCR.   
 
2.24 -  Patient Criteria for Extracting Blood  
Whole blood samples were taken from two different groups of women. The first 
group of women were pregnant between 16-22 weeks and were attending a preterm 
clinic. These women were deemed at risk for premature labour. The second group of 
women were women in active spontaneous labour. Any women who had their labour 
induced by being given oxytocin were excluded. The women who donated their blood 
were not the same women who donated their myometrial biopsies.  
 
2.25 - Extracting RNA from Whole Blood 
Whole blood was collected from women using PAXgene Blood RNA Tubes and 
incubated at room temperature for 2 hours. The PAXgene Blood RNA Kit was used to 
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extract total RNA. The tubes were centrifuged at 3000 x g for 10 minutes and the 
supernatant was discarded. The pellet was resuspended in 4ml of RNAse free water 
and vortexed. The tubes were centrifuged at 3000 x g for 10 minutes, the supernatant 
was discarded. The pellet was resuspended with 350µl of buffer BR1, and vortexed. 
The sample was transferred into 1.5ml RNAse free microcentrifuge tube, 300µl of 
buffer BR2 and 40µl of proteinase K was added to the sample. The mixture was 
transferred to a column, and then centrifuged at 16000 x g for 2 minutes. The flow 
through was transferred to a clean, RNAse free  1.5ml microcentrifuge tube and 
350µl of pure ethanol was added. The mixture was vortexed and then transferred to 
a column and centrifuged at 16000 x g for 1 minute. The flow through was discarded 
and 350µl of buffer BR3 was added to the column, the column was then centrifuged 
at 16000 x g for 1 minute. The flow through was discarded. 10µl of DNAse 1 and 70µl 
of buffer RDD was added to the column, and the column was incubated at room 
temperature for 15 minutes. 350µl of buffer BR3 was added to the column and 
thereafter centrifuged at 16000 x g for 1 minute, the flow through was removed. 
500µl of buffer BR4 was added to the column and centrifuged at 16000 x g for 1 
minute and the flow through was removed. 500µl of buffer BR4 was added to the 
column and centrifuged at 16000 x g for 3 minutes and the flow through was 
removed. The column was placed in a RNAse free 1.5ml microcentrifuge tube and 
40µl of buffer BR5 was added to the centre of the column. The column was 
centrifuged at 16000 x g for 1 minute. The concentration of the purified RNA was 
measured using a nanodrop and stored at -80°C for future use. The purified total RNA 




2.26 - Extracting Circulating Cell Free RNA (ccfRNA) from Plasma  
Whole blood was collected in BD Vacutainer Venous Blood Collection Tubes and 
ccfRNA was extracted from plasma using QIAamp ccfRNA kit. The tubes were 
centrifuged at 2000 x g for 10 minutes at 4°C. The plasma was transferred to a conical 
tube and centrifuged at 3000 x g for 10 minutes. The supernatant was transferred to 
a new tube. 300µl of buffer RPL was added for every 1ml of plasma and the mixture 
was vortexed. 100µl of buffer RRP was added for every 1ml of plasma and the mixture 
was vortexed and thereafter incubated on ice for 3 minutes. The samples were 
centrifuged at 3000 x g for 10 minutes. 1ml of ice-cold isopropanol was added to each 
sample and the mixture was transferred to a column. The samples were centrifuged 
at 3000 x g for 1 minute. The flow through was removed. 4ml of buffer RWT was 
added to the column and centrifuged at 3000 x g for 1 minute. The flow through was 
removed. 2.5ml of buffer RPE was added to the column and centrifuged at 3000 x g 
for 5 minutes. The column was placed into a clean 15ml collection tube and 200µl of 
RNAse free water was added to the centre of the column and spun at 3000 x g for 1 
minute. 800µl  of 100% ethanol was added the supernatant and then vortexed 
briefly. The mixture was transferred to a column and spun at 8000 x g for 15 seconds. 
The flow through was discarded.  500µl of buffer  RPE  was added to the column and 
it was then centrifuged at 8000 x g for 15 seconds. The flow through was discarded. 
The column was centrifuged at 8000 x g for 1 minute. The column was placed in a 
RNAse free 1.5ml microcentrifuge tube and 20µl of RNAse free water was added to 
the centre of the column. The column was centrifuged at 16000 x g for 1 minute. The 
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concentration of the purified RNA was measured using a nanodrop and the RNA was 
stored at -80°C for future use. The RNA was used for RT-PCR.  
 
2.27 - Determining cAMP Concentration  
Transfected primary myometrial cells were grown in a 96 well plate at a density of 
40000 cells/well for 48 hours. The cells were treated with 100µM of forskolin for 30 
minutes. The cAMP levels of the cells were measured using CISBIO cAMP HTFR assay 
following the manufacturer’s instructions. The fluorescence was measured using 
PHERAstar FS plate reader. The standards were plotted using GraphPad Prism and 4-
parameter curve fit was used to measure the concentration of cAMP of test samples.  
 
2.28 - Phospho-MAPK Array Kit 
Primary myometrial cells were transfected with either siControl or siPLCL-1 and 
grown on a 6 well plate. After 48 hours of transfection, 200µl of lysis buffer 6 was 
added to each well, and the cells were scraped into a 1.5ml microcentrifuge tube 
using a cell scraper. The lysates were rotated in 4°C for 30 minutes. The samples were 
centrifuged at 16000 x g for 5 minutes. The supernatant was transferred to a clean 
1.5ml microcentrifuge tube. 1.1ml of array buffer 1 and 20µl of antibody detection 
cocktail was added to each sample and the samples were incubated at room 
temperature for an hour. 2ml of array buffer 5 was added to each well of the 4 well 
multi-dish. One membrane was placed inside each well in the multi-well dish and 
incubated for one hour on a rocking platform shaker at room temperature. Array 
73 
 
buffer 5 was removed from the well dish. The lysate/antibody samples were added 
to the dish containing the membrane and the membranes were incubated overnight 
on a rocking platform shaker at 4°C. The membrane was placed in a plastic container, 
containing 20ml of wash buffer and incubated for 10 minutes at room temperature 
on a rocking platform shaker. 2ml of Streptavidin-HRP was added to each membrane 
and incubated for 30 minutes at room temperature on a platform shaker. The 
membrane was placed in a plastic container, containing 20ml of wash buffer and 
incubated for 10 minutes at room temperature on a rocking platform shaker. The 
wash buffer was removed and 1ml of chemi-reagent was added to each membrane 
and incubated for 1 minute. The membrane was exposed on an autoradiography film 
cassette and developed in a dark room. The film was visualised on a Syngene 
chemiluminescence detection machine and used to scan the film. The pixel density 
of each dot blot was measured using ImageJ. 
 
RNA Sequencing  
2.29 - Library Preparation  
The total RNA from the transfected primary myometrium samples were used for RNA 
sequencing. The cDNA was synthesised using TruSeq Stranded mRNA assay. In 
TruSeq Stranded mRNA, the mRNA was first isolated from 1µg of total RNA using an 
immobilized poly-oligo(dT) beads. The poly(A)tail of the mRNA binds to immobilized 
poly-oligo(dT) beads in high salt conditions, removal of salt then allows mRNA to be 
isolated. The RNA is then fragmented and using random primers the RNA is converted 
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into a library of cDNA fragments. Adaptors were added to both ends of the cDNA 
fragments. The cDNA fragments were then amplified using PCR, cDNA was then 
sequenced using single end high-thoroughput sequencing (Illumina SN300). 
 
2.30- Processing of RNA-sequencing Data  
 
RNA libraries were sequenced using single end high-thoroughput sequencing 
(Illumina SN300) at SourceBio.Each sequenced read was 100 base pairs in length, the 
total number of reads for all 12 samples was 280,787,298 and the average number 
of reads per sample was 23,398,942. Reads from RNA-sequencing data were aligned 
with the reference genome UCSC h19 GRCh37 using STAR. Samples were quality 
assessed using FastQC. Reads were normalised in DESeq and transcripts per 
million(TPM) calculated using R. Patient batch effect was removed using the limma 
function in R.  
 
2.31 –RNA-sequencing Analysis and Identification of Differentially 
Expressed Genes  
The reads from each gene were analysed using principle component analysis (PCA). 
PCA is a mathematical model used to reduce the dimensionality of  large data sets, 
based on the variance. The first principle component ( PC1) is the direction along the 
variables whereby there is the most variation. The second principle component (PC2) 
is the direction where the variables show the second most variation . Each variable 
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or data set represents the sequence reads of a single gene in a sample. Each gene is 
then scored on how much influence  it has on the length and direction of each PC, 
this is called loadings. Each sample has mutiple loadings for each gene and this is 
termed an eigenvector. The loadings are then combined for each sample to get a 
single value for PC1 and PC2, this is then plotted; samples with similar values will 
cluster. Therefore, PCA is a technique that is used to assess similarities in variance 
between different samples and to group similar samples together.  
Principle component analysis (PCA) and heat map plotting was conducted in R and 
the data transformed using regularized-logarithm transformation, with the function 
being: rld = rlog(dds, blind=FALSE). Heat map plotting was done using Euclidean 
distance. PCA was done using an unsupervised clustering technique.  Differential 
expression analysis was performed using DESeq2, using the Wald statistical test. 
Knockdown samples were compared to siControl samples and oxytocin treated 
samples compared to no-oxytocin samples to identify any differentially expressed 
genes (DEG), using the Wald statistical test. Genes were identified as DEG if there 
was a more than a 2-fold change and if the p value was less than 0.05 (fold change>2 
and P≤0.05). Benjamini-Hochberg procedure was applied to control the false 
discovery rate and the cut-off point was 0.05. KEGG pathway enrichment analysis 
was performed by Hyper-geometrical statistical test, using the R function ‘phyper’. 
In the KEGG pathway enrichment analysis; down regulated and up-regulated genes 
were matched with 300 different biological pathways. Using a hyper-geometrical 
statistical test, pathways with a  p value less than 0.05 were thought to be 
significantly enriched.  
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2.32 - Software for RNA Sequencing Analysis  
Read counts were aligned in STAR. Quality control was done using FASTQC. Patient 
batch effect was removed using R. Read count normalisation was done in DESeq. 
Transcripts per million was calculated in R. PCA and heat map analysis was done in R. 
KEGG enrichment pathway analysis was done in R.  
 
2.33 - Statistical Analysis 
The data was evaluated using GraphPad prism 6.0 and Excel. Student’s  two-sample 
t test was done to look for significant differences in the means of two independent 
samples (unpaired), assuming the values follow a normal distribution. A one-way 
ANOVA test was done to look for significant differences in the means of three or 
more independent samples (e.g. section 3.2.2). The one-way ANOVA test was 
followed by a post-hoc test. The post hoc test used was either  Tukey's honestly 
significant difference (HSD) post hoc test or Dunnett’s post hoc test. It was assumed 
that the values followed a normal distribution. A two-way ANOVA test was done to 
identify any significant difference in the means of samples, when there were two 
independent variables. For example, in section 4.2.2, the two independent variables 
were without oxytocin (0 hours) and with oxytocin and treatment time, thus a two-
way ANOVA test was conducted. The post hoc test following the two-way ANOVA 
was either Tukey's honestly significant difference (HSD) post hoc test or Dunnett’s 
post hoc test, and the data was assumed to follow a normal distribution. A P-value 












PLCL-1 Reduces IP3 Mediated Calcium Release in 













3.1 Introduction  
 
It is well established that a rise in calcium is vital for smooth muscle cell contraction. 
There is a lot of evidence showing that PLCL-1 inhibits intracellular calcium release.  
PLCL-1 binds to IP3 and inhibits IP3 mediated release of calcium from intracellular 
stores in COS-1 cells overexpressing PLCL-1 (Kanematsu et al, 1992) (Takeuchi et al, 
2000). Knockdown of PLCL-1 in mice neuronal cells, increases IP3 mediated release 
(Harada et al, 2005). Treating HESCs with siPLCL-1, led to a reduction in IP3 mediated 
calcium release (Muter et al, 2016). There is also a lot of evidence showing that PLCL-
1 expression is reduced in the labouring myometrium in women compared to women 
not in labour (Chan et al, 2014)( Sharp et al, 2016) (Mittal et al, 2010). Therefore, it 
is hypothesised that PLCL-1 expression is reduced during labour to release the 
inhibition PLCL-1 has on IP3  mediated  calcium release. To partly test this hypothesis, 
the effect of knocking out and overexpressing PLCL-1 on [Ca2+]i in primary myometrial 
cells was investigated.  
 
One of the objectives of this project was to create different cell lines with deleted 
regions of PLCL-1 using CRISPR-Cas9 and to use the cell lines for different assays that 
helped determine the function of each region. CRISPR-Cas9 requires cells that can be 
cultured for a few months as a clonal population of cells with the targeted deletion 
need to be created. Primary myometrial cells are only able to grow until passage 4, 
thus they are not suitable for CRISPR-Cas9. A cell line derived from myometrial cells 
would be more suitable for the use in CRISPR-Cas9. A commercially available cell line 
from uterine myometrium smooth muscle: PHM-41 cells, were first thought to be 
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suitable, however after culturing PHM-41 cells, it was observed they had a slow 
doubling rate. Therefore, a robust cell line derived from the myometrium was 
needed, this new cell line (Myla) required characterisation, to determine if they 
retained features of primary myometrial cells.   
 
3.2 Results  
3.2.1- PLCL-1 Expression Decreases in Myometrium of Labouring Women  
Western blotting showed a decrease in PLCL-1 expression in the myometrium of 
labouring women compared to women not in labour. There was a ~90% decrease in 
PLCL-1 expression in myometrium of labouring women (Figure 3.2.1).  
3.2.1 – PLCL-1 Expression in the Myometrium During Labour. A) Myometrial biopsies 
were collected from women not in labour (NIL) and women in labour (IL). The 
biopsies were mechanically homogenised and then differences in PLCL-1 expression 
between the two groups were detected using western blotting. B) Western blot band 
density of IL samples relative to NIL samples. n=4, error bars (standard deviation). 
Student’s t test P≤0.05 (*).  Figure from Dr Paul Brighton.  
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3.2.2 - Validating siPLCL-1 and PLCL-1 Transfection of Primary MSMCs Using RT-PCR 
and Western Blotting 
Primary MSMCs were transfected either with siControl, siPLCL-1 or PLCL-1 expressing 
plasmid. The transfection efficiency was ascertained using RT-PCR and western 
blotting. Knocking down PLCL-1 led to a ~60% reduction in PLCL-1 mRNA and protein 
compared to control cells. Overexpressing PLCL-1 increased detected PLCL-1 mRNA 
by 3-4 folds at both the mRNA and protein levels, compared to control (Figure 3.2.2). 
 
Figure 3.2.2 - Validating siPLCL-1 and PLCL-1 Transfections. A) Primary MSMCs were 
transfected with either siControl, siPLCL-1 or PLCL-1, fold change analysis was done 
relative to siControl. A) Western blot of transfected cell lysates. B) Western blot band 
density of siPLCL-1 and PLCL-1 relative to siControl. C) RT-PCR was conducted to 
investigate the fold change in PLCL-1 mRNA. Data was analysed using one-way 
ANOVA with Dunnett’s post hoc test.  P ≤0.05 (*), n=3, error bars represent standard 
deviation. siPLCL-1 and PLCL-1 samples were compared to siControl.  
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3.2.3 - Knocking Down PLCL-1 Increases Oxytocin Mediated Increases in [Ca2+]i, 
Whilst Overexpressing PLCL-1 Supresses Oxytocin Mediated Increases in [Ca2+]i. 
 
Transfected cells were treated with 10nM Oxytocin (OT), and the changes in calcium 
concentrations were assessed using the calcium indicator fluorescent dye indo-1, and 
this was done for 600 seconds (Figure 3.2.3b). The experiment was repeated three 
times. Figure 3.2.3b; panels A-C represent the calcium oscillations observed from one 
experiment, each line or curve represents the calcium oscillations of one cell. The 
area under graph is calculated using the trapezoidal method. Trapezoids of equal 
width are fitted from the baseline under each calcium curve from 0 seconds to 600 
seconds. The area of each trapezoid fitted under each curve is calculated. The area 
under the curve (AUC) is then the sum of the areas of all the trapezoids under the 
curve (Figure 3.2.3a). Each cell will have its own AUC, because each cell has its own 
calcium curve. The mean AUC was calculated from all the repeats (n=3).  
 
Figure 3.2.3a - Schematic Representation of how the Area Under a Calcium Curve is 
Calculated Trapezoids are fitted under the calcium  curve. The area of each trapezoid 
is calculated. The sum of the areas of all the trapezoid under the curve is then used 
as an approximation for the area under the curve.  
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Treatment with siPLCL-1 increased the number of oscillations upon stimulation with 
OT, compared to control (Figure 3.2.3b). Overexpressing PLCL-1 decreased the 
oscillation frequency compared to control. The maximum peak response in siControl 
cells was ~2, this increased to ~4 when PLCL-1 was knocked down and decreased to 
~1.5 when PLCL-1 was overexpressed. The mean area under the curve (AUC) 
increased from 107 (SD ± 28) to 382(SD ±125) in siControl and siPLCL-1 cells, 
respectively.  Overexpressing PLCL-1 reduced the mean AUC to 69 (SD ± 12) in 
comparison to control cells (Figure 3.2.3b). The increase in the oscillation frequency, 
maximum peak response and AUC when PLCL-1 was knocked down, suggests that 













Figure 3.2.3b - Effect of siPLCL-1 and PLCL-1 on [Ca2+] i. A-C) Primary myometrial 
cells were transfected with siControl, siPLCL-1 or 1µg PLCL-1 and then stained 
with indo1-am and treated with 10nM oxytocin. The cells were excited at 
345nm and fluorescent emission was observed at 475nm and 400nm, the ratio 
between the two emission spectra were plotted against time. Dotted line 
represents the baseline, these graphs are from one experiment that is an 
accurate representative of all the repeats, which were 3.  D) Graphs 
demonstrating the mean area under the curve (AUC) from the baseline, this is 
the mean AUC for all the repeats, thus n= 3. Error bars (standard deviation). 






3.2.4- Characterisation of a New Myometrial Cell Line (Myla cells) 
There was a need for a robust myometrial cell line that has a fast doubling rate, for 
efficient CRISPR-Cas9 vector transfection; to create a cell line that had deleted PLCL-
1 regions. Therefore, primary myometrial cells were transfected with a temperature 
sensitive simian virus 40 (SV40) T antigen, to induce immortalisation.  The 
immortalisation was done by Dr Anne Straube (University of Warwick). When the 
cells are incubated at a temperature of 33°C, the cells have a phenotype close to the 
wild-type SV40 T antigen-immortalized cells; with a fast doubling rate. However, 
when the cells are transferred to restrictive growth temperature at 37°C, the cells 
revert to having a morphology that is similar to primary MSMCs. Primary MSMCs 
have a spindle like morphology with an elongated shape and nucleus, this is similar 
to Myla cells grown at 37°C. However, the cells grown at 33°C do not have an 





Figure 3.2.4a – Phase Contrast Image of Primary MSMCs and Myla cells. Phase 
contrast images were taken from cells Myla cells grown at 33°C and 37°C and also 




Myla cells were loaded with the calcium indicator dye fluo4-am and treated with 
10nM OT for 10 minutes. There was a visibly larger maximal response to OT in cells 
grown at 37°C compared to those grown at 33°C, with a fluo4 intensity ratio of 8 
compared to 1.5, respectively. Additionally, the AUC of Myla cells grown at 37°C was 
greater compared to cells at 33°C (143 and 111, respectively). However, there were 
no oscillations observed in both 33°C and 37°C cells (Figure 3.2.4b) 
 
RT-PCR analysis done on Myla cells at 37°C showed a 50% increase in desmin mRNA 
levels and a 20% decrease in vimentin mRNA, compared to cells grown at 33°C (Figure 
3.2.4c). Desmin is a marker for smooth muscle cells, whilst vimentin is a marker for 
fibroblast cells (Capetanaki et al, 1997) (Owens, 1995) (Strutz et al, 1995). The RT-
PCR results show that the Myla cells change from having a fibroblast phenotype at 
33°C to having a more smooth muscle cell characteristics after they are transferred 
to 37°C, this may explain why the Myla cells grown at 37°C have a larger calcium 
response to OT.  
 
RT-PCR analysis also showed that Myla cells expressed OTR, PGFTR and CACNA1C 
(Calcium Voltage-Gated Channel Subunit Alpha1 C). There was a significant increase 
in OTR and PGFTR mRNA in the 37°C cells, a 50% and 300% increase, respectively 
(Figure 3.2.4c). There was no significant difference in expression of CACNA1C mRNA 







Figure 3.2.4b- Response of Myla cells to 10nM Oxytocin. A&B) Myla cells 
stained with fluo4am and treated with 10nM oxytocin. The ratio between the 
basal fluorescent signal before the addition of OT and the fluorescent signal 
after addition of OT was calculated.  Dotted line represents the baseline. These 
graphs are from one experiment that is an accurate representative of all the 
repeats, which were 3 C) Graph demonstrating the average area under the 
graph, which was calculated from all the repeats, n=3, error bars (standard 










Figure 3.2.4c- Characterisation of Myla cells. Total RNA was extracted from Myla 
cells, and converted to cDNA for RT-PCR. 5 genes were investigated for changes in 
their mRNA upon a change in growth temperature :  A) Desmin, B) Vimentin, C) 
Oxytocin receptor (OTR), D) Prostaglandin F2α receptors (PGFR) and E) CACNA1c. 
Data was analysed using Student’s t-test,  P≤0.05 (*), n=3, error bars represent 




Myla cells were stained for desmin and vimentin (Figure 3.2.4d). Myla cells showed 
a visible decrease in staining for vimentin when grown at 37°C, however there was 
no notable difference in desmin staining.  Staining for CACNA1C showed that the 
Myla cells and primary MSMCs both expressed CACNA1C and there was no notable 
difference in the staining between the primary cells and the cell line (Figure 3.2.4e).  
 
 
Figure 3.2.4d- Investigating the Phenotype of Myla Cells. Myla cells were grown at 
33°C and 37°C and were then stained for vimentin and desmin.  The control cells were 








Figure 3.2.4e- Staining Myla Cells Grown at 37°C and Primary MSMCs for CACNA1c. 
Myla cells were grown at 37°C and primary MSMCs were stained using a CACNA1c 
antibody.  The control cells were not exposed to primary antibodies, only to the 
secondary antibody. n=3 
 
 
3.3 Discussion  
 
PLCL-1 Expression in the Myometrium Decreases During Labour 
A consistent reduction in the expression of PLCL-1 in the myometrium of women 
during labour has been observed in many different studies.  RNA sequencing done to  
compare differences in gene expression  between non-labouring and labouring 
myometrium in humans, showed a reduction in PLCL-1 expression during labour  
(Chan et al, 2014) (Sharp et al, 2016). Comparably to the human studies; RNA 
91 
 
sequencing done on myometrium from mice, also showed a reduction in PLCL-1 
during labour (Migale et al, 2016). Similarly, to the RNA sequencing studies, 
microarrays studies done on the human myometrium showed a downregulation of 
PLCL-1 during labour (Bethin et al, 2003) (Esplin et al, 2005) (Mittal et al, 2010). The 
result from section 3.2.1 was concurrent with the previous studies; showing a 
reduction in PLCL-1 expression during labour.  
 
Preceding studies done on neuronal cells, COS-1 cells and HESCs have shown that 
PLCL-1 inhibits the release of calcium from intracellular stores, this effect was also 
observed in primary myometrial cells (Takeuchi et al, 2000) (Harada et al, 2005) 
(Muter et al, 2016).  PLCL-1 was shown to cause a reduction in oxytocin induced 
increases in intracellular calcium concentration in the myometrium (Figure 3.2.2b). 
Oxytocin is an important peptide hormone during the stimulation phase of pregnancy 
and oxytocin signalling leads to a release of calcium from intracellular stores (Section 
1.7.3). A rise in calcium is crucial for contraction to occur in the myometrium. The 
downregulation of PLCL-1 during labour (Figure 3.2.1) may be a mechanism  to lessen 
the inhibitory effect that PLCL-1 has on the release of calcium by CAPs such as 
oxytocin (Figure 3.2.2b). The downregulation of PLCL-1 may lead to an increase in the 
contraction frequency during labour, thus it may be that PLCL-1 levels in the 
myometrium are kept high during the quiescent phase of pregnancy to dampen the 
likelihood of contractions. However once full term is reached, PLCL-1 levels are 
reduced leading to an increase in intracellular calcium concentration, which increases 
the likelihood of contractions occurring.   
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Proposed Mechanism for PLCL-1 Inhibiting IP3 Mediated Calcium Release.  
PLCL-1 was shown to decrease oxytocin induced [Ca2+]i in MSMCs, and  this result 
validated previous data, which showed the same effect of PLCL-1 on [Ca2+]i (Takeuchi 
et al, 2000) (Harada et al, 2005) (Muter et al, 2016). One explanation for the 
inhibitory effects of PLCL-1 on rises in [Ca2+]i is that PLCL-1 binds to IP3, to sequester 




Figure 3.3.1- Schematic Representation of PLCL-1 Sequestering IP3. MSMC on the 
left shows the IP3 being able to bind to IP3R on endoplasmic reticulum (ER) without 
PLCL-1 present. The presence of PLCL-1 (right) means IP3 is sequestered and not able 
to bind to IP3R, thus there is no release of calcium from the ER.  
 
 
Characterisation of Myla cells  
 
Transferring the Myla cells from 33°C to 37°C led them to having characteristics that 
are associated with primary myocytes. The Myla cells changed their morphology 
from being more fibroblast like at 33°C to being more smooth muscle like at 37°C. 
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The Myla cells went from have an oval shape to becoming more elongated and  
having more contact with adjacent cells, this was similar to primary MSMCs (Figure 
3.2.4a).  
 
At 37°C the Myla cells had a larger response to oxytocin compared to cells grown at 
33°C, the larger calcium spike at 37 suggest that the Myla cells are more similar to 
primary cells in their response to oxytocin. However, both cells grown at 33°C and 
37°C showed no calcium oscillation, this is  in contrast to primary MSMCs.  
 
The RT-PCR analysis suggested that Myla cells at 37°C had gene expression profile 
that is similar to smooth muscle cells, as there was a decrease in vimentin and an 
increase in desmin (Capetanaki et al, 1997) (Owens, 1995) (Strutz et al, 1995). The 
staining for vimentin validated the RT-PCR results, however the desmin staining 
showed no difference in staining between 33°C and 37°C. The RT-PCR showed an 
increase in OTR expression, which may explain why there was a larger calcium 
response upon treatment with oxytocin.  
 
The CACNA1c gene codes for a subunit for a subunit of the L-VOCC, and it was found 
to be expressed in Myla (Qin et al, 2002). Both the primary MSMCs and the Myla cells 




Although Myla cells appear to have a morphology similar to primary MSMCs and gene 
expression similar to smooth muscle cells, there are limitations to the RT-PCR results. 
The RT-PCR results would have been more robust if the same experiment was 
repeated with primary MSMCs, which would have shown if the expression of desmin 
and vimentin in Myla cells were similar to primary cells, and not just that the gene 























Analysis of Transcriptome Changes After PLCL-1 













4.1 Introduction  
 
Calcium has been shown to regulate transcriptional expression in smooth muscle 
cells and other cell types by activating or repressing calcium sensitive transcription 
factors (Table 4.1.1) The transcriptional regulation by calcium is called excitation-
transcription coupling, it transforms temporary calcium signalling and contractile 
periods into long-lasting regulation of the smooth muscle cell transcriptome.  
Table 4.1.1- Examples of Calcium Regulating Transcriptional Changes 





































































































Any protein that changes intracellular calcium levels may indirectly influence the 
transcriptome. PLCL-1 has an effect on [Ca2+]i (Chapter 3), thus PLCL-1 may have 
transcriptional control in the myometrium. PLCL-1 expression being downregulated 
in the myometrium of women who are in labour suggests PLCL-1 may be a pro-
quiescent gene and its reduction is needed for a successful labour (Chan et al, 2014) 
(Sharp et al, 2016). Therefore, it was hypothesised that PLCL-1 may function as a pro-
quiescent gene by reducing the expression of CAPS and inducing expression of pro-
quiescent genes, this function by PLCL-1 may be mediated through its actions on 
[Ca2+]i.  The hypothesis was tested by knocking down PLCL-1 and observing changes 
in the transcriptome using RNA-sequencing. The ability of PLCL-1 to increase 
expression of pro-quiescent genes or decrease CAPs was examined.  RNA-sequencing 
was conducted on cells treated with oxytocin. The difference between the 
transcriptome of cells with or without OT was studied, and the ability of PLCL-1 to 
modulate this difference was investigated. The aim of these experiments is to 
investigate if OT can induce expression of CAPS, and if PLCL-1 can reduce this OT 
mediated expression.  
 
4.2 Results  
4.2.1- Validating PLCL-1 Knockdown Through RT-PCR and Western Blotting  
 
Protein levels of PLCL-1 was reduced in MSMC by siPLCL-1. A scrambled non-
targeting siRNA (siControl) was used as a control. Optimum knockdown of PLCL-1 was 
achieved after treatment with siPLCL-1 for 48 hours, which led to a ~75% decrease in 
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the expression of PLCL-1 (Figure 4.2.1). The primary cells were treated with either 
siControl or siPLCL-1 for 48 hours before harvesting for total RNA. The effectiveness 
of the knockdown treatment was scrutinised using qPCR and western blotting (Figure 
4.2.1). Treatment with siPLCL-1 saw a 60% decrease in mRNA and protein levels PLCL-
1. The total RNA purity and quality was tested using a bioanalyzer, the total RNA was 
























Figure 4.2.1-Validating Knockdown of PLCL-1 for RNA Sequencing. Primary MSMCs 
were transfected with siPLCL-1 for 0, 24, 48 or 72 hours A) Western blot for PLCL-1 
expression using lysates that were treated with siPLCL-1 at different time points. B) 
Relative density of western blot (a), the fold change in PLCL-1 expression was 
calculated relative to 0 hours. C) RT-PCR was done to investigate PLCL-1 mRNA fold 
change of each time point relative to 0 hours. D) Cells were transfected with siPLCL-
1 or siControl, western blot of transfected lysates. E) Western blot band density of 
siPLCL-1 relative to siControl. F) RT-PCR was conducted to investigate the fold change 
in siPLCL-1 mRNA, relative to siControl. Data from panels B and C were analysed using 
one-way ANOVA followed by Dunnett’s post hoc test. Data from panels E and F   were 





4.2.2- Investigating the Optimal Transcriptional Response to OT 
 
Twelve samples were compared; 6 siControl and 6 siPLCL-1 treated samples, in 
addition 3 of each group were treated with 10nM oxytocin. The cells were treated 
with oxytocin to examine the effects of knocking down PLCL-1 on the transcriptome 
when the cells were treated with a pro-contractile molecule. Optimal treatment time 
with oxytocin was chosen by the maximal induction of a downstream target of 
oxytocin, Cyclooxygenase 2 (COX2) (Figure 4.2.2). The primary myometrial cells were 
treated with 10nm oxytocin for 0 hours, 1.5 hours, 3 hours, 6 hours and 24 hours. 
The induction of COX2 was measured using qPCR and western blotting. Treatment 
with oxytocin for 1.5 hours showed the highest induction of COX2 mRNA levels, with 
a 3-fold induction, this rise dissipated at 3 hours and 6 hours, although an increase in 
COX2 mRNA levels (~2 fold) was still seen relative to no oxytocin treatment (0 hours). 
The increase in COX2 mRNA levels decreased after 24 hours of oxytocin to levels 
similar at 0 hours. The same pattern was observed at the protein level, COX2 levels 
increased from 1.5 hours to 6 hours, and this increase was then lost after 24 hours. 














Figure 4.2.2- Investigating the Optimal Transcriptional Response to OT. A) Primary 
myometrial cells were grown until confluent and thereafter serum starved for 24 
hours. The cells were then treated with 10nM of OT for 0, 1.5, 4, 6 and 24 hours.  
Cells were harvested and changes in translation of COX-2 after treatment with OT 
were investigated using western blotting. B) Relative density of band intensity from 
western blot (A) was calculated and relative to 0 hours treatment time. C) COX-2 
levels were measured using RT-PCR. Data was analysed using two-way ANOVA with 











4.2.3- Analysis of  RNA sequencing data 
In order to investigate how the samples, which are based on comparing oxytocin 
treatments with  no oxytocin treatment and  knockdown with control, are grouped 
together, principal component analysis (PCA) was performed as an unsupervised 
clustering technique. Samples can be grouped either using supervised or 
unsupervised learning approaches. In a supervised learning approach, for example in 
KMeans clustering, the model creates a fixed number of subgroups. This information 
is known in advance. Whereas in an unsupervised clustering approach, the number 
of clusters is unknown. The model decides the subgrouping. As an unbiased 
subgrouping the samples is desired, an unsupervised clustering technique is used. In 
PCA analysis several principal components are identified that summarise the data by 
explaining the maximum variance in the data. In Figure 4.3.2a, principal component 
1 and 2 were plotted together, which represent 77% of the variation in the data.  
Based on principal component 1, it is observed that the samples are grouped 
together depending upon on if they are treated with or without oxytocin. The effect 
of knockdown on clustering is not substantial, which is why both control and 
knockdown samples are grouped together.  
 
PC1-PC9  were analysed for the gene reads of siControl and siPLCL-1.  In PC1 and PC2 
the samples did not cluster together after knockdown of PLCL-1.  There was a clear 
separation between samples that were treated with oxytocin versus those that were 
not. PC3-PC8 did not show a clustering of samples based on knockdown of PLCL-1. 
PC9 did show a separation between siControl and siPLCL-1 samples. The genes which 
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had the most influence on PC9 were noted, and PLCL-1 was found to have the largest 






Figure 4.2.3a- Principle Component 1 Analysis. Primary myometrium cells from 6 
different biopsies were transfected and total RNA used for RNA sequencing.  Plot of 
principle component 1 and 2 (PC1, PC2), comparing siControl and siPLCL-
1(knockdown), with or without oxytocin. The siControl samples are highlighted in 
red. The siPLCL-1 samples are highlighted in green. The circles represent the samples 
that have not been treated with oxytocin. The triangles represent the samples that 
have been treated with oxytocin. There are 12 samples all together:  3x siControl no 










Figure 4.2.3b- Principle Component Analysis Plots PC1-PC10. Primary myometrium 
cells from 6 different biopsies were transfected and total RNA used for RNA 
sequencing.  Plot of principle component PC1-PC10. comparing siControl and siPLCL-
1(knockdown), with or without oxytocin.  
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Differential expression analysis was performed using R package DESeq2. Based on 
the Wald statistical test, gene expression values from knockdown and control were 
compared and a p-value is assigned to each gene. For each gene, a mean expression 
value was calculated based on all replicates of each condition.  The fold change of 
knockdown relative to control was calculated by dividing the mean expression value 
of all the  replicates of knockdown by  the mean expression value of all replicates of 
control. This was done for each gene in each comparative group; knockdown was 
compared to siControl and oxytocin treated was compared to no oxytocin treated. 
This was not done on an individual patient level, rather it was done on the mean 
values of different conditions.  
 
Gene clusters were assessed by closely looking at the clusters. In Figure 4.2.3a, it was  
observed that all samples that were treated with oxytocin clustered together to one 
side of the plot whereas untreated samples cluster to the opposite side. This shows 
that the samples are clearly grouped together depending upon oxytocin treatment. 
However, there is no such distinct clustering observed due to knockdown in each  
patient, except for one, both control and knockdown sample are grouped together.  
 
There were no differentially expressed gene due to knockdown of PLCL-1 experiment 
(fold change>2 and p-value<0.05). Therefore, patterns in gene expression were 
explored. To find any patterns in gene expression due to knockdown experiment, the 
reads for the siPLCL-1 samples were divided by reads from siControl. Fold change was 
calculated to look at which genes were either up or down regulated when PLCL-1 was 
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knocked down compared to control; using this criterion, in total 2241 genes are 
either up or downregulated (fold change >2) in at least one patient. There was no 
pattern in gene expression according to patients. No visible major gene cluster which 
was either up or down regulated in all patients was found. To better understand the 
expression a binary matrix was created; fold change>1 (log fold>0) = 1; fold change<1 
(log fold<0) = -1. This will explain which gene is either up or down irrespective of fold 
change, this method identified the same 2241 genes, which were previously 
identified (Figure 4.2.3c panel A).  Each patient had a different response to different 
conditions. The main aim in the analysis shown figure 4.2.3.c panel B was to 
investigate the qualitative response to oxytocin treatment and knockdown of PLCL-
1. Therefore, a very simple binary approach  was used whereby  it was demonstrated 
how genes are either downregulated or upregulated in different patients, ignoring 
the scale of change. Some patients might have several fold changes in expression 
value whereas others might have only a small change though that might be crucial. 
Very strong changes in some gene expression values in a patient will completely 










Figure 4.2.3c- Heat Map Illustrating Pattern of Gene Expression Due to PLCL-1 
Knockdown. Hierarchical clustering analysis was done on siControl samples treated 
with or without oxytocin. A) In order to find a pattern of gene expression due to 
knockdown of PLCL-1; fold change was calculated by dividing siPLCL-1 samples by 
siControl samples from each patient. There are 6 patients thus there are 6-fold 
change values, each patient had two samples, one treated with siControl and the 
other siPLCL-1. Colours represent log fold change, white is between -1 to 1 or without 
log it will be within fold change 2. Colour between 1 to 2 or -1 to -2 reflect fold change 
between 2 to 4. B) Gene expression pattern was visualised using a binary matrix; fold 
change>1 (log fold>0) = 1; fold change<1 (log fold<0) = -1. Plot showing changes in 





A KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway was used to predict 
the biological pathways the 2241 genes are involved in (Figure 4.2.3d). Kegg pathway 
enrichment analysis was performed by Hyper-geometrical statistical test; R function 
‘phyper’ was used for this, and siControl samples were compared with siPLCL-1 
samples. According to the Kegg pathway, genes involved in the cell cycle, DNA 
replication and the TNF pathway were downregulated when PLCL-1 was knocked 
down. Genes coding for cell adhesion proteins and PI3-AKT pathway were 

















Figure 4.2.3d- RNA 
Sequencing Analysis. Kegg 
pathway enrichment for 
differentially up and down 
regulated genes. Colour 
represents strength of 
significant enrichment. Orange 
colour is for significant 
enrichment of down-regulated 
genes and green color is for 
significant enrichment of up-
regulated genes within that 

















The transcipts per million (TPM) for each gene was calculated using R. Transcripts per 
million normalises the data for differences in sequence depths of samples and it is a 
way of analysing the differential gene expression profile of each sample. Transcripts 
per million (TPM) is used to estimate the relative molar concentration (rmc) of each 
mRNA species. The first step of TPM is to normalise for the gene length; longer genes 
will have more reads and this needs to be normalised for. The number of reads for 
each gene is divided by the gene length, this gives the reads per kilobase (RPK). The 
second step for TPM is to normalise for sequencing depth, some samples have higher 
sequencing depths than others, and thus will have more read counts for all the genes. 
The RPK for each sample is totalled and this total is then divided by a million to give 
a “per million” scaling factor. Then the read count for each gene which was 
normalised for gene length is divided by the new scaling factor of the sample it came 
from. The sum of the total normalised genes in each sample is the same when using 
TPM, this allows a comparison of the proportion of total reads that is mapped to each 
gene, between the samples (Wagner et al, 2012) (Figure 4.2.3e).  
 
PC9 showed a clear seperation of knockdown samples and control samples. Samples 
that had PLCL-1 knocked down and treated with oxytocin clustered together and 
away from samples that did not have PLCL-1 knocked down but were treated with 
oxytocin. Samples that had PLCL-1 knockdown and were not treated with oxytocin 
clustered together and away from samples that did not have PLCL-1 knocked down 
and were not treated with oxytocin.  Therefore the genes of interest that were  
chosen for RT-PCR validation were the gene that had the most influence on the 
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clustering seen in PC9 and these genes were identified by the coefficients from the 
loadings (Figure 4.2.3e) (Appendix 1, 2 and 3) . After the genes with the most 
influence on PC9 were identified, the genes that had very low read counts were 
exempted from further analysis.  
 
Thereafter, the  TPMs of the genes of interest were analysed to see if knocking down 
PLCL-1 had the same affect on the TPMs from all the patients. The TPMs  were 
originally calculated as part of the transcriptomics analysis and corrected for read 
bias. If the TPMs showed that knocking down PLCL-1 had a variable effect on the 





Figure 4.2.3e- Selection Criteria for the Genes of Interest. The top contributing genes 
to the seperation in principal component 9 (PC9) were selected using the coefficients 
from loadings. Thereafter those genes that had a too low of a read count were 
exempted from further analysis. The transcript per million (TPM) of the genes were 
used to see if PLCL-1 knockdown had the same effect in all the patient, the genes that 
showed variable change in TPM count in the 6 different patients upon PLCL-1 
knockdown, were exempted from further analysis. The genes that passed the 











Figure 4.2.3f- Transcript Per Million. Primary MSMCs were transfected with either 
siControl or siPLCL and  with or without 10nM oxytocin.Total RNA from the cells was 
extracted for RNA sequencing, and the transcipt per million for each gene was 
calculated. The above genes represent ‘genes of interest’ from the RNA sequencing 
results.  
 
There were 9 genes that met all the criteria for RT-PCR validation and they were: 
PLCL-1, WNT5A, EFHD1, PAQR5, CACNAH1, WNT7β, PDE2A, PDE3 and PDE7B. 
Treatment with siPLCL-1 showed a significant decrease in PLCL-1 mRNA. PLCL-1 
knockdown also led to a decreasse in the mRNA of WNT5A, PAQR5 and EFHD1, 
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though this decrease was not significant. There was no changes in the mRNA of  
CACNAH1, after PLCL-1 knockdown. There was a increase in the mRNA of PDE2A AND 
PDE7B after PLCL-1 knockdown. The change seen in PDE2A was not significant but it 
was in PDE7. Treatment of primary myometrial cells with siPLCL-1 increased mRNA 
of PDE7B to by 1.8 folds, this increased even further by 2.4-fold when cells were also 















Figure 4.2.3g-RT-PCR Validation of the Genes of Interest. Primary MSMCs were 
transfected with either siControl or siPLCL for 48 hours and  with (+) or without(-) 
10nm oxytocin. Data was analysed using Student’s t-test, P ≤0.05 (*), n=3, error bars 
represent standard deviation.  
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4.2.4- Investigating the Effects PLCL-1 Knockdown has on cAMP Levels 
 
The induction of PDE7B mRNA in response to PLCL-1 knockdown was replicated at 
the protein level( Figure 4.2.4a). Western blot analysis showed a 5 fold increase in 
protein production of PDE7B upon PLCL-1 knockdown. Western blotting was also 
conducted to investigate the effect of PLCL-1 knockdown on PDE3A expression, 
however there were no  bands observed. PDE7B is part of the phosphodiesterase 
family of proteins. PDE7B degrades cAMP by catalysing the hydrolytic cleavage of the 
3′-phosphodiester bond,resulting in the formation of the corresponding inactive 5′-
monophosphate, leading to a reduction cellular levels of cAMP (Sasaki et al, 2000). 
As PLCL-1 knockdown increases expression PDE7B, the effect PLCL-1 knockdown has 
on cAMP production in Myla cells was examined using a cAMP assay.  
 
A Homogeneous Time Resolved Fluorescence (HTRF) cAMP assay was used to 
examine whether PLCL-1 knockdown had any effect on cAMP production in 
myometrial cells. The endogenously produced cAMP competes for the binding for a 
cAMP recognising antibody with a fluorescently labelled cAMP, provided in the HRTF 
kit. The labelled cAMP is bound to a fluorescent acceptor (d2), a Europium cryptate 
fluorescent donor (Eu3+) is added to the kit and this allows for there to be a resonance 
energy transfer between the fluorescent donor and acceptor, this produces a 
fluorescent signal (FRET signal). The more cellular cAMP there is present, the greater 
the loss of FRET signal. HRTF allows fluorescent emission to be measured at 2 
different wavelengths; 620nm and 665nm. A standard curve is created using the ratio 
117 
 
between the 2 wavelengths with known concentrations of cAMP standards, using log 
concentrations. The standard curve is then used to extrapolate the concentration of 
cAMP in siControl and siPLCL-1 samples.  
 
Knocking down PLCL-1 decreased cAMP concentrations in myometrial cells from 
1000 pmol/L in siControl cells to 150 pmol/L when PLCL-1 was knocked down. 
Primary MSMC treated with forskolin saw a similar change in cAMP levels upon PLCL-
1 knockdown, whereby cAMP concentration changed from 3,200 pmol/ml when 
treated with siControl to 500pmol/ml when the cells were treated with siPLCL-1. 
When a PDE7 specific inhibitor was added (BRL 50481) (Smith et al,2004), there was 
no significant difference in the concentration of cAMP in between siControl and 
siPLCL-1 cells, both had a concentration around 3000pmol/ml, when cells were 













Figure 4.2.4a-Effect of siPLCL-1 on Expression of PDE7B. Primary MSMCs  were 
transfected with siControl and siPLCL-1 . A) Western blot of transfected cell lysates. 
B&C) Western blot band density of siControl and siPLCL-1, relative to siControl. Data 









Figure 4.2.4b- Effect of siPLCL-1 and PDE7 Inhibitor on cAMP Production. Primary 
Myometrial cells were transfected with siControl or siPLCL-1 for 48 hours; with or 
without PDE7 inhibitor, BRL 50481. Before cell harvesting, cells were treated without 
(a) or with (b) 100µM forskolin. Cells were then harvested for use in HRTF cAMP 
assay. Data was analysed using two-way ANOVA with Tukey’s post hoc test, P ≤0.05 





4.3 Discussion  
4.3.1- PLCL-1 Reduces Production of PDEs to Maintain Basal cAMP Levels  
Calcium is a well characterised and important second messenger that can affect 
changes in gene expression. As PLCL-1 decreases [Ca2+]i in MSMCs, the effects of 
PLCL-1 on the transcriptome was investigated. Analysis from RNA sequencing 
identified phosphodiesterases  as  ‘genes of interest’, in particular: PDE3A,PDE7B and 
PDE2A. RNA sequencing data showed that upon PLCL-1 knockdown there was an 
increase in the TPM of PDE7B and PDE2A, but a decrease in PDE3A. Validation of the 
RNA sequencing data using RT-PCR, showed that PLCL-1 was able to increase mRNA 
expression of PDE7B, but not PDE2A and PDE3A. Furthermore, western blot analysis 
illustrated that knockdown of PLCL-1 resulted in an increase in PDE7B protein 
detection.  
 
There are eleven isoforms of PDEs and within each isoform there are different splice 
variants, leading to expression of more than 55 PDEs in mammalian cells. PDE’s all 
have a conserved catalytic domain, located in the C-terminus that hydrolysis cAMP 
and cGMP into AMP and GMP respectively (Maurice et al, 2014) (Francis et al, 2011) 
(Keravis and Lugnier, 2014).  
 
PDE7B mRNA is expressed the highest in the female reproductive organs particularly 
the ovary and the endometrium, in that order (Fagerberg et al, 2014). PDE7B has 64% 
structurally homologies with PDE7A, both PDE7A and PDE7B specifically target cAMP 
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and but has no affinity for cGMP (Sasaki et al, 2000). There are two splice variants of 
PDE7B: PDE7B2 and PDE7B3 (Sasaki et al, 2002). Cyclic AMP upregulates expression 
of PDE7B in a negative feedback loop and there are multiple phosphorylation sites 
present on PDE7B that are targeted for phosphorylation by PKA (Sasaki et al, 2004) 
(Sasaki et al, 2002).  
 
Comparably to PDE7B, data from the RNA sequencing showed PLCL-1 knockdown 
increased the TPM count of PDE2A, however the effects on PDE2A were not validated 
using RT-PCR. Knockdown of PLCL-1 showed no significant change in PDE2A mRNA 
abundance  
 
As PLCL-1 can modulate the expression of PDEs in MSMC, it was postulated that PLCL-
1 may indirectly influence cAMP levels in MSMCs. PLCL-1 knockdown studies in 
MSMCs revealed a significant reduction in cAMP concentrations, suggesting that 
basal levels of cAMP are maintained by PLCL-1. The observed reduction in cAMP basal 
levels upon PLCL-1 knockdown was lost after PDE7 was inhibited. The combined data 
from the RNA-seq, western blotting and the cAMP assays, exemplifies a novel 
pathway whereby PLCL-1 indirectly keeps cAMP levels elevated by inhibiting 
phosphodiesterases from hydrolysing cAMP.  
 
Cyclic AMP is a well known pro-quiescent molecule and it mediates its pro-quiescent 
effects through PKA. One mechanism by which cAMP inhibits contractions in the 
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myometrium is by inhibiting PLC in a PKA dependent manner. Certain isoforms of PLC 
have already been shown to be phosphorylated by PKA. For example, PLCβ3 is 
phosphorylated by PKA at Ser1105, which is situated in the Gαq subunit binding domain 
of PLCβ3, this phosphorylation is thought to disrupt the binding of heterotrimeric G 
protein with PLC and consequently inhibit activation of PLC (Yue et al, 1998). Cyclic 
AMP inhibits increases in intracellular IP3 concentration, induced by oxytocin. A PKA 
specific inhibitor reverses the cAMP attenuation of the oxytocin induced increase in 
IP3 concentration in myometrial cells, this provides further evidence that cAMP 
inhibits myometrial PLC activity via PKA (Dodge and Sanborn, 1998).  
 
PLCL-1 maintains the baseline levels of cAMP in the myometrium through its 
inhibition of phosphodiesterase. Knocking down PLCL-1 leads to an increase in PDE7B 
and a reduction in cAMP. In addition, PLCL-1 inhibits IP3 mediated release in 
intracellular calcium stores (Chapter 3). As PLCL-1 binds directly to IP3, it may be that 
PLCL-1 inhibits IP3 by sequestering it. However, another mechanism by which PLCL-1 
may inhibit IP3 is by maintaining cAMP concentration in the myometrium, which 
subsequently inhibits PLC activity, which leads to a reduction the production of IP3 
from PIP2. The inhibitory effects of cAMP on PLC activity is lost in the rat myometrium 
during latter stages of gestation (Sanborn et al, 1995). PLCL-1 is downregulated 
during labour in both rodent (mice)  and human myometrium, this may partly explain 











Chapter 5  
 
 














5.1 Introduction  
 
Post-translational modulation of kinases through phosphorylation affects a wide 
variety of cellular signalling pathways, causing numerous phenotypical changes. For 
example, in MSMC, a family of MAPK proteins (Figure 5.1.1) have been shown to be 
activated by stretch in rat myometrium (Louden et al, 2004). Stretch in rat 
myometrium activates the mitogen activated protein kinases: ERK1, JNK and p38α by 
increasing their phosphorylation levels. One study showed increased 
phosphorylation of ERK1, JNK and p38α 24 hours before parturition in the gravid horn 
of the pregnant rats and not in the empty horn, suggesting that this was due to 
pregnancy induced stretch (Oldenhof et al, 2002). This increased phosphorylation of 
MAPK led to the increased transcription of c-fos. Proteins c-fos and c-jun form a 
heterodimer, to make up the transcription factor AP-1. There are several CAPs which 
have AP-1 consensus binding sites for AP-1 in their promoter region including OTR 






Figure 5.1.1 The MAPK Signalling Cascade. ERK, p38 and JNK all are part of the MAPK 
family of proteins. A cellular stimulation event leads to a cascade of phosphorylation 
that activates the substrate kinase, eventually leading to the activation of 
transcription factors, and subsequent changes to the transcriptome.  
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PLCL-1 has been shown to bind the kinase AKT and affecting its phosphorylation 
levels in HESCs (Muter et al, 2016). PLCL-1 also binds to the phosphatases PP1 and 
PP2a, which have been shown to dephosphorylate MAPKs (Yu et al, 2004) (Alvarado-
Kristensson and Andersson, 2005) (Kitatani et al, 2006). PLCL-1 decreases the activity 
of PP1 (Yoshimura et al, 2001). If PLCL-1 binds to and effects AKT phosphorylation 
levels in HESCs and modulates the activity of PP1, it might also do the same in 
MSMCs. PLCL-1 may be able to modulate transcriptional changes in MSMCs by 
regulating phosphorylation states of kinases, and this regulation may lead to a 
decrease in the expression of CAPS or increases in expression of pro-quiescent genes.  
A MAPK array assay was used to explore the ability of PLCL-1 to regulate the 
phosphorylation levels of kinases in MSMCs, this assay allows for observation of 
changes in phosphorylation levels of numerous MAPK in a time-efficient manner.  
 
5.2 Results  
 
5.2.1- The Effect of PLCL-1 Knockdown on Phosphorylation of Mitogen Activated 
Protein Kinases (MAPK)  
Primary myometrial cells were transfected with either siControl or siPLCL-1 for 48 
hours and thereafter harvested for use in a Phospho-MAPK antibody array kit/dot 
blot (Figure 5.2.1).  In the dot blot, Phospho- specific antibodies are dotted onto a 
nitrocellulose membrane and phosphorylation levels are detected using 
chemiluminescence. The dot blot has 6 reference spots as positive controls, to 
demonstrate that the Streptavidin-HRP is working and to align the membrane in the 
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correct orientation. The pixel density of each phospho- kinase was analysed using 
imageJ. Pixel density from each dot is calculated as a percentage of the density from 
the positive control reference spots, and this is plotted in the y axis.  
 
AKT/PKB is a serine/threonine specific protein kinase, there are three known 
isoforms of AKT: AKT1, AKT2 and AKT3. The phospho-MAPK dot blot has antibodies 
specific for the phospho-AKT1, AKT2, AKT3 and total phospho-AKT (AKT-PAN). In 
siControl samples the mean phosphorylation levels as a percentage of reference spot 
density in AKT1, AKT2, AKT3 and AKT-PAN were 5.98 32.36, 17.67 and 19.21 (± SD 
0.94, 2.11, 1.44, and 1.15) respectively. There was a significant reduction in the mean 
phosphorylation of AKT1 and AKT3 after PLCL-1 knockdown to 1.49% (± SD 1.23) and 
1.69% (± SD 1.36), respectively. However, there was no significant reduction in 
phosphorylation levels of AKT2 and AKT-PAN (Figure 5.2.2.). 
 
There was a no significant change in cAMP response element binding protein (CREB) 
phosphorylation levels upon PLCL-1 knockdown, Similarly to CREB, upon PLCL-1 
knockdown, there was no significant change in mean phosphorylation levels of ERK1 
and ERK 2 (Figure 5.2.2).  
 
There was no significant change in the mean phosphorylation levels of the glycogen 
synthase kinase isoforms: GSK-3 a/ß and GSK.  Mean phosphorylation levels of heat 
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shock protein 27 (HSP27) decreased from 62.42 % (± SD 3.31) to 29.61% (± SD 8.71), 
when PLCL-1 was knocked down (Figure 5.2.3).  
 
There were no significant changes in the phosphorylation levels of the c-Jun terminal 
kinase isoforms: JNK1, JNK2 or JNK3 (Figure 5.2.3). Kinases MKK6 and MSK2, mean 
phosphorylation levels decreased from 16.73% (± SD 0.79) and 29.57% (± SD 1.62) to 
5.04% (± SD 1.44) and 6.49% (± SD 2.58), respectively, upon treatment with siPLCL-
1(Figure 5.2.4). Kinase MKK3, saw no significant change in the phosphorylation state 
in siPLCL-1 lysates in comparison to siControl lysates.  
 
Two of the P38 MAPK isoforms saw a marked decrease in phosphorylation states in 
response to PLCL-1 knockdown. Isoforms P38α and P38β saw a significant decrease 
in phosphorylation from 29.65% (± SD 6.65) and 25.68% (± SD 1.61) to 3.00% (± SD 
2.52) and 2.96% (± SD 1.39), respectively (Figure 5.2.4). However there was no 
significant change in the phosphorylation levels of isoforms p38δ and p38γ.  
 
There was no change in the phosphorylation state of p53, however p70 s6 kinase saw 
an increase from 5.22% (± SD 1.03) to 25.96% (± SD 3.84). Kinases RSK1, RSK2 or TOR 










Figure 5.2.1 -Phospho-MAPK Assay. A) Schematic representation of array 
coordinates. B) Example blot from siControl lysate from primary MSMCs. C) Example 
blot from siPLCL-1 lysate from primary MSMCs. D) Table showing the corresponding 














Figure 5.2.2- Effect of siPLCL-1 on Phosphorylation of Kinases. Primary myometrial 
cells were treated with siControl (white bars) or siPLCL-1 (grey bars) for 48 hours. 
Cells were harvested for use in phospho- MAPK dot blot. Phosphorylated kinases 
were detected using chemiluminescence, and the density analysed as a percentage 
of reference spots. Data was analysed using Student’s t-test, P ≤0.05 (*), n=3, error 









Figure 5.2.3- Effect of siPLCL-1 on Phosphorylation of Kinases. Primary myometrial 
cells were treated with siControl (white bars) or siPLCL-1 (grey bars) for 48 hours. 
Cells were harvested for use in phospho- MAPK dot blot. Phosphorylated kinases 
were detected using chemiluminescence, and the density analysed as a percentage 
of reference spots. Data was analysed using Student’s t-test, P ≤0.05 (*), n=3, error 








Figure 5.2.4- Effect of siPLCL-1 on Phosphorylation of Kinases. Primary myometrial 
cells were treated with siControl (white bars) or siPLCL-1 (grey bars) for 48 hours. 
Cells were harvested for use in phospho- MAPK dot blot. Phosphorylated kinases 
were detected using chemiluminescence, and the density analysed as a percentage 
of reference spots. Data was analysed using Student’s t-test, P ≤0.05 (*), n=3, error 









Figure 5.2.5- Effect of siPLCL-1 on Phosphorylation of Kinases. Primary myometrial 
cells were treated with siControl (white bars) or siPLCL-1 (grey bars) for 48 hours. 
Cells were harvested for use in phospho- MAPK dot blot. Phosphorylated kinases 
were detected using chemiluminescence, and the density analysed as a percentage 
of reference spots. Data was analysed using Student’s t-test, P ≤0.05 (*), n=3, error 













PLCL-1 knockdown significantly decreases phosphorylation of Akt1, Akt2 and Akt3 in 
MSMCs, the same effect was shown in HESCs (Muter et al, 2016). In addition to Akt, 
a loss of PLCL-1 also leads to a reduction in phosphorylation in other proteins such 
as: GABA(A) receptor and SNAP-25 (Terunuma et al, 2004) (Gao et al, 2012). 
Therefore, one of the functions of endogenous PLCL-1 is to maintain phosphorylation 
states of protein. PLCL-1 can do this using two methods: 1) increase kinase activity 2) 
reduce phosphatase activity. Previous studies have shown that PLCL-1 is able to 
reduce activity of the phosphatase PP1 (Yoshimura et al, 2001). Expression of PLCL-1 
reduces PP1 mediated dephosphorylation of SNAP-25 (Gao et al, 2012). PLCL-1 may 
maintain phosphorylation of Akt by reducing the activity of PP1 (Figure 5.3.1). PP1 
regulates the ability of AKT to modulate gene expression by de-phosphorylating Akt 
at Thr-450.  (Xiao et al, 2010) (Thayyullathi et al, 2011). However, there is more 
evidence showing that AKT is a substrate of PP2a (Andjelković et al, 1996) ( Meier et 
al, 1998) (Di Maira et al, 2009) (Kuo et al, 2008). PLCL-1 binds both PP1 and PP2a, it 
may be that PLCL-1 regulates their activity by sequestering them away from their 
substrates. As previously mentioned phosphorylation of PLCL-1 modulates the 
binding of PLCL-1 to PP1 and PP2a. Phosphorylation of PLCL-1 causes release of PP1 







Figure 5.3.1-PLCL-1 Regulates Phosphorylation of Akt. When PLCL-1 levels are high; 
PLCL-1 can inhibit PP1 and PP2a, thus Akt is kept in a phosphorylated state. The loss 
of PLCL-1, frees PP1 and PP2a to dephosphorylate Akt, thus Akt is inhibited.  
 
 
Akt is activated via phosphorylation. The first step in Akt activation is by JNK1 and 
JNK2 which phosphorylates Akt at Thr-450 (Shao et al, 2006) ( Shaw and 
Kirshenbaum, 2006). Thereafter PI3K activation leads to it converting PIP2 into PIP3, 
which recruits PDK1 and Akt to the plasma membrane, allowing PDK1 to 
phosphorylate at Thr-308 (Stephens et al 1998) (Alessi et al, 1996).  
Phosphorylation of Akt  at Thr-308 causes a conformational change, revealing a 
hydrophobic motif in its C-terminus, this conformational change allows Akt to 
auto-phosphorylate or be phosphorylated by other kinases at Ser-473, causing Akt 
to be fully activated so that it may phosphorylate its target proteins (Behn-Krappa 
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and Newton, 1999) ( Sarbassov et al, 2005).PLCL-1 keeping Akt in a phosphorylated 
state, will allow Akt to be continuously active.  
 
AKT is a serine/threonine kinase and is involved in numerous signalling pathways; 
PLCL-1 regulating AKT phosphorylation, leads to PLCL-1 indirectly regulating 
substrates of AKT. An interesting AKT pathway in MSMCs is the PI3K/AKT/mTOR 
pathway. mTOR is a serine/threonine kinase and it exists in two complexes mTORC1 
and mTORC2, mTORC1 is involved in cell growth while mTORC2 is involved in sell 
survival (Saxton and Sabatini,2017). Akt activates mTORC1 by phosphorylating the 
inhibitory subunit of mTORC1 called PRAS40, this causes it to dissociate from 
mTORC1, (Sancak et al, 2007) (Vander Haar et al, 2007). 
 
Once activated, mTORC1 has numerous downstream targets, such as Cx43. mTORC1 
inhibits expression of Cx43, and subsequent gap junction formation (Smyth and 
Shaw,2014) (Shen et al, 2016). Nadeem et al showed that PRA expressing myometrial 
cells expressed Cx43, which formed gap junctions. Whilst PRB expressing myometrial 
cells had reduced expression of Cx43 and gap junctions, and this reduction was 
mediated by mTORC1 signalling, as inhibition of mTORC1, restored expression of 
Cx43 expression (Nadeem et al, 2016). Interestingly mTORC1 expression is reduced 
in myometrium of women IL compared to NIL (Foster et al, 2014). mTORC1 
expression was also decreased in placental samples from women IL compared to NIL 
(Lager et al, 2014). Additionally, expression of mTORC1 decreased in rat myometrium 
IL  samples compared to NIL  samples  (Jaffer et al, 2009).  
136 
 
Reduction of mTORC1 expression in myometrium during late gestation and labour, 
will stop the inhibition of mTORC1 on Cx43 expression to allow for gap junction 
formation and synchronised MSMCs contraction. A loss of PLCL-1 during labour, may 
cause reduction in AKT signalling and no activation of mTORC1, which then removes 
the inhibition of mTORC1 on Cx43 expression (Figure 5.3.2). It would be expected 
that Cx43 to be one of the differentially expressed genes identified from the RNA 
sequencing data, however Cx43 was not one of the top contributing genes 
contributing to the gene cluster seen in PC9. Nevertheless, the modulatory action of 








Figure 5.3.2- PLCL-1 may Indirectly Affect Downstream Targets of AKT. PLCL-1 
inhibits phosphatases (PP1 and PP2a), thus Akt stays phosphorylated and active. Akt 




HSP27 and Actin Filament Stabilisation  
Monomeric globular actin (G-actin) undergo polymerisation into a filamentous actin 
(F-actin). Myosin head binds to F-actin during contraction, therefore actin 
polymerisation is crucial for contraction and tension development in smooth muscle 
cells (Mehta and Gunst, 1999). There is evidence showing that isoforms of heat shock 
protein (HSP) are involved in actin filament stabilisation (Gerthoffer and Gunst, 
2001). HSPs can form large homo or hetero-oligomeric complexes. Kinases regulate 
HSP activity, phosphorylated HSP leads to a dissociation of the oligomeric complexes, 
permitting smaller phosphorylated HSPs dimers or oligomers to interact with their 
targets. The functional aspects of HSPs are mainly controlled by phosphorylation, 
which stimulates a transformation in the tertiary structure HSPs, thus changing their 
affinity to form homo- or hetero-oligomers or to interact with actin filaments (Gusev 
et al, 2002).  
 
Isoforms of HSP have been associated with modulating both contraction and 
relaxation of MSMCs. Phosphorylation of HSP20 at serine-16 by PKA has been shown 
to bind to α-smooth muscle actin and promote relaxation of the myometrium (Tyson 
et al, 2008). In contrast, HSP27 has been implicated in promoting myometrial 
contractions. There is increased phosphorylation of HSP27 at serine-15 during 
labour. Phosphorylation of HSP27 at serine-15 has been shown to stabilise F-actin 
filaments. Therefore, phosphorylation of HSP27 may promote uterine contractility by 
stabilising actin filament polymerisation (MacIntyre et al, 2008).  
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The MAPK array assay (Figure 5.4.3) showed a decrease in HSP27 phosphorylation in 
MSMCs upon PLCL-1 knockdown. Therefore, a reduction in PLCL-1 levels may lead to 
a decrease in uterine contractility due to the reduction in HSP27 phosphorylation and 
the subsequent loss in actin filament stabilisation. If PLCL-1 functions as a pro-
quiescent protein it would be expected that a loss in PLCL-1 would lead to an increase 








































The classical pathway of PR transcriptional control is thought to follow distinct stages. 
Unliganded PR is in the cytoplasm and bound by regulatory heat shock proteins (Kost 
et al, 1989) (Onate et al, 1991). Upon P4 binding the heat shock proteins dissociate, 
PR forms either homodimers or heterodimers and translocate to the nucleus (Smith, 
1993) (DeMarzo et al, 1991) (Guiochon-Mantel et al,1989). Within the nucleus, PR 
localises to palindromic DNA binding sites which have consensus PRE-regions 
(GnACAnnnTGTnC) in the promoter of PR responsive genes (Chalepakis et al, 1998) 
(Mulvhill et al, 1982) (Lieberman et al, 1993) (Yin et al, 2012). PR recruits 
transcriptional co-regulators to modulate transcription (Onate et al, 1995). However, 
this classical pathway is challenged by data that shows monomer PRs can activate 
transcription (Connaghan-Jones et al, 2008) (Jacobsen et al, 2009), unliganded PR can 
activate transcription and the PRE-sequence is still not precisely well-defined 
(Bamberger et al, 1996). Studies on PR transcription have been conducted using 
many different methods including: luciferase assay with promoters containing PREs, 
deletion of promoters, EMSA (electrophoretic mobility shift assay), DNA foot printing 
or methylation. More recently ChIP ( chromatin immunoprecipitation ) assays have 
been used to search for PR binding sites, and this is used in combination with DNA 
sequencing (ChIP-seq) or microarrays (ChIP-on-ChIP).  
 
In the pregnant myometrium PR keeps the myometrium in a non-contractile state by 
upregulating pro-quiescent genes and downregulating CAPs. One method of 
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progesterone ‘functional withdrawal’ during term is a loss in PRB mediated 
transcriptional modulation, causing an increase in CAPs expression and decrease in 
pro-quiescent genes . Previous studies on NIL vs IL myometrium transcriptome 
studies show a significant reduction in PLCL-1 expression, suggesting that PLCL-1 is 
an important pro-quiescent gene, which indicates that with its loss might be needed 
for parturition. If PLCL-1 is a pro-quiescent gene than it might be a P4 responsive 
gene.   
 
It is hypothesised that PLCL-1 acts a pro-quiescent protein by functioning as an 
effector protein for progesterone. PLCL-1 operates as an effector of progesterone by 
inhibiting the release of intracellular calcium, and thus inhibiting contractions. In 
humans, progesterone concentrations do not decrease before the onset of labour. In 
contrast, PLCL-1 levels do decrease before labour, thus the functional withdrawal of 
progesterone might be through the loss of PLCL-1.  To test this hypothesis, it must 
first be established that the expression of PLCL-1 is modulated by progesterone, this 
was done by doing simple qRT-PCR and western blotting experiments.  
 
If PLCL-1 proved to be a P4 responsive gene I wanted to take a closer look at the 
specific site of PR binding to the PLCL-1 promoter by utilising ChIP-qPCR.  
If PLCL-1 is a progesterone effector protein, PLCL-1 can then be used as biomarker 
that identifies women who are more at risk for premature labour. It would be 
expected that women who are close to term or preterm labour would express less 
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PLCL-1 than women not in labour.  A good clinical test would identify women at risk 
for preterm labour as early as possible. All the previous studies show a loss in PLCL-1 
during labour in the myometrium. However, it is not feasible to take myometrial 
biopsies from women who are not undergoing caesareans. A better method to check 
if there is a reduction in PLCL-1 levels would be to take a blood sample. A blood 
sample can also be taken at any time during the pregnancy, and can identify high risk 
women early, allowing for earlier clinical interventions. There is no study indicating 
that PLCL-1 is expressed by white blood cells, however studies have shown that PLCL-
1 is not exclusively expressed in the uterus but is also expressed by different tissues 
in the body. It must first be established that PLCL-1 is expressed by leukocytes and 
can be quantified from blood samples, therefore the concentration of PLCL-1 in 















6.2 Results  
 
6.2.1- Effect of Medroxyprogesterone Acetate (MPA), P4 and cAMP Treatment on 
PLCL-1 Expression 
 
To determine the effects of MPA and cAMP on the transcription and translation of 
PLCL-1, primary myometrium cell lines were treated with MPA and cAMP for 96 hours 
and then harvested for western blot and RT-PCR analysis. MPA is a derivative of 17α-
hydroxyprogesterone, and is a potent agonist of the progesterone receptor, cAMP 
and progesterone work synergistically to activate progesterone dependent pathways 
and together amplify the effects of MPA (Gellersen and Brosens, 2003). Treating cells 
with cAMP and MPA, increased PLCL-1 transcription by 2.2-fold (SD ± 0.28)  and 2.5-
fold (SD ± 0.56) respectively. Treating the cells with cAMP combined with MPA also 
increased PLCL-1 transcription, to 2.5-fold (SD ± 0.30). Treating the cells with cAMP, 
MPA and cAMP/MPA increased PLCL-1 protein expression by a 1.40, 1.87 and 2.42 
folds ( SD ± 0.05,0.34, 0.25 ), respectively (Figure 6.2.1a).  
 
The cells were treated with progesterone (P4) and the effect P4 had on PLCL-1 
production in primary myometrial cells was examined. P4 treatment alone, increases 
PLCL-1 mRNA by 2.2-fold (SD ± 0.11) in comparison to control. Treatment of P4 in 
combination with cAMP, increased PLCL-1 mRNA by 2.8-fold (SD ± 1.65). The largest 
increase in PLCL-1 mRNA production was seen when cells were treated with P4 and 
MPA together. P4 treatment of primary myometrial cells increased PLCL-1 protein 
levels by 4-fold (SD ± 0.51) compared to control. Treatment of cells with P4 and cAMP 
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or P4 and MPA increased protein production of PLCL-1 by 6-fold (SD ± 1.18) (Figure 
6.2.1b). MPA has a higher binding affinity for PR compared to P4, however it has less 
binding specificity than P4. MPA binds to both androgen receptor and glucocorticoid 
receptor, which P4 does not and has a much higher binding affinity for 
mineralocorticoid receptor compared to P4 (Schindler et al, 2003). The reduction in 
binding specificity of MPA compared to P4, may explain why P4  is a stronger inducer 














Figure 6.2.1a-Effect of cAMP and MPA on PLCL-1 Expression. Primary myometrium 
cells were serum starved for 24 hours and treated with either cAMP, MPA or cAMP 
and MPA together. A) Cells were harvested after 96 hours of treatment and cell 
lysates were analysed for PLCL-1 protein expression by Western blot. B) Band 
intensity from western blot was calculated and treated samples compared relative 
to control. C) mRNA fold change of PLCL-1 was analysed using RT-PCR. Data was 
analysed using one-way ANOVA with Dunnett’s post hoc test. MPA and cAMP/MPA 












Figure 6.2.1b- Effect of P4 on PLCL-1 Expression. Primary myometrium cells were 
serum starved for 24 hours and treated with either, P4, P4/cAMP or P4 and MPA 
together. A) Cells were harvested after 96 hours of treatment and cell lysates were 
analysed for PLCL-1 protein expression by Western blot. B) Band intensity from 
western blot was calculated and treated samples compared relative to control. C) 
mRNA fold change of PLCL-1 was analysed using RT-PCR. Data was analysed using 
one-way ANOVA with Dunnett’s post hoc test. MPA and cAMP/MPA treated cells 










6.2.2- Identifying what Region Within the Promoter of the PLCL-1 Locus 
Undergoes Increased Chromatin Accessibility upon Progesterone Treatment  
 
Assay for Transposase Accessible Chromatin with high-throughput sequencing 
(ATAC-seq) is a technique used to outline chromatin accessibility. The ATAC-seq 
method utilises the actions of the transposase Tn5 enzyme. Tn5 is an enzyme that 
catalyses the movement of transposable elements (TE) from one part of the genome 
to another. In ATAC-seq Tn5 is used to create a double stranded break in areas of the 
genome that are highly exposed or have increased accessibility. Adapters are then 
added to be ligated into the cut DNA. The genome is then fragmented, and the 
adapter ligated fragments are isolated, and PCR amplified for sequencing. Areas in 
the genome that are more open and accessible will have more adapters ligated into 
them, these areas will have more reads upon sequencing, and hence ATAC-seq is 
used to map chromatin accessibility (Figure 6.2.2a) 
 
 
Figure 6.2.2a – ATAC-sequencing Library (A)Schematic representation of ATAC-seq 
library preparation method.  DNA is simultaneously fragmented and tagged with 
sequencing adapters. (B) The DNA fragments are purified and preceding 
amplification, adapters are extended with a 72°C extension step. Additional 
sequence is incorporated into the adapters during the PCR, which comprise common 




Dr Raffaella Lucciola, PhD (University of Warwick) used ATAC-sequencing to map 
regions with increased chromatin accessibility when human endometrial stromal 
cells were decidualised with MPA and cAMP for 96 hours. The ATAC-seq data was 
utilised to identify regions near the PLCL-1 locus that increased chromatin 
accessibility upon treatment with MPA.  Even though the cell type used for the ATAC-
seq data was HESCs and not MSMCs, numerous peaks were identified around the 
PLCL-1 locus, which showed increased chromatin accessibility when endometrial 
stromal cells were treated with MPA and cAMP, as opposed to untreated cells. The 
ATAC-seq data was used to identify which target region to design the ChIP-qPCR 
primers for in myometrial cells.   
 
Endometrial stromal cells were decidualised for 96 hours using MPA and cAMP. 
Decidualised endometrial stromal cells and undifferentiated stromal cells were 
prepared for ATAC-seq analysis. Illumina Hiseq-2500 was used to sequence the PCR 
amplified fragments giving a sequencing depth of 30 million paired end reads, with 
100bp per fragment. The reads were mapped to the h19 genome using bowtie2-2.2.6 
and samtools-1.2.0. Peak calling was performed using MACS-2.1.0; 202,169 peaks 
were identified and HTSeq-0.6.1 (Anders et al, 2015) was used to count the reads 
overlapping the peaks and DESeq2 was used to find differential peaks (Zhang et al, 
2008) (Anders and Hubel, 2010).  
 
Numerous peaks were identified around the PLCL-1 locus, which showed increased 
chromatin accessibility when endometrial stromal cells were treated with MPA and 
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cAMP, as opposed to untreated cells. A 261bp region (chr2:198,667,819-
198,668,079) within the promoter of the PLCL-1 gene was found to have high 
chromatin accessibility when endometrial stromal cells were treated with MPA and 
cAMP. The 261bp region (chr2:198,667,819-198,668,079) was found to be significant 
using MACS 2 (P ≤0.05, N=3) when comparing MPA treated cells to control cells 
(Zhang et al, 2008). Thereafter, the q value is found from the p value using the 
Benjamini-Hochberg procedure. The q value is the FDR (false discovery rate) 
corrected p value, the empirical FDR is defined as number of control peaks / number 
of decidualised peak. The 261bp region (chr2:198,667,819-198,668,079) was found 
to be still significant after correction for the FDR using the Benjamini-Hochberg 




Figure 6.2.2b-Assessing Chromatin Accessibility of PLCL-1 Locus upon 
Decidualisation. Endometrial stromal cells were decidualised for 96 hours using MPA 
and cAMP, cells were then used for ATAC-seq analysis. A) Peaks represent level of  
chromatin accessibility, red peaks are from decidualised cells, black peaks represent 
undifferentiated stromal cells. The higher the peak the more accessible that DNA 
region is. The brackets identify the region of interest with its q value. B) Schematic 
representation of the PLCL-1 gene showing where it is located in chromosome 2, and 




6.2.3- Using ChIP-qPCR in Primary MSMCs and Myla cells, to Study Differences in 
Transcription Factor Binding to the ATAC-seq Identified 261bp region, upon 
Treatment with cAMP/MPA 
 
Chromatin immunoprecipitation is a technique that is used to study protein-DNA 
interactions. The DNA and protein are crosslinked using formaldehyde, the cells are 
lysed, and the DNA is sheared using a sonicator. Part of the sheared DNA is used as 
an input control; the rest is used for immunoprecipitation using specific antibodies. 
Non-specific binding is removed using washing, the cross-linking is then reversed, 
and the DNA is purified for qPCR.  
 
Genome browser and ENCODE was used to find transcription factor binding motif 
within the 261bp region that was identified by Atac-seq. The region was found to be 
bound by 4 transcriptions factors: STAT3, CTCF,YY1 and ZNF143. ChIP-antibodies 
specific to the 4 transcription factors were used for ChIP-qPCR. Myla and primary 
myometrial cells were serum starved and treated with either cAMP, MPA or 
cAMP/MPA for 96 before harvesting for ChIP-qPCR. Forward and reverse primers 
(Table 2.3) spanning the 261bp were designed to study differences in transcription 
factor binding to this region after cAMP/MPA treatment. ChIP-qPCR data was 
normalised using the Percentage Input method; input represents the total amount 
of chromatin that is used before immunoprecipitation. The CT values from the CHIP 
are calculated as a percentage of the CT values from the input.  
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In Myla cells, using a CTCF specific antibody, there was an increase in mean 
percentage input in cells treated with cAMP, MPA and cAMP/MPA (2.91  and 3.63, 
and 3.40, respectively) compared to control (1.56). Using a YY1 and ZNF143 specific 
antibodies a similar trend in mean percentage input as seen in CTCF samples (Figure 
6.2.3a). The STAT3 antibody did not give an adequate DNA yield for qPCR.  
 
ChIP-qPCR experiments were repeated in primary myometrial cells using the 
antibodies CTCF, YY1 and ZNF143. Using a CTCF specific antibody, the percentage 
input increased in cells treated with MPA compared to control. MPA treated cells had 
a percentage input of 2.23 compared to 1.2 in control samples.  ChIP-qPCR with 
ZNF143 and YY1 antibody in primary cells showed an increased percentage input 
when cells were treated with cAMP, MPA and cAMP/MPA compared to control, with 













Figure 6.2.3a- ChIP-qPCR of Myla Cells Using CTCF (A),YY1(B) and ZNF143 (C) 
Antibodies. Myla cells were serum starved for 24 hours before treatment with cAMP, 
MPA or cAMP/MPA for 96 hours. Cells were then prepped for ChIP-qPCR; data was 
analysed using Percentage Input Method.  Data was analysed using one-way ANOVA 





Figure 6.2.3b -ChIP-qPCR of Primary Myometrial Cells Using CTCF (A) ,YY1(B) and 
ZNF143 (C) Antibodies. Primary myometrial cells were serum starved for 24 hours 
before treatment with cAMP, MPA or cAMP/MPA for 96 hours. Cells were then 
prepped for ChIP-qPCR; data was analysed using Percentage Input Method.  Data was 
analysed using one-way ANOVA with Dunnett’s post-hoc test, p ≤0.05p (*), n=3, error 




6.2.4- Is PLCL-1 mRNA Detectable in Whole Blood from Mid-gestation to Late 
Gestation and Active Labour?  
Whole blood samples were collected from pregnant women to investigate if PLCL-1 
expression is measurable from blood. Samples were collected from women in their 
second trimester (mid-gestation) and women who were in active spontaneous 
labour. The women in their second trimester were pregnant from 16-22 weeks. RNA 
was extracted from the whole blood, this was then converted to cDNA for 
quantitative PCR.  The CT values of PLCL-1 and the housekeeping gene L19 were 
analysed. Cycle threshold (CT) is characterised as the number of cycles needed for 
the fluorescent signal to exceed the background fluorescent signal. CT values are 
inversely proportional to the quantity of target mRNA in the sample. The PLCL-1 CT 
values were normalised against the housekeeping gene (Figure 6.2.4).  Whole blood 
samples from women in their second trimester had a mean normalised CT value of 
7.25 (± SD 1.01), which decreased slightly to 7.02 (± SD 0.42) for IL samples. This 
decrease was not found to be significant when using Student’s t test. Cell free RNA 
samples from women in their second trimester had a mean normalised CT value of 
10.19 (± SD 0.70), which decreases to 8.30 (± SD 0.62) for IL samples. This decrease 









Figure 6.2.4-Expression of PLCL-1 in the Blood . Whole blood (A) or plasma (B) was 
collected from women who were in their second trimester and women in active 
spontaneous term labour (+37 weeks). RNA was extracted from for RT-PCR. PLCL-1, 
L19 mRNA levels were detected in RT-PCR. PLCL-1 CT was normalised against 
housekeeping gene (L19).   Data was analysed using Student’s t-test,  P≤0.05 (*).  , 






MPA and P4 both Increase Expression of PLCL-1 
Medroxyprogesterone acetate (MPA), is a synthetic progestin.  MPA binds to and 
activates PRs, MPA has been shown to have a stronger binding affinity for PRs 
compared to P4 (Killinger et al, 1985) (Schindler et al, 2003) (Kuhl, 2005). MPA 
significantly increased expression of PLCL-1, suggesting that PR activation causes a 
rise in PLCL-1 transcription and translation. However, MPA has a weak affinity for 
androgenic receptor (AR), which P4 does not (Bentel et al, 1999) (Phillips et al, 1987) 
(Kuhl, 2005) . Additionally, MPA has a stronger affinity for glucocorticoid receptors 
(GR) and mineralocorticoid receptor (MR) than P4 (Bamberger et al, 1999) (Kontula 
et al, 1983) (Kuhl,2005). Thus, it may be that effects of MPA on PLCL-1 expression 
possibly be through its agonistic actions on AR, GR and MR and not through its actions 
on PRs. Therefore, MSMCs were treated with P4, which also showed an increase in 
PLCL-1 expression, this shows that the increase in PLCL-1 expression by MPA and P4 
is likely to be due to the actions of progesterone receptor.   
 
Co-treatment of cAMP and P4/MPA Increases Expression of PLCL-1 
Cyclic AMP increased expression of PLCL-1, although not as much as P4 or MPA. Cyclic 
AMP has been shown to regulate transcription factors through its activation of PKA 
(Table 6.3.1). Activated PKA translocates to the nucleus, whereby it phosphorylates 
transcription factors, which bind to cAMP response elements (CRE) within the 
promoter of target genes.  Many genes that modulate myometrial contractility have 
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been identified that respond to cAMP (Table 6.3.1). The increase in PLCL-1 expression 
by cAMP, suggest that PLCL-1 transcription is regulated through the cAMP/PKA 
pathway. However, the augmented effects of cAMP/P4 or cAMP/MPA on PLCL-1 
expression, suggest that it’s through the combined effects of cAMP and progesterone 











References Results Cell type Signalling Pathway 
cAMP/PKA/CREB 
 
Human myometrial cells         - Forskolin increased cAMP, PKA and phospho-CREB levels.                            (Yulia et al, 2016) 
                                                    - Forskolin reduced OXTR mRNA. 





Human myometrial cells         - Forskolin reduced expression of OXTR, Cx43 and PTGFR.                        (Amini et al, 2019) 
                                                     - P4 amplified the forskolin induced reduction of   
                                                     - cAMP/PKA signalling pathway work synergistically with P4 to reduce expression of CAPs.  
 
Human myometrial cells         - cAMP reduced NF-κB DNA binding.                                                                (Chen et al, 2014) 
                                                     - cAMP amplified effects of P4 on gene expression. 





Airway smooth muscle cells    - cAMP reduced NF-κb DNA binding.                                                 (Oldenburger et al, 2012) 






There are many examples of cAMP and PR working synergistically and there is 
emerging evidence suggesting that the cAMP pathway integrates with the P4 
pathway and gives cellular specificity to progesterone signalling, mainly by regulating 
transcription factors that modulate PR function (Amini et al, 2019) (Chen et al, 2014). 
The cross talk between the cAMP pathway and the PR pathway is most evident in the 
decidualisation of the endometrium (Brar et al, 1997) (Gellersen and Brosens, 2005). 
Decidualisation is the differentiation of endometrial stromal cells (ESCs), whereby 
they take on a secretory phenotype and undergo morphological changes (Gellersen 
and Brosens, 2005). Progesterone acting on ESCs is vital for ECSs to undergo 
decidualisation, and one of the peptides secreted by differentiated ESCs is prolactin 
(PRL), which is used a marker for decidualisation (Brosens et al,1999) (Tellgman and 
Gellersen, 1998).  A combined treatment of HESCs with MPA and cAMP, increases 
the expression of PRL (Brosens et al, 1999). Pre-treatment of HESCs with cAMP 
before the addition of MPA, accelerated the transcription of PRL, suggesting the 
cAMP/PKA pathway sensitised cells for progestin actions, indicating a synergism 
between cAMP/PKA and P4/PR (Brosens et al, 1999).  
 
Activated PKA translocates to the nucleus and phosphorylates transcriptional 
regulators CREB and CREM (Gonzalez et al, 1989) (Hagiwara et al, 1993). 
Phosphorylated CREB/CREM recruit CREB binding protein (CBP), which has intrinsic 
histone acetyltransferase activity causing it to remodel chromatin structure for 
increased DNA accessibility, leading to increased gene expression (Kwok et al, 1994) 
(Parker et al, 1996). CBP also recruits other transcription factors such as the 
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CCAAT/enhancer-binding protein (C/EBP)(Mink et al, 1997). The PRL promoter has 
both C/EBP binding sites and PR half sites, and PR can bind to C/EBP (Pohnke et al, 
1999).  It may be that C/EBP acts as a tethering protein for PR to bind to the promoter 
of the PRL gene; illustrating the mechanism by which cAMP and P4 work 
synergistically to upregulate expression of PRL. It could also be the same mechanism 
that cAMP/P4 employ to increase chromatin accessibility near the PLCL-1 locus, 
resulting in increases expression of PLCL-1. In addition to C/EBP; STAT5 and FOXO1a 
are transcription factors induced by cAMP and are capable of binding to PR (Gellersen 
and Brosens, 2005). Additionally, CBP is recruited to the pre-initiation complex by the 
PR co-activator -1. The interaction of the cAMP inducible transcription factors with 
PR, creates a model for the cross talk between cAMP and PR, which regulates gene 
expression and may be the model that causes an increase in PLCL-1 expression in 
MSMCs upon treatment with cAMP/MPA/P4 (Figure 6.3.2).  
 
In addition to the evidence in HESCs showing the cross talk between cAMP and 
progesterone, there is also evidence that this cross talk exists in the myometrium and 
it is important for myometrial quiescence. In human MSMCs, cAMP reduces 
expression of the CAP genes: OXTR, Cx43 and PTGFR. Cotreatment of cAMP and P4 
led a further reduction in expression of OXTR, Cx43 and PTGFR (Amini et al, 2019). 
Chen et al, showed that cAMP increased PRB binding to PRE in DNA and augmented 
progesterone’s suppression of COX-2 expression and progesterone’s induced 






Figure 6.3.2- Proposed Model of cAMP/P4 Synergism to Increase Expression of PLCL-
1. Elevated levels of camp leads to increased activation of camp responsive 
transcription factors ( C/EBP, STAT5 and F0XO1a) which interact with PR to increase 
transcription of PLCL-1.  
 
 
cAMP/MPA Treatment of HESCs Increases DNA Accessibility of PLCL-1 Promoter 
and Transcription  Factor Binding in MSMCs 
 
Treatment of HESCs with cAMP/MPA led to increased chromatin accessibility of a 
261bp region (chr2:198,667,819-198,668,079) near the PLCL-1 locus. The increased 
chromatin accessibility of this region shows that upon cAMP/MPA treatment the 





ChIP-qPCR showed a significant increase in CTCF binding to the 261bp region upon 
treatment with cAMP/MPA in both primary MSMCs and Myla cells. CTCF is an 82 kDa 
protein that functions as a ubiquitously expressed transcriptional regulator 
(Filippova et al, 1996). It recognises and binds to the DNA sequence CCCTC, and 
there are around 55,000 CTCF binding regions in the genome; 50% of the sites are 
in non-coding regions, 35% are in within gene sequences and 15% are proximal to 
promoter sites (Chen et al, 2008) (Chen et al, 2012). CTCF has a conserved structure, 
that is separated into 3 different domains; N-terminal region, C-terminal region and 
central domain (Vostrov et al, 2002). The central domain has 11 zinc fingers, which 
CTCF uses to bind to DNA. CTCF is a multi-functional protein that recruits different 
binding proteins that can regulate the function of CTCF.  
 
Studies show that CTFC functions as either a transcriptional repressor or activator or 
an insulator protein (Filippova et al, 1996)( Gaszner et al, 2006) ( Klenova et al, 
1993) . Insulator sequences are short sequences found between enhancer sequence 
and gene promoters. CTCF can bind insulators sequences to impede any interaction 
between the enhancers and promoters, leading to gene repression. In the chicken β-
globin locus; CTCF was found to bind to insulator sequences, causing the formation 
of a chromatin loop that blocked any access to enhancer sequences, causing a 
repression of β-globin expression (Splinter et al, 2006). However, CTCF can also 
form a chromatin loop, so that the enhancer and the promoter can interact; there 
is transcriptional activation (Kim et al, 2015).   
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CTCF co-localises with cohesin in the genome. Cohesin is a ring-shaped protein, made 
up of three subunits: SMC1, SMC3 and SCC3. Cohesin forms a ring around chromatin 
loops, to stabilize it and increase interactions between enhancers and promoters, 
allowing transcription factors to bind to enhancers and be near promoters for 
transcriptional activation (Kagey et al, 2010) (Parelho et al, 2008) (Wendt et al, 
2008) (Figure 6.3.3).  Cohesin does not directly bind to DNA, it functions through its 
association with CTCF. ChIP-qPCR studies showed that alongside CTCF, there was 
binding of SMC3 and RAD21 (component of the cohesin complex) on the 261bp 







Figure 6.3.3- Interaction Between CTCF and Cohesin. CTCF and cohesin complex 
cause either activate or inhibit transcription. Cohesin and CTCF can create a 
chromatin loop that contains enhancers and promoters, leading to transcriptional 
activation. A chromatin loop that foils the enhancer from interacting with the 
promoter leads to inhibition of transcription. Figure from Kim et al, 2015  
  
 
CTCF is regulated by post-translational modifications and by its binding partners 
(Weth et al, 2011). One binding partner of CTCF is Yin and yang 1 (YY1), which also 
had a significant increase in binding to the 261bp region near the PLCL-1 locus, upon 
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treatment with cAMP/MPA in both primary MSMCs and Myla cells (Donohoe et al, 
2007). YY1 is a transcription factor that acts as both an activator and repressor 
(Gordon et al, 2006). Co-immunoprecipitation studies show that YY1 binds to the N-
terminus domain of CTCF. The interaction between YY1 and CTCF is particularly 
important for X-inactivation(Donohoe et al, 2007). YY1 and CTCF associate together 
to amplify transcription of Xist; a non-coding antisense RNA that is involved in 
mammalian X-inactivation (Donohoe et al, 2007). As YY1 and CTCF binding can lead 
to enhanced transcriptional activation, it may be that treatment of MSMCs with P4, 
leads to increased recruitment of YY1/CTCF to the PLCL-1 promoters leading to 
increased transcription of PLCL-1.  
 
Zinc finger protein 143 (ZNF143) is a transcriptional activator, that was first 
discovered activating transcription of the tRNA gene, through binding its promoter 
and recruiting  RNA polymerase III (Schaub et al,1999) (Hernandez-Negrete et al, 
2011). Treatment of MSMCs with cAMP/MPA increased ZNF143 binding near the 
PLCL-1 locus. Apart from its role as a transcriptional activator, ZNF143 has also been 
implicated in formation of chromatin loops; to provide proximity between distal 
enhancer sequences to promoter regions, leading to increased gene expression. 
Bailey et al proposed a model, whereby through the interactions between ZNF143, 
CTCF, RNA pol 2 and cohesin, there is interaction between distal promoters and 
























Figure 6.3.4- Proposed Model for Interactions Between ZNF143 and CTFC, and Other 
Binding Proteins.  ZNF143 binds directly to promoters, whilst CTCF binds to insulator 
sequences near enhancers. The interaction between ZNF143 and CTCF, bring 
enhancer sequences and promoter sequence near to each other. Allowing 
transcription factors (TF) that are bound to enhancers to activate transcription of 































7.1- The Challenges of Researching and Preventing Preterm Labour 
 
The complexity and uniqueness of human parturition in comparison to the available 
animal models renders it very challenging to study the mechanism of labour and 
preterm labour. There are still many questions and gaps in the knowledge of the 
different phases of pregnancy and parturition; starting from implantation through to 
involution, and the differences between term and preterm labour. Perhaps preterm 
labour is just an accelerated form of term labour and the mechanism that lead to 
both is the same, but an environmental or genetic factor triggers an acceleration of 
the biochemical pathways to parturition; causing premature labour. Another 
explanation is that there is a clear difference in the molecular pathways between 
term and preterm labour, and it is the activation of a specific pathway that causes 
premature labour. 
 
A tangible explanation to the mechanism of term and preterm labour in humans will 
require a suitable model, in which the findings can then be confidently translatable 
to humans. Currently the different animal models for studying parturition are limiting 
due to the uniqueness of human parturition. In sheep, parturition is initiated by 
foetal signals that derive from the HPA axis (Liggins et al, 1967) (Liggins et al, 1968). 
In goats, parturition follows the dissolution of the corpus luteum (Cooke et al, 1980). 
Comparative genomic studies between humans and chimpanzees, show a genome 
that is 95% similar; the greatest difference being in genes that govern reproduction 
(Chen et al, 2005) (Chimpanzee Sequencing and Analysis Consortium,2005). 
Additionally, the changes in the female pelvis, due to the evolving of humans into an 
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upright position and the relative large human cranium have had consequences for 
human parturition. It could be, that the large differences in human parturition in 
comparison to other mammals is due the distinctiveness of the human pelvis.  
Undoubtedly the main obstacle in using animal models to study human parturition is 
that most of the animal models, undergo a withdrawal of progesterone in the 
maternal systemic circulation. In humans there is no such withdrawal in circulatory 
progesterone, but the hypothesis of a functional progesterone withdrawal, which has 
different proposed mechanisms. Functional progesterone withdrawal rather than 
circulatory progesterone withdrawal may explain why progesterone is a weak 
tocolytic in humans (O’Brien et al, 2007) (Rouse et al, 2007) (Kuon et al, 2010). The 
continuous rise in preterm labour globally highlights the urgent need for better 
diagnostic tools and more effective tocolytics; this will only be achieved by using 
animal models that have a parturition process that is more similar to humans and a 
better understanding of the mechanism of progesterone and its role in human 
pregnancy.  
Any potential new tocolytic will have to consider the issue of gene redundancy in 
parturition for it to be effective at improving neonatal outcomes. Gene redundancy 
is when there are several different genes that perform the same biological function, 
thus a loss in the expression of one gene will have no consequence on the phenotype 
(Nowak et al, 1997).   A series of experiments on transgenic mice demonstrate the 
genetic redundancy in biological pathways that mediate parturition. In mice, a 
reduction in progesterone due to luteolysis initiates labour, and luteolysis is 
instigated by a rise in pre-partum PGF2α (Uozumi et al,1997) (Sugimoto et al, 1997) 
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(Bonventre et al, 1997).   In the myometrium, PGF2α and OT both bind to Gαq coupled 
GPCRs; activating the same biological cascade, which leads to contraction (Blanks et 
al, 2007) (Lopez-Bernal,2003) (Sanborn et al, 2005). OT null mice undergo normal 
delivery of offspring, whilst COX-1 null mice fail to deliver until surgical or 
pharmacological intervention produces luteolysis and subsequent progesterone 
withdrawal, re-establishing normal delivery (Nishimori et al, 1996) (Young et al, 
1996). Therefore, the transgenic mice show that a loss in either OT or prostaglandins 
(PG) does not stop contraction after progesterone withdrawal has begun.   In double 
knockout mice (OT/ COX-1 null) luteolysis does occur and labour is initiated but the 
mice experience prolonged delivery. As labour is not triggered in COX-1 null mice but 
does in double knock out mice, it shows that there is compensation when OT is 
knocked out and that the OT pathway has luteotrophic functions that is only unveiled 
in the double knockout mice (Gross et al, 1998). Treatment of OT null mice with OT, 
show that the OT null mice are more sensitive to OT compared the wild type (WT) 
mice, and at high OT dosage both OT null and WT mice undergo premature labour 
without luteolysis and progesterone withdrawal (Imamura et al, 2000). The increased 
sensitivity of OT null mice to OT, suggest an upregulation of OTR receptors in OT null 
mice compared to WT. The insertion of a neomycin cassette in COX-1 gene created a 
COX-1 knockdown mice, resulting in a reduction in production of PG but normal 
parturition, even though the levels of PG were similar to COX-1 null mice, which could 
not initiate labour. OTR was upregulated in the COX-1 knockdown mice, this shows 
that there is compensation between the OT pathway and the PG pathway, which 
suggest that there is gene redundancy in these two pathways (Yu et al, 2005). 
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Therefore, any novel tocolytic might have to have to target multiple proteins to 
bypass the genetic redundancy of parturition and prevent premature labour.  
 
This thesis showed the role of PLCL-1 in uterine quiescence, an investigation 
prompted due to its reduced expression in labouring myometrium and is ability to 
inhibit release of [Ca2+]i in neuronal cells.  
To summarise, I provide data demonstrating that:  
i. PLCL-1 regulates intracellular calcium concentrations in primary myometrial 
smooth muscle cells. The oxytocin induced rise in [Ca2+]i is amplified with the 
loss of PLCL-1 expression or subdued with the overexpression of PLCL-1.  
ii. PLCL-1 mediates changes in the transcriptome of primary MSMCS; directly 
affecting expression of CAPs or quiescent genes.  
iii. Through the inhibition of phosphodiesterases, PLCL-1 can maintain basal 
cAMP levels.  
iv. Progesterone, MPA and cAMP all increase expression of PLCL-1. MPA also 
changes the chromatin landscape of the PLCL-1 gene locus making it more 
accessible for induction of gene expression.  
v. Progesterone recruits co-factors to PLCL-1 locus; illustrating a mechanism 





7.2-PLCL-1 Decreases Myometrial Contractility  
PLCL-1 decreases myometrial contractility by regulating the contractile apparatus of 
the MSMC; PLCL-1 does this both directly and indirectly. Calcium is the central 
molecule for contraction of the smooth muscle cells, the rise [Ca2+]i leads to a cascade 
of substrate activation, eventually resulting in cross-bridge cycling (contraction-
relaxation). PLCL-1 directly inhibits cross-bridge cycling by inhibiting the rise [Ca2+]i, 
hence directly preventing contraction in MSMCs. PLCL-1 indirectly inhibits 
myometrial contractions by maintaining cAMP concentration, through its inhibition 
of PDE7B. Cyclic AMP activates PKA, which then inhibits MLCK. PLCL-1 indirectly 
promotes MSMCs quiescence by regulating the cAMP/PKA/MLCK pathway.  
 
Another explanation for the PLCL-1 mediated reduction in [Ca2+]i  could be through 
the binding of PLCL-1 to phosphatases PP1c and PP2A. PP1c is involved in the 
regulation of calcium release from ER. PPD2 is part of peptide group that selectively 
activate different phosphatases, by disruption the binding of phosphates to proteins 
that inhibit their activity (Chatterjee et al, 2012). Treating Hela cells with PPD2 causes 
a spike in calcium oscillations. The increase in [Ca2+]i  in Hela by PPD2 was due to 
release from intracellular calcium stores, as the experiments were conducted 
without the presence of external calcium. Furthermore, the increase in [Ca2+]i  by 
PPD2 was mediated by its actions on IP3 receptors on the endoplasmic reticulum (ER). 
Using IP3 receptor selective inhibitor Xestospongin C, PPD2 mediated increase in 
[Ca2+]i  was lost ( Reither et al, 2013).  
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Phosphatases also control entry of external calcium into smooth muscle cells, by 
regulating L-type VOCC. Tautomycin: a potent and selective PP1/PP2a inhibitor 
(Cheng et al, 1987) (MacKintosh and Klumpp, 1990), was shown to inhibit the 
opening of L-VOCC, this signifies that dephosphorylation of L - VOCC by PP1/PP2a 
increases its activity (Groschner et al, 1995) (Figure 7.2.1) However this study was 
opposed when the purified catalytic subunit of PP2A (PP2ac), inhibited the opening 
of L-VOCC, whilst the catalytic subunit of PP1 (PP1c) had no effect the opening of L-
VOCC (Groschner et al, 1996).  Both studies were conducted in primary vascular 




Figure 7.2.1-Modulation of L-VOCC and IP3R by Phosphatases. Protein phosphatase 
1 (PP1) dephosphorylates L-type voltage operated calcium channels (L-VOCC) and 
this may increase the open state duration of L-VOCC. Paradoxically 
dephosphorylation of L-VOCC by protein phosphatase 2a (PP2a) has an opposite 
effect on L-VOCC compared to PP1. Dephosphorylation of IP3 receptors (IP3R) on the 
endoplasmic reticulum by PP1, modulates the opening of IP3R .  
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PLCL-1 binds to the catalytic subunits of the phosphatases: PP1 and PP2a (Figure 
7.2.2). (Yoshimura et al, 2001) (Kanematsu et al, 2006). The binding sites on PLCL-1 
for PP1 and PP2a are close, however binding of the two phosphatases is mutually 
exclusive, as PP2a binding to PLCL-1 results in PP1 to dissociate from PLCL-1. 
Similarly, PP1 causes PP2a to dissociate from PLCL-1 (Sugiyama et al, 2012). PLCL-1 
affects the dephosphorylation activity of PP1 but not PP2A. PLCL-1 inhibited the 
ability of PP1 to dephosphorylate myosin light chain in a dose dependent manner, 
but no such effect was observed on the catalytic activity of PP2a (Yoshimura et al, 
2001) (Sugiyama et al, 2012) (Terunuma et al, 2004).  
 
PLCL-1 is a target protein for PKA phosphorylation. PKA phosphorylation of PLCL-1 
resulted in the dissociation of PP1 from PLCL-1, however no similar effect was seen 
on PP2a (Terunuma et al, 2004) (Sugiyama et al, 2012). The dissociation of PP1 from 
PLCL-1 upon PKA phosphorylation of PLCL-1, increased the binding affinity of PP2a to 
PLCL-1 (Sugiyama et al, 2012).  PKA phosphorylation of PLCL-1 increases activity of 
PP1; overexpressing PLCL-1 in PC12 cells accelerated SNAP-25 dephosphorylation 




Figure 7.2.2-PLCL-1 as a Scaffold Protein for Phospho-regulation. PLCL-1 binds to 
both phosphatases PP2a and PP1. Phosphorylation of PLCL-1 causes the release of 
PP1, but increases PLCL-1 binding strength to PP2A.  
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The binding of both PP1 and PP2a to PLCL-1 and PLCL-1 being a target for PKA 
phosphorylation; suggest that PLCL-1 acts a scaffold protein that regulates 
phosphorylation states of other proteins (Sugiyama et al, 2013). The phosphorylation 
states of IP3 receptor or L-VOCC can regulate their activity. As PLCL-1 may be a 
phospho-regulatory scaffold protein; PLCL-1 may indirectly regulate the 
phosphorylation states of IP3 receptor and L-VOCC, and through this regulation it may 
explain the effects of PLCL-1 on [Ca2+]i (Figure 7.2.3).  
 
Activation of PP1 causes an increase in release of [Ca2+]i from intracellular stores 
(Reither et al, 2013). PP1 also may increase the activity of L-VOCC. Overexpression of 
PLCL-1 decreases the activity of PP1, however phosphorylation of PLCL-1 causes PP1 
to be released and this allows PP1 to dephosphorylate its target protein. It may be 
that PLCL-1 sequesters PP1 and inhibits PP1, and this may stop PP1 from increasing 
intracellular [Ca2+]i  via its actions on IP3 receptors and L-VOCC.  
 
 
Figure 7.2.3 The Effect of PLCL-1’s Role as Phospho-regulatory Protein on [Ca2+]i. An 
unphosphorylated PLCL-1 sequesters both PP1 and PP2a. Phosphorylation of PLCL-1, 




7.3- Proposed Mechanisms for PLCL-1 Reduction in the Labouring 
Myometrium 
 
PLCL-1 expression is modulated by progesterone (Chapter 6), The reduction of PLCL-
1 in the labouring myometrium could be a consequence of the loss in progesterone 
signalling.  One of the proposed models of `functional’ progesterone withdrawal is 
that progesterone is synthesised and metabolised in a paracrine system. During the 
quiescence phase of pregnancy, progesterone is synthesised by the amnion, chorion 
and decidua where it then acts upon on the myometrium in a paracrine manner (Gib 
et al, 1980) (Mitchell et al, 1987). Before the onset of labour progesterone is then 
metabolised in the amnion, chorion into progesterone metabolites, keeping the 
circulatory maternal progesterone high, but low in the adjacent myometrium 
(Mahendroo et al, 1996) (Mitchell and Wong, 1993). PLCL-1 expression is increased 
by progesterone, however during labour there is a decrease in PLCL-1 expression in 
the myometrium. The PLCL-1 reduction in labouring myometrium, may be explained 
by local metabolism of progesterone in the foetal membrane and maternal decidua, 
(Figure 7.3). Another explanation for the localised myometrial reduction in PLCL-1, is 
the modulatory change in PR co-regulators. During the stimulation phase of 
pregnancy  there is a inhibition of P4  co-activators  in the myometrium, this leads to 





Figure 7.3- Proposed Model of Local Progesterone Functional Withdrawal Reducing 
PLCL-1 Expression. Progesterone is synthesised and metabolised in a paracrine 
method, by the foetal membranes and the decidua. Progesterone or progesterone 
metabolites act on the neighbouring myometrium, leading to either transcription of 
PLCL-1 or no transcription of PLCL-1.  
 
 
7.4- PLCL-1 Is an Effector Protein of Progesterone 
 
ATAC-seq data, showed an increase in chromatin accessibility, proximate to the PLCL-
1 locus upon decidualisation of HESCs. ATAC-seq data demonstrated that cAMP/MPA 
recruits histone acetyltransferases to the PLCL-1 promoter; permitting transcription 
factor binding to induce expression of PLCL-1. There are more than 300 co-regulators 
of PR. Co-regulators are sub-characterised as co-repressor or co-activators 
depending upon whether they inhibit or activate transcription, respectively. 
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Chromatin modifiers either increase chromatin accessibility or decrease it, this 
usually involves histone acetyltransferase (HAT) or histone deacetylases (HDAC), 
which modify chromatin conformation to either an open or closed state, respectively 
(Grunstein, 1997) (Strahl and Allis, 2000) (Brosens et al, 2004). An example of a co-
regulator of PR is CREB binding protein (CBP) and steroid receptor co-activator 1 
(SRC-1), which work synergistically to co-activate PR mediated transcription (Smith 
et al, 1996). SRC-1 has both intrinsic HAT activity and can recruit other HATs such as 
p300/CBP-associate factor (PCAF) for increased chromatin accessibility (Spencer et 
al, 1997). The interaction between PR and its co-regulators is thought to stabilise the 
pre-initiation complex, allowing for transcription factor binding and the recruitment 
of RNA polymerases to activate transcription (Klein-Hitpass et al, 1990).  
 
The ATAC-seq data showed that the upon treatment with cAMP/MPA, the chromatin 
conformation around the PLCL-1 locus was in an open state, indicating increased 
chromatin accessibility, suggesting that cAMP/MPA recruited histone 
acetyltransferase to the PLCL-1 promoter site. Using genome 
browser/ENCODE/Factorbook motif; the ATAC-seq identified area was shown to be 
rich in transcription factor binding. Using ChIP-qPCR on this region, I showed that 
cAMP/MPA increased binding of transcription factors: CTCF, YY1 and ZNF143. CTCF 
and YY1 are both transcriptional activators and repressors, but ZNF143 is thought to 
be only a transcriptional activator. Both ZNF143 and YY1 interact with CTCF, and 
there being evidence showing that this interaction leads to transcriptional activation 




It is hypothesised that progesterone increases transcription of PLCL-1 because PLCL-
1 acts an effector protein for progesterone’s pro-quiescent function in the 
myometrium, and a loss of PLCL-1 during labour leads to a loss in quiescence and 
activation of contractions. PLCL-1 acts as an effector protein of progesterone using 
different mechanisms, with the key mechanism being the ability of PLCL-1 to reduce 
[Ca2+] i in MSMCs. Regulation of [Ca2+] i by PLCL-1, may be the reason why PLCL-1 is 
able to modulate changes in the transcriptome, in particular changes in genes 
involved in quiescence or parturition. RNA-sequencing showed that PLCL-1 acts as an 
effector of progesterone by decreasing expression of the pro-contractile 
phosphodiesterases, leading to the inhibition of cAMP metabolism. 
 
PLCL-1 has multiple biological functions due to its nature as a scaffold protein, with 
numerous binding proteins. PLCL-1 is grouped within a rare cohort of proteins that 
can bind two of the most ubiquitous phosphatases: PP2a and PP1 (Sugiyama et al, 
2013). PLCL-1 binds to and inhibits PP1, but when phosphorylated by PKA, it releases 
PP1 but has a stronger binding affinity for PP2a. PP1 and PP2a have a vast number of 
cellular substrates, leading to either activation or inhibition of these substrates. 
Therefore, through the modulation of PP1 and PP2a, PLCL-1 is indirectly able to 
regulate a wide repertoire of proteins, which are involved in different biological 
functions including quiescence and parturition. In addition, PLCL-1 binds to and 
regulates Akt, which also has a vast number of cellular substrates. Through the 
binding of PP1, PP2a and Akt; PLCL-1 is able affect different molecular pathways and 
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cascades, which can explain the multi-functional nature of PLCL-1. Furthermore, 
PLCL-1 may have a physical function, by sequestering IP3 from binding to IP3 
receptors on the ER and releasing intracellular calcium in MSMCs. The multi-
functional nature of PLCL-1 and its diverse binding partners, categorises it as a very 
fascinating protein. The loss of PLCL-1 in the labouring myometrium leads to a loss in 
the pro-quiescent functions of PLCL-1, making PLCL-1 a viable future diagnostic 








Figure 7.4- Proposed Role of PLCL-1 in the Maintenance of Uterine Quiescence 
During Human Pregnancy. PLCL-1 employs multiple mechanisms to inhibit 
myometrial contractions. PLCL-1 acts as an effector protein of progesterone 
signalling, it affects the transcriptome by inhibiting phosphodiesterase’s, which 
metabolise the pro-quiescent cyclic nucleotides (cAMP and cGMP). PLCL-1 also 
reduces intracellular calcium concentrations.  
180 
 
7.5- Limitations and Future Direction 
 
One of the main weaknesses in this thesis is the oxytocin treatment duration for the 
RNA sequencing samples. Only one gene oxytocin responsive gene (COX2) was 
measured, when deciding what the optimal oxytocin treatment duration was. Ideally, 
more oxytocin responsive genes should have been investigated to ensure that 
treatment duration chosen was in the maximal response window. Another limitation 
is that the data obtained from the ATAC-seq was from HESC and not MSMCs. Albeit, 
the data did show increased chromatin accessibility around the PLCL-1 locus, upon 
treatment with MPA and other studies done in numerous different cell types showed 
that the target region identified from the ATAC-seq data was rich in transcription 
factor binding. The target region identified also showed  that MPA increased 
transcription factor binding in MSMCs  (Chapter 6).  
 
The blood samples did show that PLCL-1 is measurable from blood samples. A future 
direction would be to compare changes in PLCL-1 levels in the blood, between term 
women not in labour and term women in labour. This would show whether PLCL-1 is 
downregulated in blood during labour and thus if it is a potential preterm birth 
biomarker.  
 
Another area of future work with PLCL-1 is to delete the ATAC-seq identified region 
using CRISPR/cas 9 and thereafter investigate if progesterone is still able to 
upregulate PLCL-1. The deletion would show that progesterone recruits co-activators 
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only to the  ATAC-seq identified region in PLCL-1 promoter to upregulate expression 
of PLCL-1. Additionally, another area of future work could be investigating the effect 
of PLCL-1 on heat shock proteins.  
 
 
7.6- Conclusion  
 
In conclusion this thesis shows significant evidence that PLCL-1 is reduced in the 
labouring myometrium because it functions as a pro-quiescent protein. Progesterone 
upregulates transcription of PLCL-1 by increasing transcription factor binding to the 
PLCL-1 promoter. Subsequently, PLCL-1 acts as an effector protein for progesterone 
by inhibiting the release of calcium from intracellular stores and by maintaining 
baseline cAMP concentrations. The multiple mechanisms by which PLCL-1 functions 
in the myometrium, shows the complexity of pregnancy and the gene redundancy 
found not only in parturition but also in quiescence. Any future diagnostic test for 
preterm birth will have to take into consideration the multiple molecular 
mechanisms that maintain uterine quiescence, and thus will have to test for multiple 
biochemical markers. PLCL-1 could be one of the biochemical markers that is tested, 
if a method is established for testing localised PLCL-1 levels. Therefore, any further 
work on PLCL-1 will have to be on creating a diagnostic test that safely and accurately 






















Appendix 1 – Top Genes Contributing to PC9 Clustering, from their 
Loadings and Genes Up or Downregulated in all Patients 
 
Gene Symbol Gene Name 
PLCL1 phospholipase C like 1 
TBX5-AS1 TBX5 antisense RNA 1 
LOC155060 AI894139 pseudogene 
LOC101927701 long intergenic non-protein coding RNA 1812 
PLA2G3 phospholipase A2 group III 
LOC102724828 39S ribosomal protein L23, mitochondrial 
PWAR5 Prader Willi/Angelman region RNA 5 
SKOR1 SKI family transcriptional corepressor 1 
BCL2A1 BCL2 related protein A1 
WNT2 Wnt family member 2 
LDB3 LIM domain binding 3 
PDE7B phosphodiesterase 7B 
PRKG2 protein kinase cGMP-dependent 2 
SULT1A1 sulfotransferase family 1A member 1 
DHRS2 dehydrogenase/reductase 2 
TMC4 transmembrane channel like 4 
C21orf33 glutamine amidotransferase like class 1 domain containing 3A 
SPDYA speedy/RINGO cell cycle regulator family member A 
PCDHB6 protocadherin beta 6 
STX11 syntaxin 11 
DDTL D-dopachrome tautomerase like 
CRYGS crystallin gamma S 
PAQR5 progestin and adipoQ receptor family member 5 
CA9 carbonic anhydrase 9 
UCA1 urothelial cancer associated 1 
MYH1 myosin heavy chain 1 
FCHO1 FCH domain only 1 
NPB neuropeptide B 
SORCS3 sortilin related VPS10 domain containing receptor 3 
RASL11B RAS like family 11 member B 
CYP19A1 cytochrome P450 family 19 subfamily A member 1 
PARD6G-AS1 PARD6G antisense RNA 1 
SYT14 synaptotagmin 14 
COLEC10 collectin subfamily member 10 
DACT3-AS1 DACT3 antisense RNA 1 
GOLGA2P5 GOLGA2 pseudogene 5 
LOC101929295 uncharacterized LOC101929295 
HERC2P3 hect domain and RLD 2 pseudogene 3 
TMEM9B-AS1 TMEM9B antisense RNA 1 
SMG7-AS1 SMG7 antisense RNA 1 
KCNE5 




RN7SL2 RNA component of signal recognition particle 7SL2 
KCNJ15 potassium voltage-gated channel subfamily J member 15 
ESPNL espin like 
WNT7B Wnt family member 7B 
ZNF835 zinc finger protein 835 
LOC100288846 uncharacterized LOC100288846 
TLE6 TLE family member 6, subcortical maternal complex member 
RGS22 regulator of G protein signaling 22 
BMS1P5 BMS1 pseudogene 1 
IRX3 iroquois homeobox 3 
B3GALT5 beta-1,3-galactosyltransferase 5 
THEGL theg spermatid protein like 
HOXD11 homeobox D11 
EPHA7 EPH receptor A7 
CATSPER3 cation channel sperm associated 3 
FBXW9 F-box and WD repeat domain containing 9 
CD40 CD40 molecule 
FBXO16 F-box protein 16 
PI16 peptidase inhibitor 16 
ZNF572 zinc finger protein 572 
FGF10 fibroblast growth factor 10 
BEX5 brain expressed X-linked 5 
PDE2A phosphodiesterase 2A 
SAMD5 sterile alpha motif domain containing 5 
PDE3A phosphodiesterase 3A 
PHKG1 phosphorylase kinase catalytic subunit gamma 1 





Appendix 2 - Down Regulated Genes: Transcript Per Million-Fold 
Change of PC9 Genes due to PLCL-1 Knockdown 
 
GENE SYMBOL  GENE NAME  FOLD 
CHANGE 
C21ORF33 glutamine amidotransferase like class 1 domain containing 3A 0.24475 
MYH1 myosin heavy chain 1 0.26215 
BEX5 brain expressed X-linked 5 0.27297 
LDB3 LIM domain binding 3 0.29048 
HERC2P3 hect domain and RLD 2 pseudogene 3 0.41867 
DDTL D-dopachrome tautomerase like 0.45070 
SKOR1 SKI family transcriptional corepressor 1 0.45378 
ZNF835 zinc finger protein 835 0.47439 
PLCL1 phospholipase C like 1 0.49388 
CA9 carbonic anhydrase 9 0.50013 
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RASL11B RAS like family 11 member B 0.55213 
THEGL theg spermatid protein like 0.56395 
WNT7B Wnt family member 7B 0.57202 
EFHD1 EF-hand domain family member D1 0.61906 
GOLGA2P5 GOLGA2 pseudogene 5 0.65510 
WNT2 Wnt family member 2 0.69976 
LOC100288846 uncharacterized LOC100288846 0.70045 
CACNA1H calcium voltage-gated channel subunit alpha1 H 0.70238 
LOC155060 AI894139 pseudogene 0.70667 
PI16 peptidase inhibitor 16 0.71363 
CRYGS crystallin gamma S 0.71999 
SPDYA speedy/RINGO cell cycle regulator family member A 0.74702 
KCNE5 potassium voltage-gated channel subfamily E regulatory 
subunit 5 
0.77351 
B3GALT5 beta-1,3-galactosyltransferase 5 0.77747 
LOC102724828 39S ribosomal protein L23, mitochondrial 0.78078 
NPB neuropeptide B 0.78152 
WNT5A Wnt family member 5A 0.78360 
SULT1A1 sulfotransferase family 1A member 1 0.84328 
PDE3A phosphodiesterase 3A 0.85066 
PLA2G3 phospholipase A2 group III 0.86027 
HOXD11 homeobox D11 0.86765 
SAMD5 sterile alpha motif domain containing 5 0.87978 
GRK5 G protein-coupled receptor kinase 5 0.88091 
SYT14 synaptotagmin 14 0.89025 
STX11 syntaxin 11 0.89994 
EPHA7 EPH receptor A7 0.90039 
FBXW9 F-box and WD repeat domain containing 9 0.91122 
IRX3 iroquois homeobox 3 0.95849 
 
Appendix 3 - Up Regulated Genes: Transcript Per Million Fold Change 
of PC9 Genes due to PLCL-1 Knockdown 
 
GENE SYMBOL  GENE NAME  FOLD 
CHANGE 
SORCS3 sortilin related VPS10 domain containing receptor 3 3.86272 
LOC101927701 long intergenic non-protein coding RNA 1812 3.61847 
FGF10 fibroblast growth factor 10 3.31439 
SMG7-AS1 SMG7 antisense RNA 1 3.03501 
BCL2A1 BCL2 related protein A1 2.81379 
UCA1 urothelial cancer associated 1 2.50498 
TBX5-AS1 TBX5 antisense RNA 1 2.35606 
DACT3-AS1 DACT3 antisense RNA 1 2.26310 
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MMP7 matrix metallopeptidase 7 2.17142 
PDE2A phosphodiesterase 2A 2.04842 
CATSPER3 cation channel sperm associated 3 2.03671 
FBXO16 F-box protein 16 1.98600 
TMEM9B-AS1 TMEM9B antisense RNA 1 1.95586 
PRKG2 protein kinase cGMP-dependent 2 1.84421 
LOC101929295 uncharacterized LOC101929295 1.75409 
PCDHB6 protocadherin beta 6 1.72971 
TMC4 transmembrane channel like 4 1.61407 
BMS1P5 BMS1 pseudogene 1 1.60250 
CYP19A1 cytochrome P450 family 19 subfamily A member 1 1.59154 
RGS22 regulator of G protein signaling 22 1.55308 
PWAR5 Prader Willi/Angelman region RNA 5 1.49462 
PARD6G-AS1 PARD6G antisense RNA 1 1.48373 
ZNF572 zinc finger protein 572 1.46641 
PDE7B phosphodiesterase 7B 1.46559 
RN7SL2 RNA component of signal recognition particle 7SL2 1.37856 
FCHO1 FCH domain only 1 1.37470 
PAQR5 progestin and adipoQ receptor family member 5 1.35338 
TLE6 TLE family member 6, subcortical maternal complex member 1.33066 
KCNJ15 potassium voltage-gated channel subfamily J member 15 1.30830 
ESPNL espin like 1.28572 
CD40 CD40 molecule 1.27151 
DHRS2 dehydrogenase/reductase 2 1.18397 
COLEC10 collectin subfamily member 10 1.13287 
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